Nothing Special   »   [go: up one dir, main page]

WO2014001973A1 - NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS - Google Patents

NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS Download PDF

Info

Publication number
WO2014001973A1
WO2014001973A1 PCT/IB2013/055039 IB2013055039W WO2014001973A1 WO 2014001973 A1 WO2014001973 A1 WO 2014001973A1 IB 2013055039 W IB2013055039 W IB 2013055039W WO 2014001973 A1 WO2014001973 A1 WO 2014001973A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolo
pyrimidin
morpholin
benzonitrile
pyrimidine
Prior art date
Application number
PCT/IB2013/055039
Other languages
French (fr)
Inventor
Paul Galatsis
Matthew Merrill Hayward
Jaclyn HENDERSON
Bethany Lyn KORMOS
Ravi G KURUMBAIL
Antonia Friederike STEPAN
Patrick Robert Verhoest
Travis T. Wager
Lei Zhang
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014001973(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2013282869A priority Critical patent/AU2013282869B2/en
Priority to UAA201413021A priority patent/UA113436C2/en
Priority to MX2014015769A priority patent/MX2014015769A/en
Priority to ES13752678.6T priority patent/ES2637245T3/en
Priority to AP2014008147A priority patent/AP3902A/en
Priority to JP2015519416A priority patent/JP6189948B2/en
Priority to EP13752678.6A priority patent/EP2867236B1/en
Priority to CA2878054A priority patent/CA2878054C/en
Priority to CN201380034594.1A priority patent/CN104395315B/en
Priority to SG11201408044QA priority patent/SG11201408044QA/en
Priority to BR112014032913A priority patent/BR112014032913A2/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to EA201492125A priority patent/EA025186B1/en
Priority to MD20140130A priority patent/MD20140130A2/en
Priority to NZ702571A priority patent/NZ702571A/en
Priority to KR20157002334A priority patent/KR20150027267A/en
Publication of WO2014001973A1 publication Critical patent/WO2014001973A1/en
Priority to CU2014000140A priority patent/CU20140140A7/en
Priority to CR20140566A priority patent/CR20140566A/en
Priority to ZA2014/09136A priority patent/ZA201409136B/en
Priority to IL236294A priority patent/IL236294A/en
Priority to MA37678A priority patent/MA37678B2/en
Priority to PH12014502886A priority patent/PH12014502886B1/en
Priority to TN2014000537A priority patent/TN2014000537A1/en
Priority to HK15105238.4A priority patent/HK1204619A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2).
  • LRRK2 leucine-rich repeat kinase 2
  • This invention also relates to methods of inhibiting, in mammals, including humans, LRRK2 by administration of the small molecule LRRK2 inhibitors.
  • the present invention also relates to the treatment of Parkinson's Disease (PD) and other neurodegenerative and/or neurological disorders in mammals, including humans with the LRRK2 inhibitors. More particularly, this invention relates to 4-(substituted- amino)-7H-pyrrolo[2,3-c ]pyrimidine compounds useful for the treatment of neurodegenerative and/or neurological disorders, such as PD, Alzheimer's Disease (AD) and other LRRK2 associated disorders.
  • PD Parkinson's Disease
  • AD Alzheimer's Disease
  • LRRK2 is a 286 kDa active protein kinase in the ROCO protein family with a complex multidomain structure and which has structural homology to the MAP kinase kinase kinases (MAPKKK). LRRK2 has been shown to phosphorylate moeisin (at Thr 558 ), ezrin and radixin in vitro. LRRK2 has been found in various regions of the brain as well as in the heart, lung, spleen and kidney.
  • Independent domains that have been established for the LRRK2 protein include an ankyrin-like (ANK) domain, a leucine-rich repeat (LRR) domain, a Ras (renin-angiotensin system) of complex (ROC) domain, a C- terminal of ROC (COR) domain, a kinase (Kinase) domain and a C-terminal WD40 domain.
  • the ROC domain binds guanosine triphosphate (GTP) and the COR domain may be a regulator of the ROC domain's GTPase activity.
  • LRRK2 With multiple domains and both active kinase and guanosine triphosphatase (GTPase) activity, LRRK2 appears to play a complex role in multiple cellular processes. For example, LRRK2 has been associated with NFAT inhibition in the immune system and has been linked to vesicle trafficking, presynaptic homeostasis, mammalian target of rapamycin (mTOR) signaling, signaling through the receptor tyrosine kinase MET in papillary renal and thyroid carcinomas, cytoskeletal dynamics, the mitogen-activated protein kinase (MAPK) pathway, the tumor necrosis factor-a (TNF-a) pathway, the Wnt pathway and autophagy.
  • mTOR mammalian target of rapamycin
  • Parkinson's Disease is a relatively common age-related neurodegenerative disorder resulting from the progressive loss of dopamine-producing neurons and which affects up to 4% of the population over 80.
  • PD is characterized by both motoric and non-motoric symptoms such as tremor at rest, rigidity, akinesia and postural instability as well as non-motor symptoms such as impairment of cognition, sleep and sense of smell.
  • Genome-wide association studies have linked LRRK2 to PD and many patients with point mutations in LRRK2 present symptoms that are indistinguishable from those with idiopathic PD.
  • LRRK2 mutations Over 20 LRRK2 mutations have been associated with autosomal- dominant parkinsonism, and the R1441 C, R1441 G, R1441 H, Y1699C, G2019S, I2020T and N1437H missense mutations are considered to be pathogenic.
  • the LRRK2 R1441 G mutation has been shown to increase the release of proinflammatory cytokines (higher levels of TNF-a, I L- 1 ⁇ , IL-12 and lower levels of IL-10) in microglial cells from transgenic mice and thus may result in direct toxicity to neurons (Gillardon, F. et al. Neuroscience 2012, 208, 41-48).
  • LRRK2 kinase activity In a murine model of neuroinflammation, induction of LRRK2 in microglia was observed and inhibition of LRRK2 kinase activity with small molecule LRRK2 inhibitors (LRRK2-IN-1 or sunitinib) or LRRK2 knockout resulted in attenuation of TNF-a secretion and nitric oxide synthase (iNOS) induction (Moehle, M. et al. J. Neurosci. 2012, 32(5), 1602-161 1 ). The most common of the LRRK2 mutations, G2019S, is present in more than 85% of PD patients carrying LRRK2 mutations.
  • iNOS nitric oxide synthase
  • LRRK2 kinase domain This mutation, which is present in the LRRK2 kinase domain, leads to an enhancement of LRRK2 kinase activity.
  • LRRK2 expression is highest in the same regions of the brain that are impacted by PD, and LRRK2 is found in Lewy Bodies, a hallmark of PD.
  • a potent, selective, brain-penetrant kinase inhibitor for LRRK2 could be a therapeutic treatment for PD.
  • AD cerebral amyloid angiopathy
  • CM cerebral amyloid angiopathy
  • prion-mediated diseases see, e.g., Haan et al., Clin. Neurol. Neurosurg. 1990, 92(4):305-310; Glenner et al., J. Neurol. Sci. 1989, 94:1 -28).
  • AD is a progressive, neurodegenerative disorder characterized by memory impairment and cognitive dysfunction. AD affects nearly half of all people past the age of 85, the most rapidly growing portion of the United States population. As such, the number of AD patients in the United States is expected to increase from about 4 million to about 14 million by 2050.
  • LRRK2 mutations have been associated with AD-like pathology, which suggests that there may be a partial overlap between the neurodegenerative pathways in both AD and PD (Zimprach, A. et al. Neuron 2004, 44, 601-607).
  • the LRRK2 R1628P variant (COR domain) has been associated with an increased incidence of AD in a certain population, perhaps resulting from increased apoptosis and cell death (Zhao, Y. et al.; Neurobiology of Aging 201 1 , 32, 1990-1993.
  • Inflammatory bowel disease or Crohn's disease (CD) is a complex disease and is believed to result from an inappropriate immune response to microbiota in the intestinal tract.
  • IBD Inflammatory bowel disease
  • CD Crohn's disease
  • LRRK2 is a major susceptibility gene for Crohn's disease, particularly the M2397T polymorphism in the WD40 domain (Liu, Z. et al. Nat. Immunol. 201 1 , 12, 1063-1070).
  • LRRK2 deficient mice were found to be more susceptible to dextran sodium sulfate induced colitis than their wild-type counterparts, indicating that LRRK2 may play a role in the pathogenesis of IBD (Liu, Z. and Lenardo, M.; Cell Research 2012, 1-3).
  • Non-selective and selective small molecule compounds with LRRK2 inhibitory activity such as staurosporine, sunitinib, LRRK2-IN-1 , CZC-25146, TAE684 and those in WO 201 1/141756, WO 2012/028629 and WO 2012/058193 have been described. It is desirable to provide compounds which are potent and selective inhibitors of LRRK2 with a favorable pharmacokinetic profile and the ability to to traverse the blood brain barrier.
  • the present invention is directed to novel 4-(substituted-amino)-7H-pyrrolo[2,3-c ]pyrimidine compounds with LRRK2 inhibitory activity and the use of these compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases, including PD.
  • R 1 and R 2 are each independently hydrogen, d-Cealkyl, Ca-Czcycloalkyl, a four to seven membered heterocycloalkyi which contains one to three heteroatoms selected from N, O and S; or a five to six membered heteroaryl which contains one to four heteroatoms selected from N, O and S, wherein the C-pCealkyl, Ca-Czcycloalkyl, four to seven membered heterocycloalkyi, or five to six membered heteroaryl are optionally substituted with one to three R 6 ; or R 1 and R 2 taken together with the nitrogen to which they are attached are a four to seven membered heterocycloalkyi which optionally contains one to two additional heteroatoms selected from N, O and S, and optionally contains one double bond; a six to eleven membered heterobicycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; or a six to twelve membere
  • a second embodiment of a first aspect of the present invention is the compound of the first embodiment of the first aspect wherein R 4 and R 5 are each hydrogen; or a pharmaceutically acceptable salt thereof.
  • a third embodiment of a first aspect of the present invention is the compound of the second embodiment of the first aspect wherein R 1 and R 2 taken together with the nitrogen to which they are attached are azetidin-1 -yl, pyrrolidin-1-yl, piperidin-1 -yl, morpholin-4-yl, thiomorpholin-4-yl, 6-oxa-3-aza-bicyclo[3.1 .1]heptan-3-yl,
  • a fourth embodiment of a first aspect of the present invention is the compound of the third embodiment of the first aspect wherein R 1 and R 2 taken together with the nitrogen to which they are attached are piperidin-1-yl or morpholin-4-yl; each optionally substituted with a hydroxy, methyl or 5-methyl-1 ,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable salt thereof.
  • a fifth embodiment of a first aspect of the present invention is the compound of the fourth embodiment of the first aspect wherein R 1 and R 2 taken together with the nitrogen to which they are attached are morpholin-4-yl optionally substituted with a methyl or 5-methyl-1 ,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable salt thereof.
  • a sixth embodiment of a first aspect of the present invention is the compound of the second embodiment of the first aspect wherein R 1 and R 2 taken together with the nitrogen to which they are attached are methylamino, dimethylamino, diethylamino, N- methylcyclopropylamino or pyrazolylamino; each of which is optionally substituted with one to three R 6 ; or a pharmaceutically acceptable salt thereof.
  • An seventh embodiment of a first aspect of the present invention is the compound of the third embodiment of the first aspect wherein R 3 is phenyl substituted with one or two R 9 ; and each R 9 is independently selected from cyano, fluoro, chloro or methoxy; or a pharmaceutically acceptable salt thereof.
  • An eighth embodiment of a first aspect the present invention is the compound of the third embodiment of the first aspect wherein R 3 is pyrazolyl, isothiazolyl, or pyridinyl, each optionally substituted with one R 9 ; and R 9 is cyano or methyl; or a pharmaceutically acceptable salt thereof.
  • a ninth embodiment of a first aspect of the present invention is the compound of the first embodiment of the first aspect wherein R 1 and R 2 taken together with the nitrogen to which they are attached is selected from the group consisting of:
  • R 3 is 1-methylpyrazol-4-yl, 1 H-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1 ,2-thiazol-5- yl, 5-cyano-1-methylpyrrol-3-yl, 3-methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3- fluorophenyl, 2,3-difluorophenyl, 2-fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 2- methoxy-5-fluorophenyl; and R 4 and R 5 are each independently hydrogen or methyl; or a pharmaceutically acceptable salt thereof.
  • a tenth embodiment of a first aspect of the present invention is the compound of the ninth embodiment wherein R 1 and R 2 taken together with the nitrogen to which they are attached are a group selected from:
  • An eleventh embodiment of a first aspect of the present invention is the compound of the tenth embodiment of the first aspect wherein R 1 and R 2 taken together with the nitrogen to which they are d is
  • a twelfth embodiment of a faspect of the present invention is the compound of the eleventh embodiment of the first aspect wherein R 3 is 3-cyanophenyl, 1 - methylpyrazol-4-yl or 5-cyano-1-methylpyrrol-3-yl; or a pharmaceutically acceptable salt thereof.
  • a thirteenth embodiment of a first aspect of the present invention is the compound of the first embodiment of a first aspect wherein R 1 and R 2 taken together with the nitrogen to which they are attached are piperidinyl or 3-hydroxypiperidinyl;
  • R 3 is 1-methylpyrazol-4-yl, 1 H-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1 ,2-thiazol-5-yl, 3- methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3-difluorophenyl, 2- fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 2-methoxy-5-fluorophenyl; and R 4 and R 5 are each independently hydrogen or methyl; or a pharmaceutically acceptable salt thereof.
  • a first embodiment of a second aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the first through sixteenth embodiments of the first aspect of the invention, or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
  • a first embodiment of a third aspect of the present invention is a method of treating Parkinson's disease in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to any one of the first through sixteenth embodiments of the first aspect of the invention.
  • Another aspect of the present invention is the compound or pharmaceutically acceptable salt thereof according to any one of the first through sixteenth embodiments of the first aspect of the invention for use in the treatment of Parkinson's disease.
  • Another aspect of the present invention is the use of any of the preceding compounds of formula I and their compositions for inhibiting LRRK2 kinase.
  • the compounds of formula I or compositions thereof are useful for treating a neurodegenerative disease.
  • the neurodegenerative disease is Parkinson's Disease.
  • the invention is also directed to methods of treating a patient (preferably a human) for diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease, by administering a therapeutically effective amount of a compound of any of the embodiments of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a patient preferably a human
  • diseases in which the LRRK2 kinase is involved such as Parkinson's Disease
  • the invention is also directed to methods of inhibiting LRRK2 kinase activity, by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, to a mammal or a patient in need thereof.
  • the invention is also directed to methods of treating disorders responsive to the inhibition of LRRK2 kinase activity, such as neurological disorders (particularly Parkinson's disease), certain cancers, and certain immunological disorders (such as Crohn's disease and leprosy) by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, to a mammal or a patient in need thereof.
  • the invention is also directed to methods for treating conditions or diseases of the central nervous system and neurological disorders in which the LRRK2 kinase is involved, particularly Parkinson's disease (but also including other neurological diseases which may include migraine; epilepsy; Alzheimer's disease; brain injury; stroke; cerebrovascular diseases (including cerebral arteriosclerosis, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, and brain hypoxia-ischemia); cognitive disorders (including amnesia, senile dementia, HlV-associated dementia, Alzheimer's disease, Huntington's disease, Lewy body dementia, vascular dementia, drug-related dementia, tardive dyskinesia, myoclonus, dystonia, delirium, Pick's disease, Creutzfeldt- Jacob disease, HIV disease, Gilles de la Tourette's syndrome, epilepsy, muscular spasms and disorders associated with muscular spasticity or weakness including tremors, and mild cognitive impairment); mental deficiency (including spasticity, Down syndrome and fragile X syndrome); sleep disorders (including
  • DMS-IV-TR Mental Disorders
  • Preferred methods are for treating a neurological disorder, most preferably Parkinson's disease, (but also other neurological disorders such as migraine; epilepsy; Alzheimer's disease; Niemann-Pick type C; brain injury; stroke; cerebrovascular disease; cognitive disorder; sleep disorder) or a psychiatric disorder (such as anxiety; factitious disorder; impulse control disorder; mood disorder; psychomotor disorder; psychotic disorder; drug dependence; eating disorder; and pediatric psychiatric disorder) in a mammal, preferably a human, comprising administering to said mammal a therapeutically effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof.
  • the compounds of Formula I and pharmaceutically acceptable salts thereof may also be employed in methods of treating other disorders associated with LRRK2 such as Crohn's disease, leprosy and certain cancers, such as kidney, breast, lung, prostate, lung and blood cancer.
  • compositions comprising a pharmaceutically effective amount of one or more of the compounds described herein and a pharmaceutically acceptable vehicle, carrier or excipient.
  • the present invention is also directed to the use of a combination of a LRRK2 inhibitor compound of formula I, and one or more additional pharmaceutically active agent(s).
  • alkyl refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen); in one embodiment from one to six carbon atoms (i.e., C-i-Cealkyl); in another embodiment, from one to three carbon atoms (i.e., C Caalkyl).
  • substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and ferf-butyl), pentyl, isoamyl, hexyl and the like.
  • alkoxy refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen) which is in turn attached to an oxygen atom; in one embodiment from one to six carbon atoms (i.e., C-i-Cealkoxy); in another embodiment, from one to three carbon atoms (i.e., C-i-C 3 alkoxy).
  • substituents include methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, sec-butoxy and ferf-butoxy), pentoxy and the like.
  • cycloalkyl refers to a carbocyclic substituent obtained by removing a hydrogen from a saturated carbocyclic molecule and having the specified number of carbon atoms. In one embodiment, a cycloalkyl substituent has three to seven carbon atoms (i.e., C 3 -C 7 cycloalkyl). Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • cycloalkyl includes mono-, bi- and tricyclic saturated carbocycles, as well as bridged and fused ring carbocycles, as well as spiro-fused ring systems.
  • the number of atoms in a cyclic substituent containing one or more heteroatoms is indicated by the prefix "x to y membered", wherein x is the minimum and y is the maximum number of atoms forming the cyclic moiety of the substituent.
  • heterocycloalkyl refers to a substituent obtained by removing a hydrogen from a saturated or partially saturated ring structure containing the specified number of ring atoms, wherein at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. If the heterocycloalkyl substituent is in turn substituted with a group or substituent, the group or substituent may be bound to a nitrogen heteroatom, or it may be bound to a ring carbon atom, as appropriate.
  • heterocycloalkyl refers to a monocyclic ring system containing the heteroatoms N, O or S as specified.
  • heterocycloalkyl refers to a heterocycloalkyl containing from 4 to 7 atoms, including one or more heteroatoms, in the cyclic moiety of the heterocycloalkyl.
  • heterocycloalkyl refers to a non-spiro bicyclic ring system containing the heteroatoms N, O or S as specified.
  • heterobicycloalkyl refers to a heterobicycloalkyl containing from 6 to 12 atoms, including one or more heteroatoms, in the cyclic moieties of the heterobicycloalkyl.
  • heterospirocycloalkyl refers to a spirocyclic ring system containing the heteroatoms N, O or S as specified.
  • heterospirocycloalkyl means a six to twelve membered spirocyclic ring system which contains at least one heteroatom as specified.
  • hydrogen refers to a hydrogen substituent, and may be depicted as
  • hydroxy refers to -OH.
  • Compounds bearing a carbon to which one or more hydroxy substituents are attached include, for example, alcohols, enols and phenol.
  • halo or halogen refers to fluoro (which may be depicted as -F), chloro (which may be depicted as -CI), bromo (which may be depicted as -Br), or iodo (which may be depicted as -I).
  • heteroaryl refers to an aromatic ring structure containing the specified number of ring atoms in which at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
  • a five to six membered heteroaryl is an aromatic ring system which has five or six ring atoms with at least one of the ring atoms being N, O or S.
  • a five to ten membered heteroaryl is an aromatic ring system which has five to ten ring atoms with at least one of the ring atoms being N, O or S.
  • a heteroaryl may be a single ring or 2 fused rings.
  • heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, and pyridazinyl; 5-membered ring substituents such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1 ,2,3-, 1 ,2,4-, 1 ,2,5-, or 1 ,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, isobenzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl; and 6/6-membered fused rings such as quinolinyl, isoquinolinyl
  • the ring atom of the heteroaryl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom.
  • heteroaryl also includes pyridyl /V-oxides and groups containing a pyridine /V-oxide ring.
  • single-ring heterocycloalkyls examples include azetidinyl, oxetanyl, thietanyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, dihydropyranyl, piperidinyl, morpholinyl, piperazinyl, azepinyl, oxepinyl, thiepinyl, and diazepinyl.
  • 2-fused-ring heteroaryls include, indolizinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-6]-pyridinyl, pyrido[3,2-6]-pyridinyl, or pyrido[4,3-6]-pyridinyl), and pteridinyl, indolyl, isoindolyl, indoleninyl, isoindazolyl, benzazinyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl, benzopyranyl, benzothiopyranyl, benzoxazolyl, indoxazinyl, anthranilyl, benzodioxolyl, benzodioxanyl, benzoxadiazolyl, benzofuranyl
  • fused-ring heteroaryls include benzo-fused heteroaryls such as indolyl, isoindolyl, indoleninyl, isoindazolyl, benzazinyl (including quinolinyl or isoquinolinyl), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl or quinazolinyl).
  • a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-2-yl (C-attached).
  • the term "formula I" or "Formula I” may be referred to as a "compound(s) of the invention.” Such terms are also defined to include all forms of the compound of formula I, including hydrates, solvates, isomers, crystalline and noncrystalline forms, isomorphs, polymorphs, and metabolites thereof.
  • the compounds of the invention, or pharmaceutically acceptable salts thereof may exist in unsolvated and solvated forms.
  • the solvent or water When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity.
  • the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
  • the compounds of the invention may exist as clathrates or other complexes.
  • complexes such as clathrates, drug-host inclusion complexes wherein the drug and host are present in stoichiometric or non- stoichiometric amounts.
  • complexes of the compounds of the invention containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts.
  • the resulting complexes may be ionized, partially ionized, or non-ionized.
  • the compounds of the invention may have asymmetric carbon atoms.
  • the carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line ( ), a solid wedge ( " ⁇ ), or a dotted wedge ( '" ).
  • the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g., specific enantiomers, racemic mixtures, etc.) at that carbon atom are included.
  • the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of Formula I may contain more than one asymmetric carbon atom.
  • a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
  • the compounds of Formula I can exist as enantiomers and diastereomers or as racemates and mixtures thereof.
  • the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of Formula I and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
  • Stereoisomers of Formula I include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers, conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs). Also included are acid addition or base addition salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.
  • the first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts.
  • the second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
  • the present invention comprises the tautomeric forms of compounds of the invention.
  • tautomeric isomerism 'tautomerism'
  • This can take the form of proton tautomerism in compounds of the invention containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
  • the various ratios of the tautomers in solid and liquid form is dependent on the various substituents on the molecule as well as the particular crystallization technique used to isolate a compound.
  • the compounds of this invention may be used in the form of salts derived from inorganic or organic acids.
  • a salt of the compound may be advantageous due to one or more of the salt's physical properties, such as enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil.
  • a salt of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
  • the salt preferably is pharmaceutically acceptable.
  • pharmaceutically acceptable salt refers to a salt prepared by combining a compound of formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption.
  • Pharmaceutically acceptable salts are particularly useful as products of the methods of the present invention because of their greater aqueous solubility relative to the parent compound.
  • salts of the compounds of this invention are non-toxic “pharmaceutically acceptable salts.”
  • Salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids.
  • Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
  • suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylaminosulfonate, ⁇ -hydroxybutyrate, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate,
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts, i.e., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts.
  • base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.
  • Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, ⁇ /, ⁇ /'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (/V-methylglucamine), and procaine.
  • secondary, tertiary or quaternary amine salts such as tromethamine, diethylamine, ⁇ /, ⁇ /'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (/V-methylglucamine), and procaine.
  • Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl (CrCe) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.
  • PrCe lower alkyl
  • CaCe lower alkyl
  • dialkyl sulfates i.e., dimethyl, diethyl, dibutyl, and diamyl sulfates
  • long chain halides e.g., decy
  • hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.
  • prodrugs of the compound of the invention.
  • certain derivatives of the compound of the invention which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into the compound of the invention having the desired activity, for example, by hydrolytic cleavage.
  • Such derivatives are referred to as “prodrugs.” Further information on the use of prodrugs may be found in "Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella) and "Bioreversible Carriers in Drug Design,” Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association).
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of any of formula I with certain moieties known to those skilled in the art as "pro-moieties” as described, for example, in “Design of Prodrugs” by H. Bundgaard (Elsevier, 1985).
  • the present invention also includes isotopically labeled compounds, which are identical to those recited in formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2 H, 3 H, 13 C, 11 C, 14 C, 15 N, 18 0, 17 0, 32 P, 35 S, 18 F, and 36 CI, respectively.
  • Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3 H and 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • Isotopically labeled compounds of formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • a compound of the invention is administered in an amount effective to treat a condition as described herein.
  • the compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • treating also includes adjuvant and neo-adjuvant treatment of a subject.
  • the compounds of the invention may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed, by which the compound enters the blood stream directly from the mouth.
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally.
  • the compounds of the invention can also be administered intranasally or by inhalation.
  • the compounds of the invention may be administered rectally or vaginally.
  • the compounds of the invention may also be administered directly to the eye or ear.
  • the dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 100 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions. In one embodiment, the total daily dose of a compound of the invention (administered in single or divided doses) is typically from about 0.01 to about 100 mg/kg.
  • the total daily dose of the compound of the invention is from about 0.1 to about 50 mg/kg, and in another embodiment, from about 0.5 to about 30 mg/kg (i.e., mg compound of the invention per kg body weight). In one embodiment, dosing is from 0.01 to 10 mg/kg/day. In another embodiment, dosing is from 0.1 to 1 .0 mg/kg/day. Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the compound will be repeated a plurality of times in a day (typically no greater than 4 times). Multiple doses per day typically may be used to increase the total daily dose, if desired.
  • compositions may be provided in the form of tablets containing from about 0.01 mg to about 500 mg of the active ingredient, or in another embodiment, from about 1 mg to about 100 mg of active ingredient.
  • doses may range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
  • Suitable subjects according to the present invention include mammalian subjects. Mammals according to the present invention include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In one embodiment, humans are suitable subjects. Human subjects may be of either gender and at any stage of development.
  • the invention comprises the use of one or more compounds of the invention for the preparation of a medicament for the treatment of the conditions recited herein.
  • the compound of the invention can be administered as compound per se.
  • pharmaceutically acceptable salts are suitable for medical applications because of their greater aqueous solubility relative to the parent compound.
  • the present invention comprises pharmaceutical compositions.
  • Such pharmaceutical compositions comprise a compound of the invention presented with a pharmaceutically acceptable carrier.
  • the carrier can be a solid, a liquid, or both, and may be formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compounds.
  • a compound of the invention may be coupled with suitable polymers as targetable drug carriers. Other pharmacologically active substances can also be present.
  • the compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • the active compounds and compositions for example, may be administered orally, rectally, parenterally, or topically.
  • Oral administration of a solid dose form may be, for example, presented in discrete units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of at least one compound of the present invention.
  • the oral administration may be in a powder or granule form.
  • the oral dose form is sub-lingual, such as, for example, a lozenge.
  • the compounds of formula I are ordinarily combined with one or more adjuvants.
  • Such capsules or tablets may contain a controlled-release formulation.
  • the dosage forms also may comprise buffering agents or may be prepared with enteric coatings.
  • oral administration may be in a liquid dose form.
  • Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art (e.g., water). Such compositions also may comprise adjuvants, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.
  • the present invention comprises a parenteral dose form.
  • Parenteral administration includes, for example, subcutaneous injections, intravenous injections, intraperitoneal injections, intramuscular injections, intrasternal injections, and infusion.
  • Injectable preparations e.g., sterile injectable aqueous or oleaginous suspensions
  • Topical administration includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration.
  • Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams.
  • a topical formulation may include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used.
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol.
  • Penetration enhancers may be incorporated; see, for example, J. Pharm. Sci., 88 (10), 955-958, by Finnin and Morgan (October 1999).
  • Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier.
  • a typical formulation suitable for ocular or aural administration may be in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline.
  • Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g., absorbable gel sponges, collagen) and nonbiodegradable (e.g., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes.
  • a polymer such as cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, (hydroxypropyl)methyl cellulose, hydroxyethyl cellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride.
  • a preservative such as benzalkonium chloride.
  • Such formulations may also be delivered by iontophoresis.
  • the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant.
  • Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1 , 1 , 1 ,2-tetrafluoroethane or 1 , 1 , 1 ,2,3,3,3-heptafluoropropane.
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • the present invention comprises a rectal dose form.
  • rectal dose form may be in the form of, for example, a suppository. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
  • compositions of the invention may be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures.
  • effective formulations and administration procedures are well known in the art and are described in standard textbooks.
  • Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe et al., Eds., Handbook of Pharmaceutical Excipients (3 rd Ed.), American Pharmaceutical Association, Washington, 1999.
  • the compounds of the present invention can be used, alone or in combination with other therapeutic agents, in the treatment of various conditions or disease states.
  • the compound(s) of the present invention and other therapeutic agent(s) may be may be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially. Two or more compounds may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
  • the present invention includes the use of a combination of a LRRK2 inhibitor compound as provided in formula I and one or more additional pharmaceutically active agent(s). If a combination of active agents is administered, then they may be administered sequentially or simultaneously, in separate dosage forms or combined in a single dosage form. Accordingly, the present invention also includes pharmaceutical compositions comprising an amount of: (a) a first agent comprising a compound of formula I or a pharmaceutically acceptable salt of the compound; (b) a second pharmaceutically active agent; and (c) a pharmaceutically acceptable carrier, vehicle or diluent.
  • a pharmaceutical composition for use in treating Parkinson's disease may comprise a compound of formula I or a pharmaceutically acceptable salt thereof together with another agent such as a dopamine (levodopa, either alone or with a DOPA decarboxylase inhibitor), a monoamine oxidase (MAO) inhibitor, a catechol O- methyltransferase (COMT) inhibitor or an anticholinergic agent, or any combination thereof.
  • a dopamine levodopa, either alone or with a DOPA decarboxylase inhibitor
  • MAO monoamine oxidase
  • COMP catechol O- methyltransferase
  • agents to combine with the compounds of formula I for use in treating Parkinson's disease include levodopa, carbidopa, tolcapone, entacapone, selegiline, benztropine and trihexyphenidyl, or any combination thereof.
  • Pharmaceutically active agents that may be used in combination with the compounds of formula I and compositions thereof include, without limitation:
  • levodopa or its methyl or ethyl ester
  • a DOPA decarboxylase inhibitor e.g., carbidopa (SINEMET, CARBILEV, PARCOPA), benserazide (MADOPAR), omethyldopa, monofluoromethyldopa, difluoromethyldopa, brocresine, or m-hydroxybenzylhydrazine
  • anticholinergics such as amitriptyline (ELAVIL, ENDEP), butriptyline, benztropine mesylate (COGENTIN), trihexyphenidyl (ARTANE), diphenhydramine (BENADRYL), orphenadrine (NORFLEX), hyoscyamine, atropine (ATROPEN), scopolamine (TRANSDERM-SCOP), scopolamine methylbromide (PARMINE), dicycloverine (BENTY
  • catechol O-methyltransferase (COMT) inhibitors such as nitecapone, tolcapone (TASMAR), entacapone (COMTAN), and tropolone;
  • MAO monoamine oxidase
  • MAO monoamine oxidase inhibitors
  • selegiline selegiline
  • l-deprenyl selegiline hydrochloride
  • ELDEPRYL ELDEPRYL
  • ZELAPAR dimethylselegiline
  • brofaromine phenelzine
  • NARDIL phenelzine
  • PARNATE moclobemide
  • AURORIX MANERIX
  • befloxatone safinamide
  • MARPLAN isocarboxazid
  • NIAMID isocarboxazid
  • NIAMID isocarboxazid
  • NIAMID isocarboxazid
  • NIAMID isocarboxazid
  • NIAMID isocarboxazid
  • ZAMID nialamide
  • AZILECT iproniazide
  • MARSILID IPROZID
  • IPRONID iproclozide
  • toloxatone HUMORYL, PE
  • acetylcholinesterase inhibitors such as donepezil hydrochloride (ARICEPT®, MEMAC), physostigmine salicylate (ANTILIRIUM®), physostigmine sulfate (ESERINE), ganstigmine, rivastigmine (EXELON®), ladostigil, NP-0361 , galantamine hydrobromide (RAZADYNE®, REMINYL®, NIVALIN®), tacrine (COGNEX®), tolserine, memoquin, huperzine A (HUP-A; Neuro-Hitech), phenserine, bisnorcymserine (also known as BNC), and INM-176;
  • amyloid- ⁇ (or fragments thereof), such as ⁇ -
  • antibodies to amyloid- ⁇ such as ponezumab, solanezumab, bapineuzumab (also known as AAB-001 ), AAB-002 (Wyeth/Elan), Gantenerumab, intravenous Ig (GAMMAGARD®), LY2062430 (humanized m266; Lilly), and those disclosed in International Patent Publication Nos WO04/032868, WO05/025616, WO06/036291 , WO06/069081 , WO06/1 18959, in US Patent Publication Nos US2003/0073655, US2004/0192898, US2005/0048049, US2005/0019328, in European Patent Publication Nos EP0994728 and 1257584, and in US Patent No 5,750,349;
  • amyloid-lowering or -inhibiting agents include those that reduce amyloid production, accumulation and fibrillization
  • eprodisate celecoxib
  • lovastatin anapsos
  • colostrinin pioglitazone
  • clioquinol also known as PBT1 ), PBT2 (Prana Biotechnology
  • flurbiprofen ANSAID®, FROBEN®
  • R- enantiomer tarenflurbil FLURIZAN®
  • nitroflurbiprofen fenoprofen
  • FENOPRON NALFON®
  • ibuprofen ADVIL®, MOTRIN®, NUROFEN®
  • ibuprofen lysinate meclofenamic acid, meclofenamate sodium (MECLOMEN®), indomethacin (INDOCIN®), diclofenac sodium (VOLTAREN®), diclofenac potassium, sulindac (CLIN
  • H3 antagonists such as PF-3654746 and those disclosed in US Patent Publication Nos US2005-0043354, US2005-0267095, US2005-0256135, US2008-0096955, US2007-1079175, and US2008-0176925; International Patent Publication Nos WO2006/136924, WO2007/063385, WO2007/069053, WO2007/088450, WO2007/099423, WO2007/105053, WO2007/138431 , and WO2007/088462; and US Patent No 7, 1 15,600);
  • NMDA V-methyl-D-aspartate receptor antagonists
  • memantine NAMENDA, AXURA, EBIXA
  • amantadine SYMMETREL
  • acamprosate V-methyl-D-aspartate receptor antagonists, such as memantine (NAMENDA, AXURA, EBIXA), amantadine (SYMMETREL), acamprosate
  • CAMPRAL besonprodil
  • ketamine KETALAR
  • delucemine dexanabinol
  • dexefaroxan dextromethorphan
  • dextrorphan dextrorphan
  • traxoprodil CP-283097
  • himantane idantadol, ipenoxazone
  • L-701252 Merck
  • lancicemine L-701252 (Merck)
  • levorphanol DROMORAN
  • methadone DOLOPHINE
  • neramexane perzinfotel
  • phencyclidine tianeptine
  • STABLON dizocilpine
  • ibogaine ibogaine
  • voacangine tiletamine
  • riluzole RILUTEK
  • aptiganel CERESTAT
  • PDE phosphodiesterase
  • PDE1 inhibitors including (a) PDE1 inhibitors; (b) PDE2 inhibitors; (c) PDE3 inhibitors; (d) PDE4 inhibitors; (e) PDE5 inhibitors; (f) PDE9 inhibitors (e.g., PF-04447943, BAY 73-6691 (Bayer AG) and those disclosed in
  • (xiii) serotonin (5-hydroxytryptamine) 1A (5-HT-IA) receptor antagonists such as spiperone, /e ⁇ /o-pindolol, lecozotan;
  • serotonin (5-hydroxytryptamine) 2C (5-HT 2c ) receptor agonists, such as vabicaserin, and zicronapine
  • serotonin (5-hydroxytryptamine) 4 (5-HT 4 ) receptor agonists/antagonists, such as PRX-03140 (Epix) and PF-04995274;
  • serotonin (5-hydroxytryptamine) 6 (5-HT 6 ) receptor antagonists, such as mianserin (TOLVON, BOLVIDON, NORVAL), methiothepin (also known as metitepine), ritanserin, SB-271046, SB-742457 (GlaxoSmithKline), Lu AE58054 (Lundbeck A/S), SAM-760, and PRX-07034 (Epix);
  • (xvii) serotonin (5-HT) reuptake inhibitors such as alaproclate, citalopram (CELEXA, CIPRAMIL), escitalopram (LEXAPRO, CIPRALEX), clomipramine (ANAFRANIL), duloxetine (CYMBALTA), femoxetine (MALEXIL), fenfluramine (PONDIMIN), norfenfluramine, fluoxetine (PROZAC), fluvoxamine (LUVOX), indalpine, milnacipran (IXEL), paroxetine (PAXIL, SEROXAT), sertraline (ZOLOFT, LUSTRAL), trazodone (DESYREL, MOLIPAXI N), venlafaxine (EFFEXOR), zimelidine (NORMUD, ZELMID), bicifadine, desvenlafaxine (PRISTIQ), brasofensine, vilazodone, cariprazine and tesofen
  • Glycine transporter-1 inhibitors such as paliflutine, ORG-25935, and ORG-26041 ; and mGluR modulators such as AFQ-059 and amantidine;
  • AMPA-type glutamate receptor modulators such as perampanel, mibampator, selurampanel, GSK-729327, and /v- ⁇ (3S,4S)-4-[4-(5-cyanothiophen-2- yl)phenoxy]tetrahydrofuran-3-yl ⁇ propane-2-sulfonamide;
  • tau therapy targets such as davunetide
  • kits that are suitable for use in performing the methods of treatment described above.
  • the kit contains a first dosage form comprising one or more of the compounds of the present invention and a container for the dosage, in quantities sufficient to carry out the methods of the present invention.
  • kit of the present invention comprises one or more compounds of the invention.
  • the compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and transformations that are familiar to those of ordinary skill in the art.
  • the starting materials used herein are commercially available or may be prepared by routine methods known in the art [such as those methods disclosed in standard reference books such as the Compendium of Organic Synthetic Methods, Vol. I-XII (published by Wiley-lnterscience)]. Preferred methods include, but are not limited to, those described below.
  • any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991 ; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
  • conventional protecting groups such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991 ; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley &
  • the reactions for preparing compounds of the invention can be carried out in suitable solvents, which can be readily selected by one of skill in the art of organic synthesis.
  • suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature.
  • a given reaction can be carried out in one solvent or a mixture of more than one solvent.
  • suitable solvents for a particular reaction step can be selected by the skilled artisan. Reactions can be monitored according to any suitable method known in the art.
  • product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
  • spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13 C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
  • HPLC high performance liquid chromatography
  • TLC thin layer chromatography
  • Scheme 1 refers to preparation of compounds of Formula I. Referring to Scheme
  • a compound of Formula 1 -3 can be prepared by coupling a compound of Formula 1-1 with a compound of Formula 1 -2, for example, by heating a mixture of a compound of Formula 1 -1 with a compound of Formula 1-2 in the presence of a base, such as A/,/ ⁇ /-diisopropylethylamine, in an appropriate solvent, such as n-butanol, at temperatures ranging between 50 °C and 200 °C. Suitable reaction times are typically from 20 minutes to 48 hours.
  • a metal-catalyzed (such as using a palladium or copper catalyst) coupling may be employed to accomplish the aforesaid coupling.
  • a mixture of a compound of Formula 1 -1 and a compound of Formula 1-2 can be heated at temperatures ranging between 50 °C and 120 °C in the presence of a base [such as cesium carbonate], a metal catalyst [such as a palladium catalyst, e.g., palladium(ll) acetate], and a ligand [such as 1 ,1 '- binaphthalene-2,2'-diylbis(diphenylphosphane) (BINAP)] in an appropriate solvent, such as 1 ,4-dioxane.
  • a base such as cesium carbonate
  • a metal catalyst such as a palladium catalyst, e.g., palladium(ll) acetate
  • a ligand such as 1 ,1 '- binaphthalene-2,2'-diylbis(diphenylphosphane) (BINAP)
  • Suitable reaction times are typically from 30 minutes to 48 hours.
  • a compound of Formula 1-3 can subsequently be reacted with a compound of Formula R 3 -M [wherein M can be B(OH) 2 ; B(OR) 2 wherein each R is independently H or C-i-6 alkyl, or wherein two (OR) groups, together with the B atom to which they are attached, form a 5- to 10-membered heterocyclic ring optionally substituted with one or more C-i-6 alkyl; a trialkyltin moiety; or the like] by a metal-catalyzed (such as using a palladium catalyst) coupling reaction to obtain a compound of Formula 1-4.
  • Compounds of Formula R 3 -M are commercially available or can be prepared by methods analogous to those described in the chemical art.
  • a compound of Formula 1-3 can be converted to a compound of Formula 1 -5 [wherein M is defined as above].
  • a compound of Formula 1 -5 can then be reacted with a compound of Formula R 3 -X [wherein X is defined as above] by a metal-catalyzed (such as using a palladium catalyst) coupling reaction to obtain a compound of Formula I.
  • Compounds of Formula R 3 -X are commercially available or can be prepared by methods analogous to those described in the chemical art. The type of reaction employed depends on the selection of X and M. For example, when X is halogen or triflate and the R 3 -M reagent is a boronic acid or boronic ester, a Suzuki reaction may be used [A.
  • Scheme 2 also refers to preparation of compounds of Formula I.
  • compounds of Formula I may be prepared utilizing analogous chemical transformations to those described in Scheme 1 , but with a different ordering of steps.
  • a compound of Formula 1 -1 (as in Scheme 1 ) can be converted to a compound of Formula 2-1 either directly or after conversion to a compound of Formula 2-2 using methods analogous to those described in Scheme 1.
  • a compound of Formula 2-1 may then be coupled to a compound of Formula 1 -2 as in Scheme 1 , to produce a compound of Formula 1-4.
  • the coupling conditions employed may be analogous to those described for the preparation of a compound of Formula 1-3 in Scheme 1 .
  • Scheme 3 refers to a preparation of a compound of Formula 1-1.
  • compounds of Formula 3-1 are commercially available or can be made by methods described herein or other methods well known to those skilled in the art.
  • a compound of Formula 3-1 can be treated with a strong base and the intermediate can be subsequently reacted with an electrophile to obtain a compound of Formula 1-1
  • suitable reaction conditions for the reaction include mixing a compound of Formula 3-1 with a suitable base, such as lithium diisopropylamide, in a suitable reaction solvent such as tetrahydrofuran. This is followed by addition of an electrophile such as an alkyl iodide or bromide.
  • Suitable temperatures for the aforesaid reaction are typically between -78 °C and 30 °C. Suitable reaction times typically are from 20 minutes to 48 hours.
  • a compound of Formula 1-1 can be converted to a compound of Formula I using chemistry described in Schemes 1 and 2.
  • Scheme 4 refers to a preparation of a compound of Formula 4-5, wherein X is a leaving group such as Br or I.
  • X is a leaving group such as Br or I.
  • compounds of Formula 4-1 (wherein each R is independently H or C-i-6 alkyl) and Formula 4-2 are commercially available or can be made by methods described herein or other methods well known to those skilled in the art.
  • a compound of Formula 4-3 can be prepared by condensation of a compound of
  • a compound of Formula 4-3 can be converted to a compound of Formula 4-4 by treatment with a chlorinating agent, such as phosphorus oxychloride, either in the presence of a suitable solvent or neat, at a temperature ranging between 70 °C and 120 °C and a reaction time of between 1 and 24 hours.
  • a chlorinating agent such as phosphorus oxychloride
  • a compound of Formula 4-4 may then be treated with an appropriate halogenating agent, such as /V-iodosuccinimide, in a suitable solvent, such as dichloromethane, to produce a compound of Formula 4-5.
  • a suitable solvent such as dichloromethane
  • Suitable reaction temperatures range from 0 °C to 50 °C, and suitable reaction times are typically from 30 minutes to 24 hours.
  • a compound of Formula 4-5 can be protected (i.e. the pyrrole ring nitrogen is protected) by methods well known in the art and then the corresponding protected compound can be converted to a compound of Formula I using chemistry described in Schemes 1 , 2 and 3.
  • Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatography-mass spectrometry (GCMS) instrumentation. Chemical shifts for nuclear magnetic resonance (NMR) data are expressed in parts per million (ppm, ⁇ ) referenced to residual peaks from the deuterated solvents employed.
  • LCMS liquid chromatography-mass spectrometry
  • APCI atmospheric pressure chemical ionization
  • GCMS gas chromatography-mass spectrometry
  • reaction conditions length of reaction and temperature
  • Purifications may vary between experiments: in general, solvents and the solvent ratios used for eluents/gradients were chosen to provide appropriate RfS or retention times.
  • Step 1 Synthesis of 4-chloro-5-iodo-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7/-/-pyrrolo[2,3- c ]pyrimidine (C1 ).
  • Morpholine (2.45 g, 28.1 mmol) and A/,/ ⁇ /-diisopropylethylamine (6.63 g, 51.3 mmol) were added to a solution of 4-chloro-5-iodo-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ - 7H-pyrrolo[2,3-c ]pyrimidine (C1 ) (10.5 g, 25.6 mmol) in n-butanol (300 mL), and the reaction mixture was heated at reflux for 18 hours, then concentrated under reduced pressure.
  • reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. After heating at reflux for 18 hours, the reaction mixture was cooled to room temperature, diluted with water (200 ml.) and extracted with ethyl acetate (3 x 200 ml_). The combined organic layers were washed with saturated aqueous sodium chloride solution (500 ml_), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by chromatography on silica gel (Gradient: 0% to 10% ethyl acetate in petroleum ether) afforded the product as a white solid. Yield: 2.0 g, 5.5 mmol, 55%.
  • Step 1 Synthesis of 5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7/-/-pyrrolo[2,3-c ]pyrimidine (C4).
  • reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. It was then heated at 100 °C for 18 hours. After concentration in vacuo, the residue was purified via chromatography on silica gel (Eluent: 1 :1 ethyl acetate / petroleum ether) to provide the product as a yellow solid. Yield: 200 mg, 0.48 mmol, 44%.
  • Step 3 Synthesis of 5-(1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidine (1 ).
  • Step 1 Synthesis of 4-chloro-5-iodo-6-methyl-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7/-/- pyrrolo[2,3-c ]pyrimidine (C6).
  • lodomethane (52.1 g, 367 mmol) was added at -78 °C, and the reaction mixture was allowed to stir at -20 °C for 2 hours. Saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with water (100 mL) and with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via chromatography on silica gel (Eluent: 10:1 petroleum ether / ethyl acetate) afforded the product as a yellow oil.
  • Step 1 Synthesis of 6-[4-(morpholin-4-yl)-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile (C10).
  • Step 2 Synthesis of 6-[7-(hydroxymethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidin- 5-yl]pyridine-2-carbonitrile (C11 ).
  • a solution of 6-[4-(morpholin-4-yl)-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile (C10) (1 10 mg, 0.252 mmol) in trifluoroacetic acid (3 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo to provide the product as a yellow oil, which was used for the next step without additional purification.
  • Step 1 Synthesis of 3-(4-chloro-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3- c ]pyrimidin-5-yl)benzonitrile (C12).
  • C12 4-chloro-5-iodo-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H- pyrrolo[2,3-c ]pyrimidine (C1 ) (8.2 g, 20 mmol), (3-cyanophenyl)boronic acid (3.2 g, 22 mmol) and potassium carbonate (8.3 g, 60 mmol) in a mixture of 1 ,2-dimethoxyethane and water (4: 1 ratio, 250 ml.) was added [1 , 1 - bis(diphenylphosphino)ferrocene]dichloropalladium(l l) (731 mg, 1.00 mmol).
  • Morpholine (871 mg, 10 mmol) and A/,/ ⁇ /-diisopropylethylamine (2.6 g, 20 mmol) were added to a solution of 3-(4-chloro-7H-pyrrolo[2,3-c/]pyrimidin-5-yl)benzonitrile (C14) (2.5 g, 9.8 mmol) in n-butanol (100 ml_), and the reaction mixture was heated at reflux for 3 hours. Solvents were removed in vacuo and the residue was purified using chromatography on silica gel (Eluent: 1 :1 ethyl acetate / petroleum ether).
  • Step 1 Synthesis of 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 H-pyrazole (C17).
  • the product was prepared from 4-chloro-5-iodo-2-methyl-7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-c ]pyrimidine (C23) according to the method described for synthesis of 3- ⁇ 4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c ]pyrimidin- 5-yl ⁇ benzonitrile (6) in Example 6. In this case, purification was carried out via silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) to provide the product as a yellow oil. Yield: 300 mg, 0.63 mmol, 67%. LCMS m/z 475.2 [M+H + ].
  • Step 1 Synthesis of ⁇ 3-[4-(dimethylamino)-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]phenyl ⁇ methanol (C26).
  • Step 1 Synthesis of 4-chloro-5-iodo-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7/-/-pyrrolo[2,3- c ]pyrimidine-6-carbaldehyde (C28).
  • Morpholine (1.09 g, 12.5 mmol) and A/,/ ⁇ /-diisopropylethylamine (2.94 g, 22.7 mmol) were added to a solution of 4-chloro-5-iodo-7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ - 7H-pyrrolo[2,3-c ]pyrimidine-6-carbaldehyde (C28) (5.0 g, 1 1 mmol) in acetonitrile (20 mL).
  • Example 199 and Example 200
  • Step 1 Synthesis of 3-(4-chloro-7H-pyrrolo[2,3-c ]pyrimidin-5-yl)tetrahydro-2/-/-pyran-3- ol (C32).
  • 4-chloro-5-iodo-7/-/-pyrrolo[2,3-c/]pyrimidine 1.5 g, 5.4 mmol
  • n-butyllithium 2.5 M, 6.4 mL, 16.1 mmol
  • Step 3 Synthesis of 5-(5,6-dihydro-2H-pyran-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidine (199) and 5-(3,4-dihydro-2/-/-pyran-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine (200).
  • Triethylsilane (10 mL) and trifluoroacetic acid (10 mL) were added over 10 minutes to a solution of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]tetrahydro- 2H-pyran-3-ol (C33) (40 mg, 0.13 mmol) in dichloromethane (10 mL).
  • the reaction mixture was stirred at room temperature for 2 hours, whereupon it was concentrated in vacuo.
  • Step 3 Synthesis of 4-(morpholin-4-yl)-5-[3-(1 ,2,4-oxadiazol-3-yl)phenyl]-7H- pyrrolo[2,3-c ]pyrimidine (201 ).
  • Triethyl orthoformate (760 mg, 5.1 mol) and boron trifluoride diethyl etherate (370 mg, 2.6 mol) were added to a 0 °C solution of A/'-hydroxy-3-[4-(morpholin-4-yl)-7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl]benzenecarboximidamide (C35) (600 mg, 1.3 mmol) in tetrahydrofuran (25 mL).
  • Trimethylsilyl trifluoromethanesulfonate (2.9 g, 13 mmol) and triethylsilane (2.6 g,
  • the product from the previous step was treated with a solution of trifluoroacetic acid in dichloromethane (1 :5 v/v; 2 ml_), and the reaction mixture was shaken at 30 °C for 2 hours. After concentration using the Speedvac®, the residue was treated with a solution of ammonium hydroxide in methanol (1 :4 v/v; 2 ml.) and shaken at 30 °C for 16 hours.
  • Solvents were removed on the Speedvac® and the product was purified via preparative HPLC using an appropriate gradient (Column: DIKMA Diamonsil(2) C18, 5 ⁇ or Agella Venusil ASB C18, 5 ⁇ ; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile).
  • the product solution from the preceding step ( ⁇ 125 ⁇ ) was mixed with a solution of the appropriate boronic acid in /V,/V-dimethylformamide (0.25 M, 500 ⁇ _, 125 ⁇ ).
  • An aqueous solution of cesium carbonate (1.25 M, 200 ⁇ _, 250 ⁇ ) was added, followed by [1 , 1 '-bis(di-ferf-butylphosphino)ferrocene]dichloropalladium(ll) (1.6 mg, 2.5 ⁇ ), and the reaction mixture was shaken at 120 °C for 4 hours. Removal of solvent using a Speedvac® provided a residue, which was used directly in the following step.
  • the product from the previous step ( ⁇ 125 ⁇ ) was treated with a solution of concentrated hydrochloric acid in ethanol (1 :6 v/v; 2 mL), and the reaction mixture was shaken at 80 °C for 16 hours. After removal of solvent via the Speedvac®, the residue was taken up in a solution of ammonium hydroxide (30% aqueous) in methanol (1 :4 v/v, 2 mL).
  • Table 1 provides Examples 1 1-197 and Examples 203-225 of the present invention, the structure of the compound, reference to the method of preparation and characterizing data for the compound.
  • Certain of the compounds depicted in the table are racemic and others are depicted as single enantiomers with the absolute stereochemistry as shown. In certain cases the racemic compound has been separated into the individual enantiomers, although the absolute stereochemistry of the single enantiomer(s) may not have been determined.
  • the individual separated enantiomers may be referred to as ENT-1 or ENT-2, which are abbreviations for the separated enantiomer-1 and enantiomer-2, respectively. It is to be understood that one of the compounds designated as ENT-1 or ENT-2 will have the ⁇ R) absolute stereochemistry at the chiral center while the other will have the (S) absolute stereochemistry.
  • This Example was the second-eluting enantiomer from the supercritical fluid chromatographic separation. 13.
  • Conditions for analytical HPLC Column: Waters XBridge C18, 2.1 x 50 mm, 5 ⁇ ; Mobile phase A: 0.05% ammonium hydroxide in water; Mobile phase B: acetonitrile; Gradient: 5% to 100% B over 3.40 minutes; Flow rate: 0.8 mL/minute.
  • the racemic product was separated into its enantiomers using supercritical fluid chromatography.
  • the racemic product was separated into its enantiomers using supercritical fluid chromatography.
  • This Example was the first-eluting enantiomer from the supercritical fluid chromatographic separation.
  • the requisite 2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholine may be prepared from 4- benzylmorpholine-2-carbonitrile using chemistry described by D. Sakai and K. Watanabe, PCT Int. Appl. 2009, WO 2009035159 A1 20090319.
  • the requisite 2- ⁇ [(6-methylpyridin-3-yl)oxy]methyl ⁇ morpholine may be prepared via a Mitsunobu reaction between ieri-butyl 2-(hydroxymethyl)morpholine-4-carboxylate and 6- methylpyridin-3-ol, followed by acidic removal of the protecting group.
  • 2- ⁇ [5-(Difluoromethyl)-1 ,2,4-oxadiazol-3-yl]methyl ⁇ morpholine may be prepared in the following manner: reaction of (4-benzylmorpholin-2-yl)acetonitrile with hydroxylamine hydrochloride and base provides 2-(4-benzylmorpholin-2-yl)-A/'-hydroxyethanimidamide. Coupling of this compound with difluoroacetic acid may be carried out using any of a number of coupling reagents, such as 1 ,3-dicyclohexylcarbodiimide. Subsequent cyclization using thermal conditions or tetrabutylammonium fluoride (see A. R. Gangloff et al., Tetrahedron Lett. 2001 , 42, 1441-1443), followed by debenzylation, provides the requisite amine.
  • 2-(Pyrimidin-4-yl)morpholine may be prepared from 1-(4-benzylmorpholin-2- yl)ethanone via conversion to the enamine and reaction with 1 ,3,5-triazine (see D. L. Boger et al., J. Org. Chem. 1982, 47, 2673-2675), followed by debenzylation.
  • 2-[(5-Methyl-1 ,2,4-oxadiazol-3-yl)methyl]morpholine may be prepared via the chemistry described in footnote 23, by employing acetic acid in place of difluoroacetic acid.
  • 2-Chloro-1-fluoro-3-iodo-4-methoxybenzene may be prepared by iodination of 2- chloro-1 -fluoro-4-methoxybenzene according to the method of R. Sanz et al., J. Org. Chem. 2007, 72, 51 13-51 18 .
  • 5-Bromoimidazo[2, 1-ib][1 ,3]thiazole may be prepared via bromination of imidazo[2, 1-
  • Example 213 was the second-eluting enantiomer
  • Example 214 was the first-eluting isomer, using a Chiral Technologies Chiralcel OJ-3 column, and gradient of 5% to 40% methanol in carbon dioxide containing 0.05% diethylamine.
  • the Suzuki reaction was carried out using bis[di-ieri-butyl(4- dimethylaminophenyl)phosphine]dichloropalladium(ll) and cesium fluoride in a mixture of 1 ,4- dioxane and water at 100 °C for 18 hours.
  • LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen.
  • GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat # PR8976A), in the presence of a dose response of compound.
  • EEM ezrin/radixin/moesin
  • PR8976A ezrin/radixin/moesin
  • the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat # PR8975A).
  • the assay was carried out under the following protocol: 3 ⁇ _ of a working solution of substrate (233 nM LRRKtide, 1 17 ⁇ ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCI 2 , with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate.
  • the compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half- log in DMSO 1 1 times.
  • the reaction was allowed to progress at room temperature for two hours and then stopped with the addition of 7 ⁇ - of detection buffer (20 mM Tris pH 7.6, 0.01 % NP-40, 0.02% NaN 3 , 6 mM EDTA with 2 nM terbium labeled anti-phospho-ERM). After an incubation of 1 hour at room temperature, the plate was read on an Envision with an excitation wavelength of 340 nm and a reading emission at both 520 nm and 495 nm. The ratio of the 520 nm and 495 nm emission was used to analyze the data.
  • Table 2 below, provides the LRRK2 IC50 data for the compounds of the invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3- c/]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Description

NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2
INHIBITORS Field of the Invention
The present invention relates to small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2). This invention also relates to methods of inhibiting, in mammals, including humans, LRRK2 by administration of the small molecule LRRK2 inhibitors. The present invention also relates to the treatment of Parkinson's Disease (PD) and other neurodegenerative and/or neurological disorders in mammals, including humans with the LRRK2 inhibitors. More particularly, this invention relates to 4-(substituted- amino)-7H-pyrrolo[2,3-c ]pyrimidine compounds useful for the treatment of neurodegenerative and/or neurological disorders, such as PD, Alzheimer's Disease (AD) and other LRRK2 associated disorders.
Background of the Invention
LRRK2 is a 286 kDa active protein kinase in the ROCO protein family with a complex multidomain structure and which has structural homology to the MAP kinase kinase kinases (MAPKKK). LRRK2 has been shown to phosphorylate moeisin (at Thr558), ezrin and radixin in vitro. LRRK2 has been found in various regions of the brain as well as in the heart, lung, spleen and kidney. Independent domains that have been established for the LRRK2 protein include an ankyrin-like (ANK) domain, a leucine-rich repeat (LRR) domain, a Ras (renin-angiotensin system) of complex (ROC) domain, a C- terminal of ROC (COR) domain, a kinase (Kinase) domain and a C-terminal WD40 domain. The ROC domain binds guanosine triphosphate (GTP) and the COR domain may be a regulator of the ROC domain's GTPase activity.
With multiple domains and both active kinase and guanosine triphosphatase (GTPase) activity, LRRK2 appears to play a complex role in multiple cellular processes. For example, LRRK2 has been associated with NFAT inhibition in the immune system and has been linked to vesicle trafficking, presynaptic homeostasis, mammalian target of rapamycin (mTOR) signaling, signaling through the receptor tyrosine kinase MET in papillary renal and thyroid carcinomas, cytoskeletal dynamics, the mitogen-activated protein kinase (MAPK) pathway, the tumor necrosis factor-a (TNF-a) pathway, the Wnt pathway and autophagy. Recent genome-wide association (GWA) genetic studies have implicated LRRK2 in the pathogenesis of various human diseases such as PD, inflammatory bowel disease (Crohn's disease), cancer and leprosy (Lewis, P.A. and Manzoni, C. Science Signaling 2012, 5(207), pe2).
Parkinson's Disease is a relatively common age-related neurodegenerative disorder resulting from the progressive loss of dopamine-producing neurons and which affects up to 4% of the population over 80. PD is characterized by both motoric and non-motoric symptoms such as tremor at rest, rigidity, akinesia and postural instability as well as non-motor symptoms such as impairment of cognition, sleep and sense of smell. Genome-wide association studies have linked LRRK2 to PD and many patients with point mutations in LRRK2 present symptoms that are indistinguishable from those with idiopathic PD. Over 20 LRRK2 mutations have been associated with autosomal- dominant parkinsonism, and the R1441 C, R1441 G, R1441 H, Y1699C, G2019S, I2020T and N1437H missense mutations are considered to be pathogenic. The LRRK2 R1441 G mutation has been shown to increase the release of proinflammatory cytokines (higher levels of TNF-a, I L- 1 β , IL-12 and lower levels of IL-10) in microglial cells from transgenic mice and thus may result in direct toxicity to neurons (Gillardon, F. et al. Neuroscience 2012, 208, 41-48). In a murine model of neuroinflammation, induction of LRRK2 in microglia was observed and inhibition of LRRK2 kinase activity with small molecule LRRK2 inhibitors (LRRK2-IN-1 or sunitinib) or LRRK2 knockout resulted in attenuation of TNF-a secretion and nitric oxide synthase (iNOS) induction (Moehle, M. et al. J. Neurosci. 2012, 32(5), 1602-161 1 ). The most common of the LRRK2 mutations, G2019S, is present in more than 85% of PD patients carrying LRRK2 mutations. This mutation, which is present in the LRRK2 kinase domain, leads to an enhancement of LRRK2 kinase activity. In the human brain LRRK2 expression is highest in the same regions of the brain that are impacted by PD, and LRRK2 is found in Lewy Bodies, a hallmark of PD. Recent studies indicate that a potent, selective, brain-penetrant kinase inhibitor for LRRK2 could be a therapeutic treatment for PD.
Dementia results from a wide variety of distinctive pathological processes. The most common pathological processes causing dementia are AD, cerebral amyloid angiopathy (CM) and prion-mediated diseases (see, e.g., Haan et al., Clin. Neurol. Neurosurg. 1990, 92(4):305-310; Glenner et al., J. Neurol. Sci. 1989, 94:1 -28). AD is a progressive, neurodegenerative disorder characterized by memory impairment and cognitive dysfunction. AD affects nearly half of all people past the age of 85, the most rapidly growing portion of the United States population. As such, the number of AD patients in the United States is expected to increase from about 4 million to about 14 million by 2050. LRRK2 mutations have been associated with AD-like pathology, which suggests that there may be a partial overlap between the neurodegenerative pathways in both AD and PD (Zimprach, A. et al. Neuron 2004, 44, 601-607). In addition, the LRRK2 R1628P variant (COR domain) has been associated with an increased incidence of AD in a certain population, perhaps resulting from increased apoptosis and cell death (Zhao, Y. et al.; Neurobiology of Aging 201 1 , 32, 1990-1993.
An increased incidence of certain non-skin cancers such as renal, breast, lung and prostate cancers, as well as acute myelogenous leukemia (AML), has been reported in Parkinson's disease patients with the LRRK2 G2019S mutation (Saunders- Pullman, R. et al.; Movement Disorders, 2010, 25(15), 2536-2541 ). Since the G2019S mutation is associated with increased LRRK2 kinase activity, inhibition of this activity may be useful in the treatment of cancer, such as kidney, breast, lung, prostate and blood cancers.
Inflammatory bowel disease (IBD) or Crohn's disease (CD) is a complex disease and is believed to result from an inappropriate immune response to microbiota in the intestinal tract. Genome-wide association studies have recently identified LRRK2 as a major susceptibility gene for Crohn's disease, particularly the M2397T polymorphism in the WD40 domain (Liu, Z. et al. Nat. Immunol. 201 1 , 12, 1063-1070). In a recent study LRRK2 deficient mice were found to be more susceptible to dextran sodium sulfate induced colitis than their wild-type counterparts, indicating that LRRK2 may play a role in the pathogenesis of IBD (Liu, Z. and Lenardo, M.; Cell Research 2012, 1-3).
Both non-selective and selective small molecule compounds with LRRK2 inhibitory activity such as staurosporine, sunitinib, LRRK2-IN-1 , CZC-25146, TAE684 and those in WO 201 1/141756, WO 2012/028629 and WO 2012/058193 have been described. It is desirable to provide compounds which are potent and selective inhibitors of LRRK2 with a favorable pharmacokinetic profile and the ability to to traverse the blood brain barrier. Accordingly, the present invention is directed to novel 4-(substituted-amino)-7H-pyrrolo[2,3-c ]pyrimidine compounds with LRRK2 inhibitory activity and the use of these compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases, including PD. Summary of the Invention
A first embodiment of a first aspect of the present invention is a compound of Formula I
Figure imgf000006_0001
or a pharmaceutically acceptable salt thereof wherein R1 and R2 are each independently hydrogen, d-Cealkyl, Ca-Czcycloalkyl, a four to seven membered heterocycloalkyi which contains one to three heteroatoms selected from N, O and S; or a five to six membered heteroaryl which contains one to four heteroatoms selected from N, O and S, wherein the C-pCealkyl, Ca-Czcycloalkyl, four to seven membered heterocycloalkyi, or five to six membered heteroaryl are optionally substituted with one to three R6; or R1 and R2 taken together with the nitrogen to which they are attached are a four to seven membered heterocycloalkyi which optionally contains one to two additional heteroatoms selected from N, O and S, and optionally contains one double bond; a six to eleven membered heterobicycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; or a six to twelve membered heterospirocycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; and wherein the four to seven membered heterocycloalkyi, six to eleven membered heterobicycloalkyl or six to twelve membered heterospirocycloalkyl is optionally substituted with one to three R7; R3 is phenyl or a five to ten membered heteroaryl which contains one to four heteroatoms selected from N, O and S; wherein the phenyl and five to ten membered heteroaryl are optionally substituted with one to three R9 and wherein the phenyl is optionally fused with a C5- Cecycloalkyl or a five to six membered heterocycloalkyi which contains one to three heteroatoms selected from N, O and S and which is optionally substituted with oxo; R4 and R5 are each independently hydrogen or Ci-C3alkyl; R6 at each occurrence is independently selected from Ci-C3alkyl, d-Caalkoxy, hydroxy, halo, -NRaRb, - C(0)NRaRb, or a four to seven membered heterocycloalkyi which contains one to three heteroatoms selected from N, O and S; R7 at each occurrence is independently selected from halo, hydroxy, cyano, -NRaRb, -C(0)NRaRb, C C6alkyl, C C6alkoxy, phenyl, a five to six membered heteroaryl containing one to four heteroatoms selected from N, O and S, or two R7 when attached to the same carbon and taken together can be oxo; wherein the Ci-C6alkyl, phenyl and five to six membered heteroaryl are optionally substituted with one to three R8; R8 at each occurrence is independently hydroxy, halo, cyano, d-dalkoxy, NRaRb, d-dalkyl optionally substituted with one to three halo, d-dcycloalkyl, phenoxy optionally substituted with cyano, or a five to six membered heteroaryloxy containing one to four heteroatoms selected from N, O and S and which is optionally substituted with one or two halo or C-|-C3alkyl; R9 at each occurrence is independently cyano, halo, hydroxy, Ci-C3alkyl-S-, -CO2H, -C(0)NH2, - S(0)2NH2, C C3alkyl optionally substituted with one to three halo or hydroxy, or d- Caalkoxy optionally substituted with one to three halo or hydroxy; and Ra and Rb at each occurrence are each independently hydrogen, d-Cealkyl, d-dcycloalkyl or -C(0)d- C6alkyl.
A second embodiment of a first aspect of the present invention is the compound of the first embodiment of the first aspect wherein R4 and R5 are each hydrogen; or a pharmaceutically acceptable salt thereof.
A third embodiment of a first aspect of the present invention is the compound of the second embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are azetidin-1 -yl, pyrrolidin-1-yl, piperidin-1 -yl, morpholin-4-yl, thiomorpholin-4-yl, 6-oxa-3-aza-bicyclo[3.1 .1]heptan-3-yl,
Figure imgf000007_0001
each of which is optionally substituted with one to three R7; or a pharmaceutically acceptable salt thereof.
A fourth embodiment of a first aspect of the present invention is the compound of the third embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are piperidin-1-yl or morpholin-4-yl; each optionally substituted with a hydroxy, methyl or 5-methyl-1 ,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable salt thereof.
A fifth embodiment of a first aspect of the present invention is the compound of the fourth embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are morpholin-4-yl optionally substituted with a methyl or 5-methyl-1 ,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable salt thereof.
A sixth embodiment of a first aspect of the present invention is the compound of the second embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are methylamino, dimethylamino, diethylamino, N- methylcyclopropylamino or pyrazolylamino; each of which is optionally substituted with one to three R6; or a pharmaceutically acceptable salt thereof.
An seventh embodiment of a first aspect of the present invention is the compound of the third embodiment of the first aspect wherein R3 is phenyl substituted with one or two R9; and each R9 is independently selected from cyano, fluoro, chloro or methoxy; or a pharmaceutically acceptable salt thereof.
An eighth embodiment of a first aspect the present invention is the compound of the third embodiment of the first aspect wherein R3 is pyrazolyl, isothiazolyl, or pyridinyl, each optionally substituted with one R9; and R9 is cyano or methyl; or a pharmaceutically acceptable salt thereof.
A ninth embodiment of a first aspect of the present invention is the compound of the first embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached is selected from the group consisting of:
Figure imgf000009_0001
R3 is 1-methylpyrazol-4-yl, 1 H-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1 ,2-thiazol-5- yl, 5-cyano-1-methylpyrrol-3-yl, 3-methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3- fluorophenyl, 2,3-difluorophenyl, 2-fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 2- methoxy-5-fluorophenyl; and R4 and R5 are each independently hydrogen or methyl; or a pharmaceutically acceptable salt thereof.
A tenth embodiment of a first aspect of the present invention is the compound of the ninth embodiment wherein R1 and R2 taken together with the nitrogen to which they are attached are a group selected from:
Figure imgf000010_0001
An eleventh embodiment of a first aspect of the present invention is the compound of the tenth embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are d is
Figure imgf000010_0002
or a pharmaceutically acceptable salt thereof.
A twelfth embodiment of a faspect of the present invention is the compound of the eleventh embodiment of the first aspect wherein R3 is 3-cyanophenyl, 1 - methylpyrazol-4-yl or 5-cyano-1-methylpyrrol-3-yl; or a pharmaceutically acceptable salt thereof.
A thirteenth embodiment of a first aspect of the present invention is the compound of the first embodiment of a first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are piperidinyl or 3-hydroxypiperidinyl; R3 is 1-methylpyrazol-4-yl, 1 H-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1 ,2-thiazol-5-yl, 3- methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3-difluorophenyl, 2- fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 2-methoxy-5-fluorophenyl; and R4 and R5 are each independently hydrogen or methyl; or a pharmaceutically acceptable salt thereof.
A fourteenth embodiment of a first aspect of the invention is a compound of the first embodiment of the first aspect selected from the group consisting of:
5- (1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile;
3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile; 3- {4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrro^
(3-{4-[(3S)-3-methylpiperidin-1 -yl]-7H-pyrrolo[2,3-o0pyrimidin-5-yl}phenyl)methan
4- (morpholin-4-yl)-5-(1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
{3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol;
3-[4-(3,3-dimethylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(piperidin-1-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
1-(5-phenyl-7H-pyrrolo[2,3-Q0pyrimidin-4-yl)piperidine-3-carboxamide;
3- {4-[(3S)-3-hydroxypiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-methylpiperidin-1-yl]-5-phenyl-7H-pyrrolo[2,3-c ]pyrimidine;
3- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-methylpiperidin-1-yl]-5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-o0pyrimidin
5- phenyl-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
[1-(5-phenyl-7H-pyrrolo[2,3-(^pyrimidin-4-yl)piperidin-4-yl]methanol;
1-{5-[3-(hydroxymethyl)phenyl]-7H-pyrrolo[2,3-<^py^
1-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-Q0pyrimidin-4-yl]piperidine-3-carbonitrile;
4-(3,5-c/'s-dimethylpiperidin-1-yl)-5-(1-methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidine;
4- methoxy-3-[4-(3-methylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile^
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-4-methoxybenzonitrile;
5- (5-chloro-2-methoxyphenyl)-/V,/V-dimethyl-7H-pyrro^^
3-{4-[4-(1 H-imidazol-2-yl)piperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitn 3-{4-[3-(methoxymethyl)piperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile; 3-[4-(9-methyl-1 -oxa-4,9-diazaspiro[5.5]undec-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5- yl]benzonitrile;
3-[4-(3-methoxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri /V3-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-<^p
3-[4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[4-(1 H-pyrazol-3-yl)piperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidin-5-yl}benzonitrile;
3-{4-[(3S)-3-fluoropyrrolidin-1 -yl]-7H-pyrrolo[2,3-Q0pyrimidin-5-yl}benzonitrile;
3-{4-[2-(1 H-pyrazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile; 3-{4-[3-(1 H-pyrazol-3-yl)piperidin-1-yl]-7H^
3-{4-[3-(1 H-imidazol-2-yl)piperidin-1-yl]-7H-pyrrolo[^^
3-{4-[(1 -methylpiperidin-3-yl)amino]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri 3-[4-(3-oxo-2J-diazaspiro[4.5]dec-7-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile;
3-[4-((3R)-3-methylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-(4-{[2-(morpholin-4-yl)ethyl]amino}-7H-pyrrolo[2,3-(^pyrimidin-5-yl)benzonitri 3-[4-(2-oxa-7-azaspiro[4.5]dec-7-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile; /V-{1 -[5-(3-cyanophenyl)-7H-pyrrolo[2,3-a0py
5-(1 H-indazol-5-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidine;
3- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzenesulfonami
5-(2-fluorophenyl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidine;
5-(1 H-indazol-4-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidine;
5-(6-fluoro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3- c ]pyrimidine;
5- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}-2,3-dihydro-1 H- isoindol-1-one;
4- [(3S)-3-methylpiperidin-1-yl]-5-(pyridin-3-yl)-7H-pyrrolo[2,3-Q0pyrimidine;
4-[(3S)-3-methylpiperidin-1-yl]-5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-o0pyrimidine;
4-[(3S)-3-methylpiperidin-1-yl]-5-(7H-pyrrolo[2,3-6]pyridin-5-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
6- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}-2,3-dihydro-1 H- isoindol-1-one;
4-[(3S)-3-methylpiperidin-1-yl]-5-(1 H-pyrrolo[3,2-0]pyridin-6-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
4-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}phenol;
4- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzamide;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}phenol;
5- (2-chloro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1 -yl]-7/-/-pyrrolo[2,3- c ]pyrimidine;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzamide;
3-[4-(3-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(4-methylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzoic acid; 3-[4-(methylamino)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile; 3- [4-(3,5-c/'s-dimethylpiperidin-1-yl)-^
methoxybenzonitrile;
4- methoxy-3-{4-[(3S)-3-methylpiperidin-1-yl]-7H^
2- fluoro-3-{4-[(3S)-3-methylpiperidin-1 -yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri
/V,/V-dimethyl-5-phenyl-7H-pyrrolo[2,3-( ]pyrimidin-4-amine;
3- [4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-2-fluorobenzonitrile;
3-[4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-((3R)-3-methylpyrrolidin-1 -yl)-7H-pyrrolo^
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-4-fluorobenzonitrile;
3-[4-(diethylamino)-7H-pyrrolo[2,3-( ]pyrimidin-5-yl]benzonitrile;
3-{4-[(2/?)-2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5- yl}benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-5-fluorobenzonitrile;
3-{4-[2-(1 H-pyrazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-^
3-[4-((3S)-3-methylpyrrolidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
2- fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3- {4-[(2/?)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri
4- fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
4- (4-fluoropiperidin-1 -yl)-5-(1 -methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
2-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-( ]pyrimidin-5-yl]benzonitrile;
5- (3-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3-fluoro-5-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(2,5-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-( ]pyrimidine;
{2-fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol; 5-(2,4-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3,5-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
4- (morpholin-4-yl)-5-phenyl-7/-/-pyrrolo[2,3-c ]pyrimidine;
5- (5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(2-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine; 5-(5-fluoro-2-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(3-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
{2-fluoro-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol;
5-(4-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
{3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol;
5-(2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-[3-(methylsulfanyl)phenyl]-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
4-(morpholin-4-yl)-5-(pyridin-3-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]isoquinoline;
5- (5-bromopyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2-chloro-5-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-( ]pyrimidine;
5-(3-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(1 -methyl-1 H-pyrazol-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3-[4-(4-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
3-methyl-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-Q0pyrimidin-5- yl}benzonitrile;
3-[4-(6-oxa-3-azabicyclo[3.1.1]hept-3-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile;
3- chloro-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
4- methoxy-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
5- (5-chloro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
6- methyl-5-(1 -methyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
3- methoxy-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
5-(1 -methyl-1 H-pyrazol-4-yl)-4-(thiomorpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine; 1 -[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-4-yl]piperidin-3-ol;
4- [(2S)-2-methylmorpholin-4-yl]-5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
4-[(2R)-2-methylmorpholin-4-yl]-5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
4-(3-fluoropiperidin-1 -yl)-5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-</]pyrimidine; {4-[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-4-yl]morpholin-2- yl}methanol; 5-(1-methyl-1 H-pyrazol-4-yl)-4-(2-{[(6-methylpyridin-3-yl)oxy]methyl}morpholin pyrrolo[2,3-c ]pyrimidine;
/V,/V-dimethyl-5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrro^
/V-cyclopropyl-/V-methyl-5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-4- amine;
3-[4-(3,3-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile;
3-[4-(3-aminopiperidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(2-{[5-(difluoromethyl)-1 ,2,4-oxadiazol-3-yl]methyl}morpholin-4-yl)-7H-pyrrolo[2,3- c ]pyrimidin-5-yl]benzonitrile;
3-{4-[2-(1 ,3-thiazol-2-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitri
3-[4-(4-oxopiperidin-1-yl)-7H-pyrrolo[2,3-( ]pyrimidin-5-yl]benzonitrile;
3-{4-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5- yl}benzonitrile;
3-{4-[2-(3-hydroxyphenyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile
3-{4-[2-(5-cyclopropyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
3-[4-(3,3-difluoropyrrolidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-(4-{2-[(3-cyanophenoxy)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-(^pyrimidin-5- yl)benzonitrile;
3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
1-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-Q0pyrimidin-4-yl]piperidine-3-carboxamide;
3-[4-(2-ethylmorpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(pyrimidin-4-yl)morpholin-4-yl]-7H-pyrroto^
3-{4-[2-(3-cyclopropyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
3-(4-{2-[(dimethylamino)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-(^pyrimidin-5- yl)benzonitrile;
3-[4-(1 H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-(4-{2-[(5-methyl-1 ,2,4-oxadiazol-3-yl)methyl]morpholin-4-yl}-7H-pyrrolo[2,3- c ]pyrimidin-5-yl)benzonitrile;
3-{4-[3-(5-methyl-1 ,3,4-oxadiazol-2-yl)piperidin-1-yl]-7H-pyrrolo[2,3-o ]pyrimidin-5- yl}benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-5-methoxybenzonitrile;
5-(1-ethyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine; 5-(5-chloropyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(6-methoxypyrazin-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine; 3-{4-[(3S)-3-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
2- fluoro-3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,^^
3- {4-[(3R)-3-hydroxypiperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
1- [5-(3-fluorophenyl)-7H-pyrrolo[2,3-c ]pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/- pyrrolo[2,3-c ]pyrimidine;
2- fluoro-3-[4-(4-fluoropiperidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
4- (4-fluoropiperidin-1 -yl)-5-(2-methoxyphenyl)-7H-pyrrolo[2,3-c ]pyrimidine;
5- (3-fluoro-5-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidine;
3- [4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-2-fluorobenzonitrile;
1-[5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-Q0pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidine;
1-[5-(3-fluoro-5-methoxyphenyl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]piperidin-3-ol;
1- [5-(2-methoxyphenyl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]piperidin-3-ol;
2- fluoro-3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
2-fluoro-3-{4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5- yl}benzonitrile;
4- (azetidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-7H-pyrrolo[2,3-c ]pyrimidine;
4- [(2S)-2-methylmorpholin-4-yl]-5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-(^pyrimidi
5- (3-fluorophenyl)-4-(pyrrolidin-1-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
5-(3-fluorophenyl)-4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3- c ]pyrimidine;
5-(2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidine;
5-(2-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-(^pyrimidin-4-amine;
2-fluoro-3-{4-[(3S)-3-fluoropyrrolidin-1 -yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-fluoropyrrolidin-1-yl]-5-(2-methoxyphenyl)-7H-pyrrolo[2,3-Q0pyrimidine;
5- (2-methoxyphenyl)-4-(pyrrolidin-1 -yl)-7H-pyrrolo[2,3-c/]pyrimidine;
5-(3-fluoro-5-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-(^pyrimidin-4-amine 2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile; 5-(5-fluoro-2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3- c ]pyrimidine;
2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2^
5-(5-fluoro-2-methoxyphenyl)-4-(3-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(3-fluorophenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidine;
5-(5-fluoro-2-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo^
2-fluoro-3-[4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidine;
2- fluoro-3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
5-(4-methyl-1 ,3-thiazol-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(4-methylpyridin-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2-fluoro-6-methoxyphenyl)-/V,/V-dimethyl-^
5-(2-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2,6-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3-methyl-1 ,2-thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(2-chloro-3-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine
5-(4-methoxypyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3- {4-[2-((5 ?)-5-methyl-1 ,2,4-oxadiazol-3-yl)morpho
yl}benzonitrile;
3-{4-[2-((5S)-5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
3-{4-[(2S)-2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-Q0pyrimidin-5- yl}benzonitrile;
or a pharmaceutically acceptable salt thereof.
A fifteenth embodiment of a first aspect of the present invention is a compound of the first embodiment of a first aspect selected from the group consisting of:
5- (1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile;
3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
3- {4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl}benzonitrile;
4- (morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3-[4-(piperidin-1-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile; 2-fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitn
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
1- [5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]piperidin-3-ol;
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
2- fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitri 2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2^
2- fluoro-3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
5-(3-methyl-1 ,2-thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine; and
3- {4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
or a pharmaceutically acceptable salt thereof.
A sixteenth embodiment of a first aspect of the present invention is the compound of the first embodiment of the first aspect selected from the group consisting of:
3- [6-(difluoromethyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile; 5-(5,6-dihydro-2/-/-pyran-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
5-(3,4-dihydro-2/-/-pyran-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
4- (morpholin-4-yl)-5-[3-(1 ,2,4-oxadiazol-3-yl)phenyl]-7/-/-pyrrolo[2,3-c ]pyrimidine;
3- {4-[2-(3-methyl-1 ,2-oxazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c ]pyrimidin-5- yl}benzonitrile;
2-methyl-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]pyridin-2(1 /-/)-one;
5- (imidazo[2, 1-6][1 ,3]thiazol-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
re/-3-{4-[(3aS,6aS)-hexahydro-5H-furo[2,3-c]pyrrol-5-yl]-7H-pyrrolo[2,3-c ]pyrimidin-5- yl}benzonitrile;
re/-3-{4-[(3aR,6aS)-tetrahydro-1 H-furo[3,4-c]pyrrol-5(3H)-yl]-7H-pyrrolo[2,3-c ]pyrimidin- 5-yl}benzonitrile; re/-3-{4-[(4aR,7aS)-hexahydrocyclopenta[b][1 ,4]oxazin-4(4aH)-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
4- [5-(3-cyanophenyl)-7H-pyrrolo[2,3-<^pyrimidin-4-yl]m
3- [4-(2,2-dimethylmorpholin-4-yl)-7H-pyrrolo[2,3-<^p
5- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]thiophene-2-carboni
5- (imidazo[1 ,2-6]pyridazin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidi
2-fluoro-3-{4-[2(R)-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
2- fluoro-3-{4-[2(S)-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
6- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]pyridine-2-carboxamide^
4- (morpholin-4-yl)-5-(pyrazolo[1 ,5-a]pyrimidin-3-yl)-7H-pyrrolo[2,3-o0pyrimidi
1-methyl-4-[4-(morpholin-4-yl)-7H-pyTO^
5- (6-methylimidazo[2, 1 -b][1 ,3]thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
3- {4-[2-(1 ,2-oxazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzoni
1-methyl-4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-1 H-imi
carbonitrile;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]thiophene-2-carboni
4-(morpholin-4-yl)-5-(pyrazolo[1 ,5-a]pyridin-3-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
1 ,5-dimethyl-4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-1 H-pyTO
carbonitrile;
1-methyl-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1 /-/-pyrazole-5- carbonitrile; and
3-{4-[2-(cyanomethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
or a pharmaceutically acceptable salt thereof.
A first embodiment of a second aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the first through sixteenth embodiments of the first aspect of the invention, or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier. A first embodiment of a third aspect of the present invention is a method of treating Parkinson's disease in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to any one of the first through sixteenth embodiments of the first aspect of the invention.
Another aspect of the present invention is the compound or pharmaceutically acceptable salt thereof according to any one of the first through sixteenth embodiments of the first aspect of the invention for use in the treatment of Parkinson's disease.
Another aspect of the present invention is the use of any of the preceding compounds of formula I and their compositions for inhibiting LRRK2 kinase. In a further embodiment, the compounds of formula I or compositions thereof are useful for treating a neurodegenerative disease. In yet another embodiment, the neurodegenerative disease is Parkinson's Disease.
Accordingly, the invention is also directed to methods of treating a patient (preferably a human) for diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease, by administering a therapeutically effective amount of a compound of any of the embodiments of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The invention is also directed to methods of inhibiting LRRK2 kinase activity, by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, to a mammal or a patient in need thereof. The invention is also directed to methods of treating disorders responsive to the inhibition of LRRK2 kinase activity, such as neurological disorders (particularly Parkinson's disease), certain cancers, and certain immunological disorders (such as Crohn's disease and leprosy) by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, to a mammal or a patient in need thereof.
The invention is also directed to methods for treating conditions or diseases of the central nervous system and neurological disorders in which the LRRK2 kinase is involved, particularly Parkinson's disease (but also including other neurological diseases which may include migraine; epilepsy; Alzheimer's disease; brain injury; stroke; cerebrovascular diseases (including cerebral arteriosclerosis, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, and brain hypoxia-ischemia); cognitive disorders (including amnesia, senile dementia, HlV-associated dementia, Alzheimer's disease, Huntington's disease, Lewy body dementia, vascular dementia, drug-related dementia, tardive dyskinesia, myoclonus, dystonia, delirium, Pick's disease, Creutzfeldt- Jacob disease, HIV disease, Gilles de la Tourette's syndrome, epilepsy, muscular spasms and disorders associated with muscular spasticity or weakness including tremors, and mild cognitive impairment); mental deficiency (including spasticity, Down syndrome and fragile X syndrome); sleep disorders (including hypersomnia, circadian rhythm sleep disorder, insomnia, parasomnia, and sleep deprivation) and psychiatric disorders such as anxiety (including acute stress disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, post-traumatic stress disorder, agoraphobia, and obsessive-compulsive disorder); factitious disorder (including acute hallucinatory mania); impulse control disorders (including compulsive gambling and intermittent explosive disorder); mood disorders (including bipolar I disorder, bipolar II disorder, mania, mixed affective state, major depression, chronic depression, seasonal depression, psychotic depression, seasonal depression, premenstrual syndrome (PMS) premenstrual dysphoric disorder (PDD), and postpartum depression); psychomotor disorder; psychotic disorders (including schizophrenia, schizoaffective disorder, schizophreniform, and delusional disorder); drug dependence (including narcotic dependence, alcoholism, amphetamine dependence, cocaine addiction, nicotine dependence, and drug withdrawal syndrome); eating disorders (including anorexia, bulimia, binge eating disorder, hyperphagia, obesity, compulsive eating disorders and pagophagia); sexual dysfunction disorders; urinary incontinence; neuronal damage disorders (including ocular damage, retinopathy or macular degeneration of the eye, tinnitus, hearing impairment and loss, and brain edema) and pediatric psychiatric disorders (including attention deficit disorder, attention deficit/hyperactive disorder, conduct disorder, and autism) in a mammal, preferably a human, comprising administering to said mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.
The text revision of the fourth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR) (2000, American Psychiatric Association, Washington D.C.) provides a diagnostic tool for identifying many of the disorders described herein. The skilled artisan will recognize that there are alternative nomenclatures, nosologies, and classification systems for disorders described herein, including those as described in the DMS-IV-TR, and that terminology and classification systems evolve with medical scientific progress.
Preferred methods are for treating a neurological disorder, most preferably Parkinson's disease, (but also other neurological disorders such as migraine; epilepsy; Alzheimer's disease; Niemann-Pick type C; brain injury; stroke; cerebrovascular disease; cognitive disorder; sleep disorder) or a psychiatric disorder (such as anxiety; factitious disorder; impulse control disorder; mood disorder; psychomotor disorder; psychotic disorder; drug dependence; eating disorder; and pediatric psychiatric disorder) in a mammal, preferably a human, comprising administering to said mammal a therapeutically effective amount of a compound of Formula I or pharmaceutically acceptable salt thereof. In addition, the compounds of Formula I and pharmaceutically acceptable salts thereof may also be employed in methods of treating other disorders associated with LRRK2 such as Crohn's disease, leprosy and certain cancers, such as kidney, breast, lung, prostate, lung and blood cancer.
Also provided herein are compositions comprising a pharmaceutically effective amount of one or more of the compounds described herein and a pharmaceutically acceptable vehicle, carrier or excipient.
The present invention is also directed to the use of a combination of a LRRK2 inhibitor compound of formula I, and one or more additional pharmaceutically active agent(s).
Other features and advantages of this invention will be apparent from this specification and the appendent claims which describe the invention. Definitions
The term "alkyl" refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen); in one embodiment from one to six carbon atoms (i.e., C-i-Cealkyl); in another embodiment, from one to three carbon atoms (i.e., C Caalkyl). Examples of such substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and ferf-butyl), pentyl, isoamyl, hexyl and the like.
The term "alkoxy" refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen) which is in turn attached to an oxygen atom; in one embodiment from one to six carbon atoms (i.e., C-i-Cealkoxy); in another embodiment, from one to three carbon atoms (i.e., C-i-C3alkoxy). Examples of such substituents include methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, sec-butoxy and ferf-butoxy), pentoxy and the like.
The term "cycloalkyl" refers to a carbocyclic substituent obtained by removing a hydrogen from a saturated carbocyclic molecule and having the specified number of carbon atoms. In one embodiment, a cycloalkyl substituent has three to seven carbon atoms (i.e., C3-C7cycloalkyl). Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term "cycloalkyl" includes mono-, bi- and tricyclic saturated carbocycles, as well as bridged and fused ring carbocycles, as well as spiro-fused ring systems.
In some instances, the number of atoms in a cyclic substituent containing one or more heteroatoms (i.e., heteroaryl or heterocycloalkyl) is indicated by the prefix "x to y membered", wherein x is the minimum and y is the maximum number of atoms forming the cyclic moiety of the substituent. The term "heterocycloalkyl" refers to a substituent obtained by removing a hydrogen from a saturated or partially saturated ring structure containing the specified number of ring atoms, wherein at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. If the heterocycloalkyl substituent is in turn substituted with a group or substituent, the group or substituent may be bound to a nitrogen heteroatom, or it may be bound to a ring carbon atom, as appropriate. As used herein, the term "heterocycloalkyl" as used herein refers to a monocyclic ring system containing the heteroatoms N, O or S as specified. Thus, for example, "four to seven membered heterocycloalkyl" refers to a heterocycloalkyl containing from 4 to 7 atoms, including one or more heteroatoms, in the cyclic moiety of the heterocycloalkyl. The term "heterobicycloalkyl" as used herein refers to a non-spiro bicyclic ring system containing the heteroatoms N, O or S as specified. Thus, for example, "six to twelve membered heterobicycloalkyl" refers to a heterobicycloalkyl containing from 6 to 12 atoms, including one or more heteroatoms, in the cyclic moieties of the heterobicycloalkyl. The term "heterospirocycloalkyl" as used herein refers to a spirocyclic ring system containing the heteroatoms N, O or S as specified. For example, "six to twelve membered heterospirocycloalkyl" means a six to twelve membered spirocyclic ring system which contains at least one heteroatom as specified.
The term "hydrogen" refers to a hydrogen substituent, and may be depicted as
-H.
The term "hydroxy" or "hydroxyl" refers to -OH. Compounds bearing a carbon to which one or more hydroxy substituents are attached include, for example, alcohols, enols and phenol.
The term "halo" or "halogen" refers to fluoro (which may be depicted as -F), chloro (which may be depicted as -CI), bromo (which may be depicted as -Br), or iodo (which may be depicted as -I).
The term "heteroaryl" refers to an aromatic ring structure containing the specified number of ring atoms in which at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. A five to six membered heteroaryl is an aromatic ring system which has five or six ring atoms with at least one of the ring atoms being N, O or S. Similarly, a five to ten membered heteroaryl is an aromatic ring system which has five to ten ring atoms with at least one of the ring atoms being N, O or S. A heteroaryl may be a single ring or 2 fused rings. Examples of heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, and pyridazinyl; 5-membered ring substituents such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1 ,2,3-, 1 ,2,4-, 1 ,2,5-, or 1 ,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, isobenzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl; and 6/6-membered fused rings such as quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and 1 ,4-benzoxazinyl. In a group that has a heteroaryl substituent, the ring atom of the heteroaryl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom. Similarly, if the heteroaryl substituent is in turn substituted with a group or substituent, the group or substituent may be bound to the at least one heteroatom, or it may be bound to a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom. The term "heteroaryl" also includes pyridyl /V-oxides and groups containing a pyridine /V-oxide ring.
Examples of single-ring heterocycloalkyls include azetidinyl, oxetanyl, thietanyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, dihydropyranyl, piperidinyl, morpholinyl, piperazinyl, azepinyl, oxepinyl, thiepinyl, and diazepinyl.
Examples of 2-fused-ring heteroaryls include, indolizinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-6]-pyridinyl, pyrido[3,2-6]-pyridinyl, or pyrido[4,3-6]-pyridinyl), and pteridinyl, indolyl, isoindolyl, indoleninyl, isoindazolyl, benzazinyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl, benzopyranyl, benzothiopyranyl, benzoxazolyl, indoxazinyl, anthranilyl, benzodioxolyl, benzodioxanyl, benzoxadiazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, benzothiazolyl, benzothiadiazolyl, benzimidazolyl, benzotriazolyl, benzoxazinyl, benzisoxazinyl, pyrrolopyridinyl, pyrazolopyridinyl and imidazothiazolyl.
Other examples of fused-ring heteroaryls include benzo-fused heteroaryls such as indolyl, isoindolyl, indoleninyl, isoindazolyl, benzazinyl (including quinolinyl or isoquinolinyl), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl or quinazolinyl).
The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-2-yl (C-attached).
If substituents are described as being "independently selected" from a group, each instance of a substituent is selected independent of the other. Each substituent therefore may be identical to or different from the other substituent(s).
As used herein the term "formula I" or "Formula I" may be referred to as a "compound(s) of the invention." Such terms are also defined to include all forms of the compound of formula I, including hydrates, solvates, isomers, crystalline and noncrystalline forms, isomorphs, polymorphs, and metabolites thereof. For example, the compounds of the invention, or pharmaceutically acceptable salts thereof, may exist in unsolvated and solvated forms. When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
The compounds of the invention may exist as clathrates or other complexes.
Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein the drug and host are present in stoichiometric or non- stoichiometric amounts. Also included are complexes of the compounds of the invention containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J. Pharm. Sci., 64 (8), 1269-1288 by Haleblian (August 1975).
The compounds of the invention may have asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line ( ), a solid wedge ( "^^ ), or a dotted wedge ( '" ). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers (e.g., specific enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of Formula I may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included. For example, unless stated otherwise, it is intended that the compounds of Formula I can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of Formula I and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
Stereoisomers of Formula I include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, geometric isomers, rotational isomers, conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs). Also included are acid addition or base addition salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.
When any racemate crystallizes, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
The present invention comprises the tautomeric forms of compounds of the invention. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism ('tautomerism') can occur. This can take the form of proton tautomerism in compounds of the invention containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism. The various ratios of the tautomers in solid and liquid form is dependent on the various substituents on the molecule as well as the particular crystallization technique used to isolate a compound.
The compounds of this invention may be used in the form of salts derived from inorganic or organic acids. Depending on the particular compound, a salt of the compound may be advantageous due to one or more of the salt's physical properties, such as enhanced pharmaceutical stability in differing temperatures and humidities, or a desirable solubility in water or oil. In some instances, a salt of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
Where a salt is intended to be administered to a patient (as opposed to, for example, being used in an in vitro context), the salt preferably is pharmaceutically acceptable. The term "pharmaceutically acceptable salt" refers to a salt prepared by combining a compound of formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption. Pharmaceutically acceptable salts are particularly useful as products of the methods of the present invention because of their greater aqueous solubility relative to the parent compound. For use in medicine, the salts of the compounds of this invention are non-toxic "pharmaceutically acceptable salts." Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Suitable pharmaceutically acceptable acid addition salts of the compounds of the present invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
Specific examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylaminosulfonate, β-hydroxybutyrate, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, and undecanoate.
Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, i.e., sodium or potassium salts; alkaline earth metal salts, e.g., calcium or magnesium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. In another embodiment, base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.
Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, Λ/,Λ/'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (/V-methylglucamine), and procaine. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl (CrCe) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e., dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.
In one embodiment, hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.
Also within the scope of the present invention are so-called "prodrugs" of the compound of the invention. Thus, certain derivatives of the compound of the invention which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into the compound of the invention having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as "prodrugs." Further information on the use of prodrugs may be found in "Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella) and "Bioreversible Carriers in Drug Design," Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association). Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of any of formula I with certain moieties known to those skilled in the art as "pro-moieties" as described, for example, in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985).
The present invention also includes isotopically labeled compounds, which are identical to those recited in formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 11C, 14C, 15N, 180, 170, 32P, 35S, 18F, and 36CI, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
DETAILED DESCRIPTION OF THE INVENTION
Typically, a compound of the invention is administered in an amount effective to treat a condition as described herein. The compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the medicinal arts.
The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above. The term "treating" also includes adjuvant and neo-adjuvant treatment of a subject.
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed, by which the compound enters the blood stream directly from the mouth.
In another embodiment, the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
In another embodiment, the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. In another embodiment, the compounds of the invention can also be administered intranasally or by inhalation. In another embodiment, the compounds of the invention may be administered rectally or vaginally. In another embodiment, the compounds of the invention may also be administered directly to the eye or ear.
The dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, age, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 100 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions. In one embodiment, the total daily dose of a compound of the invention (administered in single or divided doses) is typically from about 0.01 to about 100 mg/kg. In another embodiment, the total daily dose of the compound of the invention is from about 0.1 to about 50 mg/kg, and in another embodiment, from about 0.5 to about 30 mg/kg (i.e., mg compound of the invention per kg body weight). In one embodiment, dosing is from 0.01 to 10 mg/kg/day. In another embodiment, dosing is from 0.1 to 1 .0 mg/kg/day. Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the compound will be repeated a plurality of times in a day (typically no greater than 4 times). Multiple doses per day typically may be used to increase the total daily dose, if desired.
For oral administration, the compositions may be provided in the form of tablets containing from about 0.01 mg to about 500 mg of the active ingredient, or in another embodiment, from about 1 mg to about 100 mg of active ingredient. Intravenously, doses may range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
Suitable subjects according to the present invention include mammalian subjects. Mammals according to the present invention include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In one embodiment, humans are suitable subjects. Human subjects may be of either gender and at any stage of development.
In another embodiment, the invention comprises the use of one or more compounds of the invention for the preparation of a medicament for the treatment of the conditions recited herein. For the treatment of the conditions referred to above, the compound of the invention can be administered as compound per se. Alternatively, pharmaceutically acceptable salts are suitable for medical applications because of their greater aqueous solubility relative to the parent compound.
In another embodiment, the present invention comprises pharmaceutical compositions. Such pharmaceutical compositions comprise a compound of the invention presented with a pharmaceutically acceptable carrier. The carrier can be a solid, a liquid, or both, and may be formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compounds. A compound of the invention may be coupled with suitable polymers as targetable drug carriers. Other pharmacologically active substances can also be present.
The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and compositions, for example, may be administered orally, rectally, parenterally, or topically.
Oral administration of a solid dose form may be, for example, presented in discrete units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of at least one compound of the present invention. In another embodiment, the oral administration may be in a powder or granule form. In another embodiment, the oral dose form is sub-lingual, such as, for example, a lozenge. In such solid dosage forms, the compounds of formula I are ordinarily combined with one or more adjuvants. Such capsules or tablets may contain a controlled-release formulation. In the case of capsules, tablets, and pills, the dosage forms also may comprise buffering agents or may be prepared with enteric coatings.
In another embodiment, oral administration may be in a liquid dose form. Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art (e.g., water). Such compositions also may comprise adjuvants, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents. In another embodiment, the present invention comprises a parenteral dose form. "Parenteral administration" includes, for example, subcutaneous injections, intravenous injections, intraperitoneal injections, intramuscular injections, intrasternal injections, and infusion. Injectable preparations (e.g., sterile injectable aqueous or oleaginous suspensions) may be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents.
In another embodiment, the present invention comprises a topical dose form. "Topical administration" includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration. Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams. A topical formulation may include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. When the compounds of this invention are administered by a transdermal device, administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated; see, for example, J. Pharm. Sci., 88 (10), 955-958, by Finnin and Morgan (October 1999).
Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier. A typical formulation suitable for ocular or aural administration may be in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g., absorbable gel sponges, collagen) and nonbiodegradable (e.g., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, (hydroxypropyl)methyl cellulose, hydroxyethyl cellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant. Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1 , 1 , 1 ,2-tetrafluoroethane or 1 , 1 , 1 ,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
In another embodiment, the present invention comprises a rectal dose form. Such rectal dose form may be in the form of, for example, a suppository. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Other carrier materials and modes of administration known in the pharmaceutical art may also be used. Pharmaceutical compositions of the invention may be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures. The above considerations in regard to effective formulations and administration procedures are well known in the art and are described in standard textbooks. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe et al., Eds., Handbook of Pharmaceutical Excipients (3rd Ed.), American Pharmaceutical Association, Washington, 1999.
The compounds of the present invention can be used, alone or in combination with other therapeutic agents, in the treatment of various conditions or disease states. The compound(s) of the present invention and other therapeutic agent(s) may be may be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially. Two or more compounds may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
The phrases "concurrent administration," "co-administration," "simultaneous administration," and "administered simultaneously" mean that the compounds are administered in combination.
The present invention includes the use of a combination of a LRRK2 inhibitor compound as provided in formula I and one or more additional pharmaceutically active agent(s). If a combination of active agents is administered, then they may be administered sequentially or simultaneously, in separate dosage forms or combined in a single dosage form. Accordingly, the present invention also includes pharmaceutical compositions comprising an amount of: (a) a first agent comprising a compound of formula I or a pharmaceutically acceptable salt of the compound; (b) a second pharmaceutically active agent; and (c) a pharmaceutically acceptable carrier, vehicle or diluent.
Various pharmaceutically active agents may be selected for use in conjunction with the compounds of Formula I, depending on the disease, disorder, or condition to be treated. For example, a pharmaceutical composition for use in treating Parkinson's disease may comprise a compound of formula I or a pharmaceutically acceptable salt thereof together with another agent such as a dopamine (levodopa, either alone or with a DOPA decarboxylase inhibitor), a monoamine oxidase (MAO) inhibitor, a catechol O- methyltransferase (COMT) inhibitor or an anticholinergic agent, or any combination thereof. Particularly preferred agents to combine with the compounds of formula I for use in treating Parkinson's disease include levodopa, carbidopa, tolcapone, entacapone, selegiline, benztropine and trihexyphenidyl, or any combination thereof. Pharmaceutically active agents that may be used in combination with the compounds of formula I and compositions thereof include, without limitation:
(i) levodopa (or its methyl or ethyl ester), alone or in combination with a DOPA decarboxylase inhibitor (e.g., carbidopa (SINEMET, CARBILEV, PARCOPA), benserazide (MADOPAR), omethyldopa, monofluoromethyldopa, difluoromethyldopa, brocresine, or m-hydroxybenzylhydrazine); (ii) anticholinergics, such as amitriptyline (ELAVIL, ENDEP), butriptyline, benztropine mesylate (COGENTIN), trihexyphenidyl (ARTANE), diphenhydramine (BENADRYL), orphenadrine (NORFLEX), hyoscyamine, atropine (ATROPEN), scopolamine (TRANSDERM-SCOP), scopolamine methylbromide (PARMINE), dicycloverine (BENTYL, BYCLOMINE, DIBENT, DILOMINE), tolterodine (DETROL), oxybutynin (DITROPAN, LYRINEL XL, OXYTROL), penthienate bromide, propantheline (PRO-BANTHINE), cyclizine, imipramine hydrochloride (TOFRANIL), imipramine maleate (SURMONTIL), lofepramine, desipramine (NORPRAMIN), doxepin (SINEQUAN, ZONALON), trimipramine (SURMONTIL), and glycopyrrolate (ROBINUL);
(iii) catechol O-methyltransferase (COMT) inhibitors, such as nitecapone, tolcapone (TASMAR), entacapone (COMTAN), and tropolone;
(iv) monoamine oxidase (MAO) inhibitors, such as selegiline (EMSAM), selegiline hydrochloride (l-deprenyl, ELDEPRYL, ZELAPAR), dimethylselegiline, brofaromine, phenelzine (NARDIL), tranylcypromine (PARNATE), moclobemide (AURORIX, MANERIX), befloxatone, safinamide, isocarboxazid (MARPLAN), nialamide (NIAMID), rasagiline (AZILECT), iproniazide (MARSILID, IPROZID, IPRONID), iproclozide, toloxatone (HUMORYL, PERENUM), bifemelane, desoxypeganine, harmine (also known as telepathine or banasterine), harmaline, linezolid (ZYVOX, ZYVOXID), and pargyline (EUDATIN, SUPIRDYL);
(v) acetylcholinesterase inhibitors, such as donepezil hydrochloride (ARICEPT®, MEMAC), physostigmine salicylate (ANTILIRIUM®), physostigmine sulfate (ESERINE), ganstigmine, rivastigmine (EXELON®), ladostigil, NP-0361 , galantamine hydrobromide (RAZADYNE®, REMINYL®, NIVALIN®), tacrine (COGNEX®), tolserine, memoquin, huperzine A (HUP-A; Neuro-Hitech), phenserine, bisnorcymserine (also known as BNC), and INM-176;
(vi) amyloid-β (or fragments thereof), such as Αβ-|.-|5 conjugated to pan HLA DR- binding epitope (PADRE®), ACC-001 (Elan/Wyeth), and Affitope;
(vii) antibodies to amyloid-β (or fragments thereof), such as ponezumab, solanezumab, bapineuzumab (also known as AAB-001 ), AAB-002 (Wyeth/Elan), Gantenerumab, intravenous Ig (GAMMAGARD®), LY2062430 (humanized m266; Lilly), and those disclosed in International Patent Publication Nos WO04/032868, WO05/025616, WO06/036291 , WO06/069081 , WO06/1 18959, in US Patent Publication Nos US2003/0073655, US2004/0192898, US2005/0048049, US2005/0019328, in European Patent Publication Nos EP0994728 and 1257584, and in US Patent No 5,750,349;
amyloid-lowering or -inhibiting agents (including those that reduce amyloid production, accumulation and fibrillization) such as eprodisate, celecoxib, lovastatin, anapsos, colostrinin, pioglitazone, clioquinol (also known as PBT1 ), PBT2 (Prana Biotechnology), flurbiprofen (ANSAID®, FROBEN®) and its R- enantiomer tarenflurbil (FLURIZAN®), nitroflurbiprofen, fenoprofen (FENOPRON, NALFON®), ibuprofen (ADVIL®, MOTRIN®, NUROFEN®), ibuprofen lysinate, meclofenamic acid, meclofenamate sodium (MECLOMEN®), indomethacin (INDOCIN®), diclofenac sodium (VOLTAREN®), diclofenac potassium, sulindac (CLINORIL®), sulindac sulfide, diflunisal (DOLOBID®), naproxen (NAPROSYN®), naproxen sodium (ANAPROX®, ALEVE®), insulin-degrading enzyme (also known as insulysin), the gingko biloba extract EGb-761 (ROKAN®, TEBONIN®), tramiprosate (CEREBRIL®, ALZHEMED®), KIACTA®), neprilysin (also known as neutral endopeptidase (NEP)), scyllo-inositol (also known as scyllitol), atorvastatin (LIPITOR®), simvastatin (ZOCOR®), ibutamoren mesylate, BACE inhibitors such as LY450139 (Lilly), BMS-782450, GSK-188909; gamma secretase modulators and inhibitors such as ELND-007, BMS-708163 (Avagacestat), and DSP8658 (Dainippon); and RAGE (receptor for advanced glycation end-products) inhibitors, such as TTP488 (Transtech) and TTP4000 (Transtech), and those disclosed in US Patent No 7,285,293, including PTI-777; alpha-adrenergic receptor agonists, and beta-adrenergic receptor blocking agents (beta blockers); anticholinergics; anticonvulsants; antipsychotics; calcium channel blockers; catechol O-methyltransferase (COMT) inhibitors; central nervous system stimulants; corticosteroids; dopamine receptor agonists and antagonists; dopamine reuptake inhibitors; gamma-aminobutyric acid (GABA) receptor agonists; immunosuppressants; interferons; muscarinic receptor agonists; neuroprotective drugs; nicotinic receptor agonists; norepinephrine (noradrenaline) reuptake inhibitors; quinolines; and trophic factors;
histamine 3 (H3) antagonists, such as PF-3654746 and those disclosed in US Patent Publication Nos US2005-0043354, US2005-0267095, US2005-0256135, US2008-0096955, US2007-1079175, and US2008-0176925; International Patent Publication Nos WO2006/136924, WO2007/063385, WO2007/069053, WO2007/088450, WO2007/099423, WO2007/105053, WO2007/138431 , and WO2007/088462; and US Patent No 7, 1 15,600);
(xi) /V-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine (NAMENDA, AXURA, EBIXA), amantadine (SYMMETREL), acamprosate
(CAMPRAL), besonprodil, ketamine (KETALAR), delucemine, dexanabinol, dexefaroxan, dextromethorphan, dextrorphan, traxoprodil, CP-283097, himantane, idantadol, ipenoxazone, L-701252 (Merck), lancicemine, levorphanol (DROMORAN), methadone, (DOLOPHINE), neramexane, perzinfotel, phencyclidine, tianeptine (STABLON), dizocilpine (also known as MK-801 ), ibogaine, voacangine, tiletamine, riluzole (RILUTEK), aptiganel (CERESTAT), gavestinel, and remacimide;
(xii) phosphodiesterase (PDE) inhibitors, including (a) PDE1 inhibitors; (b) PDE2 inhibitors; (c) PDE3 inhibitors; (d) PDE4 inhibitors; (e) PDE5 inhibitors; (f) PDE9 inhibitors (e.g., PF-04447943, BAY 73-6691 (Bayer AG) and those disclosed in
US Patent Publication Nos US2003/0195205, US2004/0220186, US2006/01 1 1372, US2006/0106035, and USSN 12/1 18,062 (filed May 9, 2008)); and (g) PDE10 inhibitors such as 2-({4-[1-methyl-4-(pyridin-4-yl)-1 H-pyrazol-3- yl]phenoxy}methyl)quinoline (PF-2545920);
(xiii) serotonin (5-hydroxytryptamine) 1A (5-HT-IA) receptor antagonists, such as spiperone, /e\/o-pindolol, lecozotan;
(xiv) serotonin (5-hydroxytryptamine) 2C (5-HT2c) receptor agonists, such as vabicaserin, and zicronapine; serotonin (5-hydroxytryptamine) 4 (5-HT4) receptor agonists/antagonists, such as PRX-03140 (Epix) and PF-04995274;
(xv) serotonin (5-hydroxytryptamine) 3C (5-HT3c) receptor antagonists, such as Ondansetron (Zofran);
(xvi) serotonin (5-hydroxytryptamine) 6 (5-HT6) receptor antagonists, such as mianserin (TOLVON, BOLVIDON, NORVAL), methiothepin (also known as metitepine), ritanserin, SB-271046, SB-742457 (GlaxoSmithKline), Lu AE58054 (Lundbeck A/S), SAM-760, and PRX-07034 (Epix);
(xvii) serotonin (5-HT) reuptake inhibitors such as alaproclate, citalopram (CELEXA, CIPRAMIL), escitalopram (LEXAPRO, CIPRALEX), clomipramine (ANAFRANIL), duloxetine (CYMBALTA), femoxetine (MALEXIL), fenfluramine (PONDIMIN), norfenfluramine, fluoxetine (PROZAC), fluvoxamine (LUVOX), indalpine, milnacipran (IXEL), paroxetine (PAXIL, SEROXAT), sertraline (ZOLOFT, LUSTRAL), trazodone (DESYREL, MOLIPAXI N), venlafaxine (EFFEXOR), zimelidine (NORMUD, ZELMID), bicifadine, desvenlafaxine (PRISTIQ), brasofensine, vilazodone, cariprazine and tesofensine;
(xviii) Glycine transporter-1 inhibitors such as paliflutine, ORG-25935, and ORG-26041 ; and mGluR modulators such as AFQ-059 and amantidine;
(xix) AMPA-type glutamate receptor modulators such as perampanel, mibampator, selurampanel, GSK-729327, and /v-{(3S,4S)-4-[4-(5-cyanothiophen-2- yl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide;
(xx) P450 inhibitors, such as ritonavir;
(xxi) tau therapy targets, such as davunetide;
and the like. The present invention further comprises kits that are suitable for use in performing the methods of treatment described above. In one embodiment, the kit contains a first dosage form comprising one or more of the compounds of the present invention and a container for the dosage, in quantities sufficient to carry out the methods of the present invention.
In another embodiment, the kit of the present invention comprises one or more compounds of the invention.
General Synthetic Schemes
The compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and transformations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art [such as those methods disclosed in standard reference books such as the Compendium of Organic Synthetic Methods, Vol. I-XII (published by Wiley-lnterscience)]. Preferred methods include, but are not limited to, those described below.
During any of the following synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981 ; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991 ; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
Compounds of Formula I, or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.
One skilled in the art will recognize that in many cases, the compounds in Schemes 1 through 4 will be generated as a mixture of diastereomers and/or enantiomers; these may be separated at various stages of the synthetic schemes using conventional techniques or a combination of such techniques, such as, but not limited to, crystallization, normal-phase chromatography, reversed phase chromatography and chiral chromatography, to afford the single enantiomers of the invention.
It will be understood by one skilled in the art that the various symbols, superscripts and subscripts used in the schemes, methods and examples are used for convenience of representation and/or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts or subscripts in the appended claims. The schemes are representative of methods useful in synthesizing the compounds of the present invention. They are not to constrain the scope of the invention in any way.
The reactions for preparing compounds of the invention can be carried out in suitable solvents, which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan. Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
DETAILED DESCRIPTION OF THE INVENTION
Compounds of Formula I and intermediates thereof may be prepared according to the following reaction schemes and accompanying discussion. Unless otherwise indicated, R1, R2, R3, R4 and R5 in the reaction schemes and discussions that follow are as defined hereinabove. In general, the compounds of this invention may be made by processes which include processes analogous to those known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compounds of this invention and intermediates thereof are provided as further features of the invention and are illustrated by the following reaction schemes. Other processes may be described in the experimental section. The schemes and examples provided herein (including the corresponding description) are for illustration only, and not intended to limit the scope of the present invention.
Scheme 1 refers to preparation of compounds of Formula I. Referring to Scheme
1 , compounds of Formula 1-1 and 1-2 [wherein X is a leaving group such as Br or I, and Pg is a suitable protecting group, such as 2-(trimethylsilyl)ethoxymethyl (SEM), p- toluenesulfonyl (tosyl) or ferf-butoxycarbonyl (BOC)] are commercially available or can be made by methods described herein or other methods well known to those skilled in the art.
A compound of Formula 1 -3 can be prepared by coupling a compound of Formula 1-1 with a compound of Formula 1 -2, for example, by heating a mixture of a compound of Formula 1 -1 with a compound of Formula 1-2 in the presence of a base, such as A/,/\/-diisopropylethylamine, in an appropriate solvent, such as n-butanol, at temperatures ranging between 50 °C and 200 °C. Suitable reaction times are typically from 20 minutes to 48 hours. Alternatively, a metal-catalyzed (such as using a palladium or copper catalyst) coupling may be employed to accomplish the aforesaid coupling. In this variant of the coupling, a mixture of a compound of Formula 1 -1 and a compound of Formula 1-2 can be heated at temperatures ranging between 50 °C and 120 °C in the presence of a base [such as cesium carbonate], a metal catalyst [such as a palladium catalyst, e.g., palladium(ll) acetate], and a ligand [such as 1 ,1 '- binaphthalene-2,2'-diylbis(diphenylphosphane) (BINAP)] in an appropriate solvent, such as 1 ,4-dioxane. Suitable reaction times are typically from 30 minutes to 48 hours.
A compound of Formula 1-3 can subsequently be reacted with a compound of Formula R3-M [wherein M can be B(OH)2; B(OR)2 wherein each R is independently H or C-i-6 alkyl, or wherein two (OR) groups, together with the B atom to which they are attached, form a 5- to 10-membered heterocyclic ring optionally substituted with one or more C-i-6 alkyl; a trialkyltin moiety; or the like] by a metal-catalyzed (such as using a palladium catalyst) coupling reaction to obtain a compound of Formula 1-4. Compounds of Formula R3-M are commercially available or can be prepared by methods analogous to those described in the chemical art. Alternatively, a compound of Formula 1-3 can be converted to a compound of Formula 1 -5 [wherein M is defined as above]. A compound of Formula 1 -5 can then be reacted with a compound of Formula R3-X [wherein X is defined as above] by a metal-catalyzed (such as using a palladium catalyst) coupling reaction to obtain a compound of Formula I. Compounds of Formula R3-X are commercially available or can be prepared by methods analogous to those described in the chemical art. The type of reaction employed depends on the selection of X and M. For example, when X is halogen or triflate and the R3-M reagent is a boronic acid or boronic ester, a Suzuki reaction may be used [A. Suzuki, J. Organomet. C em. 1999, 576, 147-168; N. Miyaura and A. Suzuki, C em. Rev. 1995, 95, 2457-2483; A. F. Littke et al., J. Am. Chem. Soc. 2000, 122, 4020-4028]. Alternatively, when X is halogen or triflate and M is trialkyltin, a Stille coupling may be employed [V. Farina et al., Organic Reactions 1997, 50, 1-652]. Where X is Br, I or triflate and M is Zn or Mg, a Negishi coupling or Kumada coupling may be used [E. Erdik, Tetrahedron 1992, 48, 9577-9648; T. Banno et al., J. Organomet. Chem. 2002, 653, 288-291 ]. Removal of the protecting group from compounds of Formula 1-4 under conditions well known to those skilled in the art affords compounds of Formula I. heme 1
Figure imgf000043_0001
Scheme 2 also refers to preparation of compounds of Formula I. Referring to Scheme 2, compounds of Formula I may be prepared utilizing analogous chemical transformations to those described in Scheme 1 , but with a different ordering of steps. A compound of Formula 1 -1 (as in Scheme 1 ) can be converted to a compound of Formula 2-1 either directly or after conversion to a compound of Formula 2-2 using methods analogous to those described in Scheme 1. A compound of Formula 2-1 may then be coupled to a compound of Formula 1 -2 as in Scheme 1 , to produce a compound of Formula 1-4. The coupling conditions employed may be analogous to those described for the preparation of a compound of Formula 1-3 in Scheme 1 . heme 2
Figure imgf000043_0002
2-2 Scheme 3 refers to a preparation of a compound of Formula 1-1. Referring to Scheme 3, compounds of Formula 3-1 are commercially available or can be made by methods described herein or other methods well known to those skilled in the art. A compound of Formula 3-1 can be treated with a strong base and the intermediate can be subsequently reacted with an electrophile to obtain a compound of Formula 1-1 Examples of suitable reaction conditions for the reaction include mixing a compound of Formula 3-1 with a suitable base, such as lithium diisopropylamide, in a suitable reaction solvent such as tetrahydrofuran. This is followed by addition of an electrophile such as an alkyl iodide or bromide. Suitable temperatures for the aforesaid reaction are typically between -78 °C and 30 °C. Suitable reaction times typically are from 20 minutes to 48 hours. A compound of Formula 1-1 can be converted to a compound of Formula I using chemistry described in Schemes 1 and 2.
Scheme 3
Figure imgf000045_0001
Scheme 4 refers to a preparation of a compound of Formula 4-5, wherein X is a leaving group such as Br or I. Referring to Scheme 4, compounds of Formula 4-1 (wherein each R is independently H or C-i-6 alkyl) and Formula 4-2 are commercially available or can be made by methods described herein or other methods well known to those skilled in the art.
A compound of Formula 4-3 can be prepared by condensation of a compound of
Formula 4-1 with a compound of Formula 4-2, for example, through heating a compound of Formula 4-1 and a compound of Formula 4-2 in the presence of a base, such as sodium methoxide, in an appropriate solvent, such as ethanol, at temperatures ranging between 50 °C and 100 °C. Suitable reaction times are typically between 1 and 24 hours. A compound of Formula 4-3 can be converted to a compound of Formula 4-4 by treatment with a chlorinating agent, such as phosphorus oxychloride, either in the presence of a suitable solvent or neat, at a temperature ranging between 70 °C and 120 °C and a reaction time of between 1 and 24 hours. A compound of Formula 4-4 may then be treated with an appropriate halogenating agent, such as /V-iodosuccinimide, in a suitable solvent, such as dichloromethane, to produce a compound of Formula 4-5. Suitable reaction temperatures range from 0 °C to 50 °C, and suitable reaction times are typically from 30 minutes to 24 hours. A compound of Formula 4-5 can be protected (i.e. the pyrrole ring nitrogen is protected) by methods well known in the art and then the corresponding protected compound can be converted to a compound of Formula I using chemistry described in Schemes 1 , 2 and 3.
Scheme 4
Figure imgf000045_0002
4-1 4-2 4-3 4-4 4-5 Experimental Procedures and Working Examples
The following illustrate the synthesis of various compounds of the present invention. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.
Experiments were generally carried out under inert atmosphere (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate. In some cases, Sure-Seal™ products from the Aldrich Chemical Company, Milwaukee, Wisconsin were used. In other cases, commercial solvents were passed through columns packed with 4A molecular sieves, until the following QC standards for water were attained: a) <100 ppm for dichloromethane, toluene, /V,/V-dimethylformamide and tetrahydrofuran; b) <180 ppm for methanol, ethanol, 1 ,4-dioxane and diisopropylamine. For very sensitive reactions, solvents were further treated with metallic sodium, calcium hydride or molecular sieves, and distilled just prior to use.
Products were generally dried under vacuum before being carried on to further reactions or submitted for biological testing. Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatography-mass spectrometry (GCMS) instrumentation. Chemical shifts for nuclear magnetic resonance (NMR) data are expressed in parts per million (ppm, δ) referenced to residual peaks from the deuterated solvents employed.
For syntheses referencing procedures in other Examples or Methods, reaction conditions (length of reaction and temperature) may vary. In general, reactions were followed by thin layer chromatography or mass spectrometry, and subjected to work-up when appropriate. Purifications may vary between experiments: in general, solvents and the solvent ratios used for eluents/gradients were chosen to provide appropriate RfS or retention times. Preparation P1
5-lodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]m
Figure imgf000047_0001
Step 1. Synthesis of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3- c ]pyrimidine (C1 ).
A solution of 4-chloro-5-iodo-7H-pyrrolo[2,3-c ]pyrimidine (9.8 g, 35 mmol) in tetrahydrofuran (250 mL) was cooled to 0 °C and treated with sodium hydride (60% in oil, 1.54 g, 38.5 mmol) in three portions. After the reaction mixture had stirred at 0 °C for 1 hour, 2-(trimethylsilyl)ethoxymethyl chloride (6.4 g, 38 mmol) was added drop-wise, and the reaction mixture was warmed to room temperature and allowed to stir for 3 hours. The reaction was quenched with saturated aqueous sodium chloride solution (250 mL), and the organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Silica gel chromatography (Eluent: 10:1 petroleum ether / ethyl acetate) afforded the product as a white solid. Yield: 8 g, 20 mmol, 57%. 1H NMR (400 MHz, DMSO-d6) δ 8.69 (s, 1 H), 8.14 (s, 1 H), 5.60 (s, 2H), 3.51 (t, J=8 Hz, 2H), 0.82 (t, J=8 Hz, 2H), -0.10 (s, 9H).
Step 2. Synthesis of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (P1 ).
Morpholine (2.45 g, 28.1 mmol) and A/,/\/-diisopropylethylamine (6.63 g, 51.3 mmol) were added to a solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-c ]pyrimidine (C1 ) (10.5 g, 25.6 mmol) in n-butanol (300 mL), and the reaction mixture was heated at reflux for 18 hours, then concentrated under reduced pressure. Aqueous hydrochloric acid (0.1 M, 100 mL) was added and the resulting solid was collected by filtration, washed with water (20 mL) and dried under vacuum to provide the product as a yellow solid. Yield: 8.0 g, 17 mmol, 66%. LCMS m/z 461.2 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1 H), 7.81 (s, 1 H), 5.52 (s, 2H), 3.80- 3.86 (m, 4H), 3.46-3.53 (m, 6H), 0.77-0.84 (m, 2H), -0.10 (s, 9H).
Preparation P2
4-(Morpholin-4-yl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/]pyrimidine (P2)
Figure imgf000048_0001
To a solution of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (P1 ) (500 mg, 1.09 mmol) and 4,4,5, 5-tetramethyl-1 , 3,2- dioxaborolane (543 mg, 4.24 mmol) in 1 ,4-dioxane (20 mL) was added tris(dibenzylideneacetone)dipalladium(0) (99.7 mg, 0.109 mmol), triethylamine (439 mg, 4.34 mmol) and 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos, 51.8 mg, 0.109 mmol), and the reaction mixture was heated at 95 °C for 18 hours. After cooling to room temperature, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via silica gel chromatography (Gradient: 0% to 30% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 415 mg, 0.901 mmol, 83%. LCMS m/z 461.3 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.45 (s, 1 H), 7.73 (s, 1 H), 5.59 (s, 2H), 3.87-3.93 (m, 4H), 3.68-3.74 (m, 4H), 3.49-3.56 (m, 2H), 1.35 (s, 12H), 0.87-0.93 (m, 2H), -0.06 (s, 9H). Preparation P3
5-Bromo-4-chlo -7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-c ]pyrimidin
Figure imgf000049_0001
4-Methylbenzenesulfonyl chloride (5.21 g, 27.3 mmol) was added to a suspension of 5-bromo-4-chloro-7H-pyrrolo[2,3-c ]pyrimidine (6.34 g, 27.3 mmol) in acetone (70 mL). After addition of an aqueous solution of sodium hydroxide (1.1 1 g, 27.8 mmol in 15 mL water), the reaction mixture was stirred at room temperature for 16 hours. The mixture was then diluted with water (125 mL), stirred for 10 minutes, and filtered. The collected solids were washed with water to afford the product as a solid. Yield: 8.88 g, 23.0 mmol, 84%. LCMS m/z 385.9, 387.9, 389.8 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 8.84 (s, 1 H), 8.42 (s, 1 H), 8.06 (br d, J=8.4 Hz, 2H), 7.46-7.51 (m, 2H), 2.37 (br s, 3H).
Preparation P4
7-[(4-Methylphenyl)sulfonyl]-4-(3-methylpiperidin-1 -yl)-5-(4,4,5,5-tetramethyl-1 ,3,2-
Figure imgf000049_0002
5-Bromo-7-[(4-methylphenyl)sulfonyl]-4-(3-methylpiperidin-1-yl)-7/-/-pyrrolo[2,3- c ]pyrimidine (racemic version of C15, see Example 7) (1.44 g, 3.20 mmol) was added to a solution of triethylamine (1 .3 g, 13 mmol) in 1 ,4-dioxane (15 mL). 4,4,5,5-Tetramethyl- 1 ,3,2-dioxaborolane (1 .64 g, 12.8 mmol) was then slowly added, and the mixture was degassed by bubbling nitrogen through it for 5 minutes. 2-Dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl (XPhos, 137 mg, 0.287 mmol) and tris(dibenzylideneacetone)dipalladium(0) (146 mg, 0.160 mmol) were then introduced, and the reaction mixture was heated at 95 °C for 18 hours. After cooling, the mixture was filtered through cotton and the filtrate was concentrated in vacuo. Chromatography on silica gel (Gradient: 0% to 75% ethyl acetate in heptane) afforded the product as a solid. Yield: 1 .25 g, 2.52 mmol, 79%. 1H NMR (400 MHz, CDCI3) δ 8.41 (s, 1 H), 8.10 (br d, J=8.4 Hz, 2H), 7.95 (s, 1 H), 7.30 (br d, J=8.6 Hz, 2H), 4.28 (br d, J=13 Hz, 1 H), 4.18- 4.24 (m, 1 H), 2.99 (ddd, J=13, 1 1 , 4 Hz, 1 H), 2.70 (dd, J=12.9, 10.9 Hz, 1 H), 2.40 (s, 3H), 1.77-1.85 (m, 1 H), 1 .56-1.70 (m, 4H), 1 .35 (s, 12H), 0.88 (d, J=6.6 Hz, 3H).
Preparation P5
5-lodo-4-[(3S)-3-methylpiperidin-1-yl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- c ]pyrimidine (P5)
Figure imgf000050_0001
4-Chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C1 ) was converted to the product using the method described for synthesis of 5-bromo- 7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1 -yl]-7H-pyrrolo[2,3-c ]pyrimidine (C15) in Example 7. Yield: 7.38 g, 15.6 mmol, 80%. LCMS m/z 473.1 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.42 (s, 1 H), 7.34 (s, 1 H), 5.55 (s, 2H), 4.06-4.17 (m, 2H), 3.50- 3.57 (m, 2H), 2.91 (ddd, J=12.6, 1 1.5, 3.5 Hz, 1 H), 2.58 (dd, J=12.6, 10.8 Hz, 1 H), 1.95- 2.07 (m, 1 H), 1.76-1.95 (m, 3H), 1.1 1-1.23 (m, 1 H), 0.96 (d, J=6.8 Hz, 3H), 0.88-0.94 (m, 2H), -0.04 (s, 9H). Preparation P6
-Chloro-5-(1-methyl-1 H-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine (P6)
Figure imgf000051_0001
Step 1. Synthesis of 4-chloro-5-(1-methyl-1 H-pyrazol-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c ]pyrimidine (C2).
To a solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (C1 ) (4.1 g, 10 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 H-pyrazole (2.1 g, 10 mmol) and potassium carbonate (2.8 g, 20 mmol) in aqueous 1 ,4-dioxane was added dichlorobis(triphenylphosphine)palladium(ll) (350 mg, 0.50 mmol). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. After heating at reflux for 18 hours, the reaction mixture was cooled to room temperature, diluted with water (200 ml.) and extracted with ethyl acetate (3 x 200 ml_). The combined organic layers were washed with saturated aqueous sodium chloride solution (500 ml_), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by chromatography on silica gel (Gradient: 0% to 10% ethyl acetate in petroleum ether) afforded the product as a white solid. Yield: 2.0 g, 5.5 mmol, 55%. 1H NMR (400 MHz, CDCI3) δ 8.66 (s, 1 H), 7.68 (d, J=0.5 Hz, 1 H), 7.62 (br s, 1 H), 7.36 (s, 1 H), 5.68 (s, 2H), 3.99 (s, 3H), 3.54-3.59 (m, 2H), 0.91 -0.97 (m, 2H), -0.03 (s, 9H).
Step 2. Synthesis of 4-chloro-5-(1-methyl-1 H-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine (P6).
4-Chloro-5-(1-methyl-1 H-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-c ]pyrimidine (C2) was converted to the product using the method described for synthesis of 3-[6-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5- yl]benzonitrile (2) in Example 2. In this case the product, obtained as a yellow solid, was purified by recrystallization from ethyl acetate, rather than via preparative HPLC. Yield: 1.0 g, 4.3 mmol, 43% over two steps. LCMS m/z 234.0 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 12.66 (br s, 1 H), 8.58 (s, 1 H), 7.91 (s, 1 H), 7.69 (d, J=2.5 Hz, 1 H), 7.63 (d, J=0.7 Hz, 1 H), 3.89 (s, 3H).
Preparation P7
W,W-Dimethyl-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidin-4-amine (P7)
Figure imgf000052_0001
5-lodo-W,W-dimethyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrTolo[2,3- c ]pyrimidin-4-amine [C3, prepared from 4-chloro-5-iodo-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C1 ) according to the method described for synthesis of 3-[4-(dimethylamino)-7H-pyrrolo[2,3-c ]pyrimidin-5- yl]benzonitrile (5) in Example 5] was converted to the product according to the method described for synthesis of 4-(morpholin-4-yl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan- 2-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (P2) in Preparation P2. The product was obtained as a yellow solid. Yield: 342 mg, 0.817 mmol, 69%.
LCMS m/z 419.3 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.37 (s, 1 H), 7.57 (s, 1 H), 5.56 (s, 2H), 3.49-3.57 (m, 2H), 3.25 (s, 6H), 1 .36 (s, 12H), 0.86-0.94 (m, 2H), -0.06 (s, 9H).
Example 1
5-(1 -Methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine (1 )
Figure imgf000053_0001
1
Step 1. Synthesis of 5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c ]pyrimidine (C4).
To a solution of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (P1 ) (500 mg, 1.1 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-1 H-pyrazole (272 mg, 1.31 mmol) in a mixture of ethanol and water (4:1 , 10 mL) were added dichlorobis(triphenylphosphine)palladium(ll) (41 mg, 58 μηηοΙ) and potassium carbonate (447 mg, 3.23 mmol). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. It was then heated at 100 °C for 18 hours. After concentration in vacuo, the residue was purified via chromatography on silica gel (Eluent: 1 :1 ethyl acetate / petroleum ether) to provide the product as a yellow solid. Yield: 200 mg, 0.48 mmol, 44%. 1H NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1 H), 7.86 (s, 1 H), 7.59 (s, 1 H), 7.52 (s, 1 H), 5.57 (s, 2H), 3.90 (s, 3H), 3.50-3.58 (m, 6H), 3.20-3.27 (m, 4H), 0.83 (dd, J=8.0, 7.9 Hz, 2H), -0.09 (s, 9H).
Step 2. Synthesis of [5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3- c ]pyrimidin-7-yl]methanol (C5).
A solution of 5-(1 -methyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C4) (200 mg, 0.48 mmol) in trifluoroacetic acid (5 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure to afford the product as a yellow oil, which was used for the next step without additional purification.
Step 3. Synthesis of 5-(1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidine (1 ).
A solution of [5-(1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidin-7-yl]methanol (C5) (material from the previous step, <0.48 mmol) in methanol (5 mL) was brought to a pH of >12 via addition of solid potassium carbonate. The reaction mixture was stirred for 30 minutes, filtered, and concentrated in vacuo. Purification via preparative HPLC (Column: Agella Venusil ASB C18, 5 μηη; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; Eluent: 13% B) provided the product as a yellow solid. Yield over two steps: 90 mg, 0.32 mmol, 67%. LCMS m/z 285.1 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 12.96 (br s, 1 H), 8.47 (s, 1 H), 7.85 (s, 1 H), 7.57 (s, 1 H), 7.52 (d, J=2.5 Hz, 1 H), 3.90 (s, 3H), 3.53-3.59 (m, 4H), 3.45- 3.51 (m, 4H).
Example 2
-[6-Methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (2)
Figure imgf000054_0001
Figure imgf000055_0001
Step 1 . Synthesis of 4-chloro-5-iodo-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (C6).
To a -78 °C solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (C1 ) (15.0 g, 36.6 mmol) in tetrahydrofuran (500 mL) was added lithium diisopropylamide (2 M solution in heptane / tetrahydrofuran / ethylbenzene, 183 mL, 366 mmol), and the reaction mixture was stirred at -20 °C for 2 hours, then re-cooled to -78 °C. lodomethane (52.1 g, 367 mmol) was added at -78 °C, and the reaction mixture was allowed to stir at -20 °C for 2 hours. Saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with water (100 mL) and with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via chromatography on silica gel (Eluent: 10:1 petroleum ether / ethyl acetate) afforded the product as a yellow oil. Yield: 10 g, 24 mmol, 66%. LCMS m/z 424.1 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.58 (s, 1 H), 5.69 (s, 2H), 3.48-3.54 (m, 2H), 2.60 (s, 3H), 0.88-0.95 (m, 2H), -0.05 (s, 9H). Step 2. Synthesis of 3-(4-chloro-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl)benzonitrile (C7).
To a solution of 4-chloro-5-iodo-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (C6) (300 mg, 0.71 mmol) and (3-cyanophenyl)boronic acid (104 mg, 0.708 mmol) in a mixture of 1 ,2-dimethoxyethane and water (5:1 , 10 mL) was added potassium carbonate (193 mg, 1.40 mmol) and [1 , 1 - bis(diphenylphosphino)ferrocene]dichloropalladium(l l) (17 mg, 23 μηηοΙ). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. After heating at reflux for 18 hours, the reaction mixture was cooled to room temperature and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over sodium sulfate, filtered and concentrated in vacuo. Purification via silica gel chromatography (Gradient: 0% to 20% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 140 mg, 0.351 mmol, 50%. LCMS m/z 399.2 [M+H+]. Step 3. Synthesis of 3-[6-methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C8).
To a solution of 3-(4-chloro-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl)benzonitrile (C7) (140 mg, 0.351 mmol) in n-butanol (5 ml.) was added morpholine (30.6 mg, 0.351 mmol) and A/,/\/-diisopropylethylamine (90.9 mg, 0.703 mmol). The reaction mixture was heated at 100 °C for 18 hours, then concentrated in vacuo to provide the product as a yellow solid. Yield: 125 mg, 0.278 mmol, 79%. LCMS m/z 450.3 [M+H+].
Step 4. Synthesis of 3-[7-(hydroxymethyl)-6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidin-5-yl]benzonitrile (C9).
A solution of 3-[6-methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C8) (125 mg, 0.278 mmol) in trifluoroacetic acid (10 mL) was stirred at room temperature for 2 hours, then concentrated in vacuo to provide the product as a yellow solid (125 mg). This was used in the next step without additional purification. LCMS m/z 349.9 [M+H+].
Step 5. Synthesis of 3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidin-5- yl]benzonitrile (2).
A solution of 3-[7-(hydroxymethyl)-6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidin-5-yl]benzonitrile (C9) (from the previous step, 125 mg, <0.278 mmol) in acetonitrile (5 mL) was adjusted to a pH of >1 1 by addition of solid potassium carbonate. The mixture was filtered and concentrated in vacuo; purification via preparative HPLC (Column: Boston Symmetrix ODS-H, 5 μηη; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; Gradient: 19% to 39% B) afforded the product as a yellow solid. Yield: 54 mg, 0.17 mmol, 61 % over two steps. LCMS m/z 319.9 [M+H*]. 1H NMR (400 MHz, DMSO-d6) δ 12.17 (br s, 1 H), 8.34 (s, 1 H), 7.77-7.83 (m, 2H), 7.65-7.74 (m, 2H), 3.27-3.33 (m, 4H), 2.98-3.06 (m, 4H), 2.36 (s, 3H). Example 3
Figure imgf000057_0001
3
Step 1. Synthesis of 6-[4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile (C10).
To a solution of 6-bromopyridine-2-carbonitrile (80 mg, 0.44 mmol) and 4- (morpholin-4-yl)-5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (P2) (241 mg, 0.523 mmol) in 1 ,4-dioxane (2.5 mL) and water (0.5 mL) was added tetrakis(triphenylphosphine)palladium(0) (51 mg, 44 μηηοΙ) and sodium carbonate (140 mg, 1.32 mmol). The reaction mixture was heated at 120 °C under microwave irradiation for 15 minutes, then diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo; purification via preparative thin layer chromatography (Eluent: 1 :1 petroleum ether / ethyl acetate) afforded the product as a brown oil. Yield: 1 10 mg, 0.252 mmol, 57%. 1H NMR (400 MHz, CDCI3) δ 8.52 (s, 1 H), 7.84-7.93 (m, 2H), 7.74 (s, 1 H), 7.59 (dd, J=7.0, 1.2 Hz, 1 H), 5.66 (s, 2H), 3.56-3.65 (m, 6H), 3.34-3.40 (m, 4H), 0.93 (dd, J=8.3, 8.0 Hz, 2H), -0.05 (s, 9H).
Step 2. Synthesis of 6-[7-(hydroxymethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidin- 5-yl]pyridine-2-carbonitrile (C11 ). A solution of 6-[4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile (C10) (1 10 mg, 0.252 mmol) in trifluoroacetic acid (3 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo to provide the product as a yellow oil, which was used for the next step without additional purification.
Step 3. Synthesis of 6-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2- carbonitrile (3).
A solution of 6-[7-(hydroxymethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidin- 5-yl]pyridine-2-carbonitrile (C11 ) (from the previous step, 85 mg, <0.25 mmol) in acetonitrile (3 mL) was brought to a pH of >12 via addition of solid potassium carbonate. After 30 minutes at room temperature, the reaction mixture was filtered and concentrated in vacuo. Purification via preparative HPLC (Column: Phenomenex Gemini C18, 8 μηη; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 10% to 50% B) afforded the product as a white solid. Yield: 15.2 mg, 49.6 mol, 20% over two steps. LCMS m/z 307.2 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1 H), 8.13 (dd, J=8.1 , 7.7 Hz, 1 H), 7.96 (br d, J=8 Hz, 1 H), 7.89 (br d, J=8 Hz, 1 H), 7.86 (s, 1 H), 3.50-3.55 (m, 4H), 3.19-3.24 (m, 4H).
Example 4
-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (4)
Figure imgf000058_0001
Step 1. Synthesis of 3-(4-chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- c ]pyrimidin-5-yl)benzonitrile (C12). To a stirred mixture of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-c ]pyrimidine (C1 ) (8.2 g, 20 mmol), (3-cyanophenyl)boronic acid (3.2 g, 22 mmol) and potassium carbonate (8.3 g, 60 mmol) in a mixture of 1 ,2-dimethoxyethane and water (4: 1 ratio, 250 ml.) was added [1 , 1 - bis(diphenylphosphino)ferrocene]dichloropalladium(l l) (731 mg, 1.00 mmol). The reaction mixture was degassed and then charged with nitrogen; this procedure was carried out a total of three times. The reaction mixture was heated at reflux for 3 hours, then cooled to room temperature and diluted with saturated aqueous sodium chloride solution (100 ml_). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification via silica gel column chromatography (Eluent: 10: 1 petroleum ether / ethyl acetate) provided the product as a yellow oil. Yield:
5.0 g, 12 mmol, 60%. 1H NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1 H), 8.13 (s, 1 H), 8.00- 8.02 (m, 1 H), 7.84-7.92 (m, 2H), 7.68 (dd, J=7.8, 7.8 Hz, 1 H), 5.70 (s, 2H), 3.60 (dd, J=8.0, 8.0 Hz, 2H), 0.86 (dd, J=8.0, 8.0 Hz, 2H), -0.08 (s, 9H).
Step 2. Synthesis of 3-[4-chloro-7-(hydroxymethyl)-7H-pyrrolo[2,3-c/]pyrimidin-5- yl]benzonitrile (C13).
A solution of 3-(4-chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- c ]pyrimidin-5-yl)benzonitrile (C12) (3.8 g, 9.9 mmol) in trifluoroacetic acid (25 ml.) was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo to afford the product (4 g, >100% mass recovery) as a yellow oil, which was used in the next step without further purification.
Step 3. Synthesis of 3-(4-chloro-7H-pyrrolo[2,3-c ]pyrimidin-5-yl)benzonitrile (C14).
A solution of 3-[4-chloro-7-(hydroxymethyl)-7H-pyrrolo[2,3-c ]pyrimidin-5- yl]benzonitrile (C13) (4 g from the previous step, <9.9 mmol) in methanol (100 ml.) was adjusted to pH >12 by addition of solid potassium carbonate. Solvent was removed in vacuo and the residue was mixed with water (100 ml_). The resulting solid was isolated via filtration and washed with water, providing the product as a white solid. Yield: 1 .3 g,
5.1 mmol, 52% over two steps. LCMS m/z 255.0 [M+H+].
Step 4. Synthesis of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (4).
Morpholine (871 mg, 10 mmol) and A/,/\/-diisopropylethylamine (2.6 g, 20 mmol) were added to a solution of 3-(4-chloro-7H-pyrrolo[2,3-c/]pyrimidin-5-yl)benzonitrile (C14) (2.5 g, 9.8 mmol) in n-butanol (100 ml_), and the reaction mixture was heated at reflux for 3 hours. Solvents were removed in vacuo and the residue was purified using chromatography on silica gel (Eluent: 1 :1 ethyl acetate / petroleum ether). Subsequent recrystallization from ethyl acetate and ferf-butyl methyl ether afforded the product as a white solid. Yield: 770 mg, 2.52 mmol, 26%. LCMS m/z 306.0 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 12.34 (br s, 1 H), 8.41 (s, 1 H), 7.99-8.02 (m, 1 H), 7.89 (br d, J=8 Hz, 1 H), 7.76 (br d, J=7.5 Hz, 1 H), 7.71 (s, 1 H), 7.68 (dd, J=7.8, 7.8 Hz, 1 H), 3.44-3.50 (m, 4H), 3.1 1 -3.17 (m, 4H).
Example 5
methylamino)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (5)
Figure imgf000060_0001
C14 5
A mixture of 3-(4-chloro-7H-pyrrolo[2,3-c ]pyrimidin-5-yl)benzonitrile (C14) (157 mg, 0.616 mmol), dimethylamine (189 mg, 4.19 mmol) and triethylamine (182 mg, 1 .80 mmol) in n-butanol (12 ml.) was heated under microwave irradiation at 150 °C for 25 minutes. After concentration in vacuo, the residue was purified by preparative HPLC (Column: Phenomenex Gemini C18, 8 μηη; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 25% to 65% B) to give the product as a white solid. Yield: 72.1 mg, 0.274 mmol, 44%. LCMS m/z 263.8 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 12.15 (br s, 1 H), 8.28 (s, 1 H), 7.93 (br s, 1 H), 7.78 (br d, J=7.8 Hz, 1 H), 7.73 (br d, J=7.8 Hz, 1 H), 7.62 (br dd, J=8.0, 7.8 Hz, 1 H), 7.57 (br s, 1 H), 2.73 (s, 6H).
Example 6
3-{4-[(2S)-2-Methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl}benzonitrile (6)
Figure imgf000060_0002
C14 6 To a solution of 3-(4-chloro-7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl)benzonitrile (C14) (100 mg, 0.393 mmol) and (2S)-2-methylmorpholine (54 mg, 0.53 mmol) in n-butanol (20 ml.) was added /V,/V-diisopropylethylamine (152 mg, 1.18 mol), and the reaction mixture was heated at 100 °C for 18 hours. The reaction mixture was then concentrated in vacuo; purification via preparative HPLC (Column: Phenomenex Gemini C18, 8 μηη; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 27% to 47% B) provided the product as a white solid. Yield: 17.5 mg, 54.8 μηηοΙ, 14%. LCMS m/z 320.2 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 10.71 (br s, 1 H), 8.53 (br s, 1 H), 7.73- 7.89 (m, 2H), 7.51-7.69 (m, 2H), 7.28 (s, 1 H, assumed; partially obscured by solvent peak), 3.56-3.77 (m, 3H), 3.39-3.54 (m, 2H), 2.86-2.98 (m, 1 H), 2.53-2.65 (m, 1 H), 0.93- 1.03 (m, 3H).
Example 7
(3- -[(3S)-3-Methylpiperidin-1-yl]-7H-pyrrolo[2,3-c ]pyrimidin-5-yl}phenyl)methanol (7)
Figure imgf000061_0001
Step 1. Synthesis of 5-bromo-7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1 - yl]-7H-pyrrolo[2,3-c ]pyrimidine (C15).
5-Bromo-4-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-c ]pyrimidine (P3) was reacted with the hydrochloride salt of (3S)-3-methylpiperidine according to the method described for preparation of 3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile (6) in Example 6. In this case, purification was effected via silica gel chromatography (Eluent: 5:1 petroleum ether / ethyl acetate), providing the product as a white solid. Yield: 4.3 g, 9.6 mmol, 92%.
Step 2. Synthesis of (3-{7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1-yl]-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl}phenyl)methanol (C16).
A mixture of 5-bromo-7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1-yl]-
7H-pyrrolo[2,3-c ]pyrimidine (C15) (0.225 g, 0.501 mmol), [3- (hydroxymethyl)phenyl]boronic acid (0.104 g, 0.684 mmol), sodium carbonate (0.159 g, 1.50 mmol) and dichlorobis(triphenylphosphine)palladium(ll) (36 mg, 51 μηηοΙ) in acetonitrile (2 mL) and water (2 mL) was heated to 150 °C under microwave irradiation for 15 minutes. The reaction was concentrated in vacuo to afford the product (0.35 g, >100%), which was used directly in the following step without additional purification. Step 3. Synthesis of (3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c ]pyrimidin-5- yl}phenyl)methanol (7).
To a stirred solution of (3-{7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin- 1-yl]-7H-pyrrolo[2,3-c ]pyrimidin-5-yl}phenyl)methanol (C16) from the previous step (<0.50 mmol) in 2-propanol (20 mL) was added lithium hydroxide monohydrate (0.42 g, 10 mmol) and water (3 mL) and the reaction mixture was stirred at room temperature for 18 hours. After concentration in vacuo, the residue was purified by preparative HPLC (Column: Waters XBridge; Mobile phase A: 0.1 % ammonia in water; Mobile phase B: acetonitrile; Gradient: 44% to 60% B) to provide the product as a white solid. Yield: 130 mg, 0.403 mmol, 80% over two steps. LCMS m/z 323.4 [M+H+]. 1H NMR (400 MHz, CD3OD) δ 8.24 (s, 1 H), 7.46 (br s, 1 H), 7.35-7.43 (m, 2H), 7.30 (br d, J=6 Hz, 1 H), 7.23 (s, 1 H), 4.67 (s, 2H), 3.89 (br d, J=13 Hz, 1 H), 3.79 (br d, J=12 Hz, 1 H), 2.58-2.69 (m, 1 H), 2.27 (dd, J=12.0, 11 .0 Hz, 1 H), 1.62-1.71 (m, 1 H), 1.30-1.52 (m, 3H), 0.87-1.01 (m, 1 H), 0.60 (d, J=6.5 Hz, 3H).
Example 8
4-(Morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine, formate salt (8)
Figure imgf000063_0001
Step 1. Synthesis of 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1 ,3,2- dioxaborolan-2-yl)-1 H-pyrazole (C17).
3,4-Dihydro-2H-pyran (5.6 g, 67 mmol) and trifluoroacetic acid (1.17 g, 10.3 mmol) were added to a solution of 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 /-/- pyrazole (10.0 g, 51.5 mmol) in toluene (200 mL), and the reaction mixture was heated to 90 °C for 2 hours. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate (200 mL) and saturated aqueous sodium bicarbonate solution (100 mL), and the aqueous layer was extracted with ethyl acetate (100 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Silica gel chromatography (Gradient: 10% to 50% ethyl acetate in petroleum ether) provided the product as a white solid. Yield: 13.4 g, 48.2 mmol, 94%. 1H NMR (400 MHz, CDCI3) δ 7.94 (s, 1 H), 7.83 (s, 1 H), 5.41 (dd, J=9.5, 2.5 Hz, 1 H), 4.01-4.08 (m, 1 H), 3.65-3.74 (m, 1 H), 1.98-2.18 (m, 3H), 1.6-1.76 (m, 3H), 1.32 (s, 12H).
Step 2. Synthesis of 4-chloro-5-[1-(tetrahydro-2H-pyran-2-yl)-1 H-pyrazol-4-yl]-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c ]pyrimidine (C18).
A mixture of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3- c ]pyrimidine (C1 ) (2.0 g, 4.9 mmol), 1-(tetrahydro-2H-pyran-2-yl)-4-(4,4,5,5-tetramethyl- 1 ,3,2-dioxaborolan-2-yl)-1 H-pyrazole (C17) (1 .91 g, 6.87 mmol), potassium phosphate (4.0 g, 19 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.10 g, 87 μηηοΙ) was degassed several times with nitrogen and irradiated in a microwave synthesizer at 130 °C for 1 .5 hours. The reaction mixture was partitioned between ethyl acetate (400 mL) and water (60 mL), and the aqueous layer was extracted with ethyl acetate (200 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Chromatography on silica gel (Gradient: 10% to 80% ethyl acetate in petroleum ether) afforded the product as a brown oil. Yield: 1.33 g, 3.06 mmol, 62%. 1H NMR (400 MHz, CDCI3) δ 8.67 (s, 1 H), 7.87 (s, 1 H), 7.76 (s, 1 H), 7.38 (s, 1 H), 5.68 (s, 2H), 5.46 (dd, J=9.4, 2.9 Hz, 1 H), 4.08-4.15 (m, 1 H), 3.71 -3.79 (m, 1 H), 3.57 (dd, J=8.3, 8.0 Hz, 2H), 2.04-2.24 (m, 3H), 1.61-1.79 (m, 3H), 0.94 (dd, J=8.3, 8.3 Hz, 2H), -0.03 (s, 9H).
Step 3. Synthesis of 4-(morpholin-4-yl)-5-[1-(tetrahydro-2/-/-pyran-2-yl)-1 H-pyrazol-4-yl]- 7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C19).
A solution of 4-chloro-5-[1-(tetrahydro-2H-pyran-2-yl)-1 /-/-pyrazol-4-yl]-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C18) (3.3 g, 7.6 mmol), morpholine (0.99 g, 1 1 mmol) and A/,/\/-diisopropylethylamine (6 mL, 34 mmol) in n- butanol (15 mL) was irradiated in a microwave synthesizer at 100 °C for 30 minutes. After removal of solvents in vacuo, the residue was purified by silica gel chromatography (Gradient: 10% to 50% ethyl acetate in petroleum ether) to provide the product as a brown oil. Yield: 2.6 g, 5.4 mmol, 71%. 1 H NMR (400 MHz, CDCI3) δ 8.50 (s, 1 H), 7.79 (s, 1 H), 7.71 (s, 1 H), 7.17 (s, 1 H), 5.62 (s, 2H), 5.44 (dd, J=6.5, 6.0 Hz, 1 H), 4.08-4.15 (m, 1 H), 3.71-3.79 (m, 1 H), 3.62-3.67 (m, 4H), 3.58 (dd, J=8.5, 8.0 Hz, 2H), 3.33-3.39 (m, 4H), 2.06-2.19 (m, 3H), 1 .62-1.79 (m, 3H), 0.93 (dd, J=8.5, 7.5 Hz, 2H), -0.04 (s, 9H). Step 4. Synthesis of 4-(morpholin-4-yl)-5-(1 H-pyrazol-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c ]pyrimidine (C20).
To a solution of 4-(morpholin-4-yl)-5-[1 -(tetrahydro-2/-/-pyran-2-yl)-1 H-pyrazol-4- yl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C19) (4.0 g, 8.2 mmol) in dichloromethane (20 mL) was added a solution of hydrogen chloride in 1 ,4- dioxane (4 M, 100 mL). The reaction mixture was stirred at room temperature for 2 hours, then poured into a mixture of ethyl acetate (300 mL) and saturated aqueous sodium bicarbonate solution (300 mL). The aqueous layer was extracted with ethyl acetate (2 x 300 mL), and the combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification via silica gel chromatography (Gradient: 10% to 80% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 2.18 g, 5.44 mmol, 66%. LCMS m/z 401.3 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.51 (s, 1 H), 7.78 (s, 2H), 7.19 (s, 1 H), 5.64 (s, 2H), 3.56-3.66 (m, 6H), 3.34- 3.40 (m, 4H), 0.91-0.98 (m, 2H), -0.03 (s, 9H).
Step 5. Synthesis of [4-(morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin- 7-yl]methanol (C21 ).
4-(Morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (C20) (0.13 g, 0.32 mmol) was dissolved in trifluoroacetic acid (10 mL) and stirred at room temperature for 2 hours. Removal of solvent in vacuo provided the product (100 mg) as a brown solid; this was used in the next step without further purification. LCMS m/z 301.2 [M+H+].
Step 6. Synthesis of 4-(morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine, formate salt (8).
To a solution of [4-(morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7H-pyrrolo[2,3- c ]pyrimidin-7-yl]methanol (C21 ) (from the previous step, 0.10 g, <0.32 mmol) in acetonitrile (10 mL) was added potassium carbonate (0.34 g, 2.5 mmol) and the reaction mixture was stirred at room temperature for 30 minutes. The mixture was filtered and the filter cake was washed with ethyl acetate (3 x 20 mL). The combined filtrates were concentrated in vacuo; purification via preparative HPLC (Column: DIKMA Diamonsil(2) C18, 5 μηη; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; Gradient: 0% to 17% B) afforded the product as a pale solid. Yield: 36 mg, 0.1 1 mmol, 34% over 2 steps. LCMS m/z 271 .2 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 10.72 (br s, 1 H), 8.47 (s, 1 H), 7.78 (s, 2H), 7.19 (s, 1 H), 3.60-3.67 (m, 4H), 3.41-3.48 (m, 4H).
Example 9
3-[2-M (9)
Figure imgf000066_0001
Step 1. Synthesis of 4-chloro-5-iodo-2-methyl-7/-/-pyrrolo[2,3-c/]pyrimidine (C22).
To a solution of 4-chloro-2-methyl-7H-pyrrolo[2,3-c ]pyrimidine (400 mg, 2.4 mmol) in dichloromethane (10 ml.) was added /V-iodosuccinimide (537 mg, 2.39 mmol). The mixture was stirred at room temperature for 2 hours, then washed with aqueous sodium sulfite solution, dried over sodium sulfate, filtered, and concentrated in vacuo to provide the product as a brown solid. Yield: 330 mg, 1.12 mmol, 47%. LCMS m/z 293.8 [M+H+].
Step 2. Synthesis of 4-chloro-5-iodo-2-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (C23).
4-Chloro-5-iodo-2-methyl-7H-pyrrolo[2,3-c ]pyrimidine (C22) was converted to the product according to the method used for synthesis of 4-chloro-5-iodo-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-(^pyrimidine (C1 ) in Preparation P1 . The product was obtained as a yellow oil. Yield: 400 mg, 0.94 mmol, 84%. LCMS m/z 424.0 [M+H+].
Step 3. Synthesis of 5-iodo-2-methyl-4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C24).
The product was prepared from 4-chloro-5-iodo-2-methyl-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C23) according to the method described for synthesis of 3-{4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c ]pyrimidin- 5-yl}benzonitrile (6) in Example 6. In this case, purification was carried out via silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) to provide the product as a yellow oil. Yield: 300 mg, 0.63 mmol, 67%. LCMS m/z 475.2 [M+H+].
Step 4. Synthesis of 3-[2-methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C25).
To a solution of 5-iodo-2-methyl-4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C24) (100 mg, 0.21 mmol), (3-cyanophenyl)boronic acid (62 mg, 0.42 mmol) and potassium carbonate (100 mg, 0.72 mmol) in a mixture of ethanol and water (4:1 , 5 mL) was added
dichlorobis(triphenylphosphine)palladium (15 mg, 21 μηηοΙ). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. After the reaction mixture had heated at 90 °C for 3 hours, it was allowed to cool and concentrated in vacuo. Purification via preparative thin layer chromatography (Eluent: 1 :1 petroleum ether / ethyl acetate) provided the product as a yellow oil. Yield: 52 mg, 0.12 mmol, 57%. LCMS m/z 451.3 [M+H+].
Step 5. Synthesis of 3-[2-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidin-5- yl]benzonitrile (9).
3-[2-Methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- c ]pyrimidin-5-yl]benzonitrile (C25) was converted to the product using the method described for synthesis of 5-(1-methyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-c ]pyrimidine (1 ) in Example 1. In this case, preparative HPLC purification was carried out using a Phenomenex Gemini C18 column, 8 μηη; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 30% to 50% B. The product was obtained as a white solid. Yield: 17.3 mg, 54.2 μηηοΙ, 45% over 2 steps. LCMS m/z 320.1 [M+H+]. 1H NMR (400 MHz, CD3OD) δ 7.91 -7.93 (m, 1 H), 7.85-7.88 (m, 1 H), 7.60-7.69 (m, 2H), 7.38 (s, 1 H), 3.51 -3.55 (m, 4H), 3.24-3.28 (m, 4H), 2.59 (s, 3H).
Example 10
{ -[4-(Dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol (10)
Figure imgf000068_0001
10
Step 1 . Synthesis of {3-[4-(dimethylamino)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]phenyl}methanol (C26).
A solution of 5-iodo-/V,/\/-dimethyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-4-amine (C3) (418 mg, 1.00 mmol), [3- (hydroxymethyl)phenyl]boronic acid (228 mg, 1.50 mmol), tetrakis(triphenylphosphine)palladium(0) (1 15 mg, 0.100 mmol), and cesium carbonate (625 mg, 1 .92 mmol) in 1 ,4-dioxane (6 mL) and water (1.5 mL) was purged with nitrogen, then heated under microwave irradiation at 120 °C for 20 minutes. The reaction mixture was diluted with saturated aqueous sodium chloride solution (50 mL) and extracted with dichloromethane (3 x 60 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. Chromatography on silica gel (Gradient: 2% to 17% ethyl acetate in petroleum ether) afforded the product as a brown oil. Yield: 369 mg, 0.926 mmol, 93%. LCMS m/z 399.0 [M+H+].
Step 2. Synthesis of 3-[4-(dimethylamino)-7-(hydroxymethyl)-7/-/-pyrrolo[2,3-c ]pyrimidin- 5-yl]benzyl trifluoroacetate (C27).
A solution of {3-[4-(dimethylamino)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]phenyl}methanol (C26) (397 mg, 0.996 mmol) in trifluoroacetic acid (10 mL) was stirred at room temperature for 2 hours. The reaction mixture was concentrated in vacuo to provide the product (400 mg) as a brown oil. This material was taken directly into the following step. LCMS m/z 395.1 [M+H+].
Step 3. Synthesis of {3-[4-(dimethylamino)-7H-pyrrolo[2,3-c/]pyrimidin-5- yl]phenyl}methanol (10).
A mixture of 3-[4-(dimethylamino)-7-(hydroxymethyl)-7H-pyrrolo[2,3-c ]pyrimidin- 5-yl]benzyl trifluoroacetate (C27) (from the previous step, 400 mg, <0.996 mmol) and potassium carbonate (500 mg, 3.6 mmol) in methanol (10 mL) was stirred at 80 °C for 30 minutes. The reaction mixture was diluted with saturated aqueous sodium chloride solution (50 mL) and extracted with dichloromethane (3 x 60 mL); the combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via preparative HPLC (Column: Phenomenex Gemini C18, 8 μηη; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 21 % to 33% B) afforded the product as a white solid. Yield: 77.7 mg, 0.290 mmol, 29% over two steps. LCMS m/z 268.9 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 10.83 (br s, 1 H), 8.39 (s, 1 H), 7.50 (br s, 1 H), 7.38-7.42 (m, 2H), 7.29-7.34 (m, 1 H), 7.1 1 (s, 1 H), 4.78 (s, 2H), 2.84 (s, 6H).
Example 198
3-[6-(Difluoromethyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile
(198)
Figure imgf000070_0001
Step 1. Synthesis of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3- c ]pyrimidine-6-carbaldehyde (C28).
A solution of diisopropylamine (2.9 g, 29 mmol) in tetrahydrofuran (30 ml.) was cooled to -78 °C and treated drop-wise with n-butyllithium (2.5 M, 1 1.6 ml_, 29 mmol). The reaction mixture was stirred at 0 °C for 1 hour, and then cooled to -78 °C. A solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3- c ]pyrimidine (C1 ) (8.0 g, 20 mmol) in tetrahydrofuran (10 ml.) was added drop-wise, and stirred was continued at -78 °C for 1 hour. After drop-wise addition of a solution of ethyl formate (2.6 g, 35 mmol) in tetrahydrofuran (10 ml.) to the -78 °C reaction mixture, it was allowed to warm to room temperature and stir for 18 hours. It was then cooled to 0 °C, and the reaction was quenched by addition of saturated aqueous ammonium chloride solution (20 ml_), then extracted with ethyl acetate (3 x 50 ml_). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 ml_), dried over sodium sulfate, filtered, and concentrated. Purification via silica gel chromatography (Gradient: 0% to 25% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 5.0 g, 1 1 mmol, 55%. 1H NMR (400 MHz, CDCI3) δ 10.1 1 (s, 1 H), 8.80 (s, 1 H), 6.05 (s, 2H), 3.55-3.62 (m, 2H), 0.89-0.96 (m, 2H), -0.05 (s, 9H). Step 2. Synthesis of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine-6-carbaldehyde (C29).
Morpholine (1.09 g, 12.5 mmol) and A/,/\/-diisopropylethylamine (2.94 g, 22.7 mmol) were added to a solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-c ]pyrimidine-6-carbaldehyde (C28) (5.0 g, 1 1 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at reflux for 16 hours, whereupon it was cooled and concentrated in vacuo; the residue was purified by chromatography on silica gel (Gradient: 0% to 20% ethyl acetate in petroleum ether) to provide the product as a yellow oil. Yield: 4.0 g, 8.2 mmol, 74%. 1H NMR (400 MHz, CDCI3) δ 9.99 (s, 1 H), 8.54 (s, 1 H), 6.01 (s, 2H), 3.92-3.98 (m, 4H), 3.70-3.75 (m, 4H), 3.58-3.65 (m, 2H), 0.91-0.96 (m, 2H), -0.05 (s, 9H).
Step 3. Synthesis of 3-[6-formyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C30).
5-lodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3- c ]pyrimidine-6-carbaldehyde (C29) was converted to the product using the method described for synthesis of 3-(4-chloro-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl)benzonitrile (C7) in Example 2. The product was obtained as a yellow solid. Yield: 1 .5 g, 3.2 mmol, 78%. 1H NMR (400 MHz, CDCI3) δ 9.75 (s, 1 H), 8.60 (s, 1 H), 7.77-7.83 (m, 2H), 7.72-7.76 (m, 1 H), 7.67 (br dd, J=8, 8 Hz, 1 H), 6.09 (s, 2H), 3.66-3.71 (m, 2H), 3.38-3.44 (m, 4H), 3.23-3.28 (m, 4H), 0.94-1.01 (m, 2H), -0.03 (s, 9H).
Step 4. Synthesis of 3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C31 ).
A solution of 3-[6-formyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C30) (200 mg, 0.43 mmol) and (diethylamino)sulfur trifluoride (276 mg, 1.71 mmol) in dichloromethane (10 mL) was stirred at 40 °C for 16 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate solution (10 mL) and extracted with dichloromethane (3 x 20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over sodium sulfate, filtered, and concentrated; purification by preparative thin-layer chromatography on silica gel (Eluent: 1 :1 ethyl acetate / petroleum ether) afforded the product as a yellow solid. Yield: 150 mg, 0.31 mmol, 72%. 1H NMR (400 MHz, CDCI3) δ 8.58 (s, 1 H), 7.76 (ddd, J=7.3, 1.6, 1.5 Hz, 1 H), 7.72-7.74 (m, 1 H), 7.61-7.70 (m, 2H), 6.74 (t, JHF=52.5 HZ, 1 H), 5.86 (s, 2H), 3.65-3.72 (m, 2H), 3.34-3.42 (m, 4H), 3.15-3.21 (m, 4H), 0.95-1.02 (m, 2H), -0.02 (s, 9H).
Step 5. Synthesis of 3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidin- 5-yl]benzonitrile (198).
A solution of 3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C31 ) (10 mg, 21 μηηοΙ) in trifluoroacetic acid (2 mL) was stirred at room temperature for 24 hours. The reaction mixture was concentrated and purified by preparative reversed phase high- performance liquid chromatography (Column: DIKMA Diamonsil(2) C18, 5 μηη; Eluent: 22% acetonitrile in water containing 0.225% formic acid) to provide the product as a white solid. Yield: 2.0 mg, 5.6 mol, 27%. LCMS m/z 355.9 [M+H+]. 1H NMR (400 MHz, DMSO-d6) 8 13.06 (br s, 1 H), 8.47 (s, 1 H), 7.92 (ddd, J=6.7, 2.1 , 1.7 Hz, 1 H), 7.83-7.85 (m, 1 H), 7.69-7.76 (m, 2H), 7.02 (t, JHF=52.5 HZ, 1 H), 3.22-3.30 (m, 4H), 3.03-3.10 (m, 4H).
Example 199 and Example 200
5-(5,6-Dihydro-2/-/-pyran-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine (199) and 5-(3,4-Dihydro-2H-pyran-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine (200)
Figure imgf000072_0001
199 200
Step 1. Synthesis of 3-(4-chloro-7H-pyrrolo[2,3-c ]pyrimidin-5-yl)tetrahydro-2/-/-pyran-3- ol (C32). To a -78 °C solution of 4-chloro-5-iodo-7/-/-pyrrolo[2,3-c/]pyrimidine (1.5 g, 5.4 mmol) in tetrahydrofuran (50 mL) was added n-butyllithium (2.5 M, 6.4 mL, 16.1 mmol) drop-wise. After the reaction mixture had been stirred at -78 °C for 2 hours, it was treated with dihydro-2H-pyran-3(4/-/)-one (1.61 g, 16.1 mmol), warmed to room temperature, and stirred for 18 hours. The reaction was quenched with water (50 mL), and the aqueous layer was extracted with ethyl acetate (3 x 30 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated. Silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 200 mg, 0.79 mmol, 15%. LCMS m/z 254.0 [M+H+].
Step 2. Synthesis of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]tetrahydro- 2H-pyran-3-ol (C33).
To a solution of 3-(4-chloro-7H-pyrrolo[2,3-c/]pyrimidin-5-yl)tetrahydro-2/-/-pyran- 3-ol (C32) (200 mg, 0.79 mmol) and morpholine (134 mg, 1 .54 mol) in n-butanol (10 mL) was added A/,/\/-diisopropylethylamine (305 mg, 2.36 mol), and the reaction mixture was heated at 70 °C for 2 hours. After concentration in vacuo, preparative reversed phase high-performance liquid chromatography (Column: Phenomenex Gemini C18, 8 μηη; Mobile phase A: aqueous ammonia, pH 10; Mobile phase B: acetonitrile; Gradient: 9% to 29% B) provided the product as a white solid. Yield: 180 mg, 0.59 mmol, 75%. LCMS m/z 305.1 [M+H+]. 1H NMR (400 MHz, CDCI3 + D20) δ 8.73 (s, 1 H), 7.52 (s, 1 H), 3.92-4.03 (m, 4H), 3.74-3.88 (m, 4H), 3.32-3.40 (m, 2H), 3.15-3.24 (m, 2H), 2.07-2.16 (m, 1 H), 1 .88-2.06 (m, 2H), 1.57-1.68 (m, 1 H).
Step 3. Synthesis of 5-(5,6-dihydro-2H-pyran-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidine (199) and 5-(3,4-dihydro-2/-/-pyran-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine (200).
Triethylsilane (10 mL) and trifluoroacetic acid (10 mL) were added over 10 minutes to a solution of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]tetrahydro- 2H-pyran-3-ol (C33) (40 mg, 0.13 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at room temperature for 2 hours, whereupon it was concentrated in vacuo. Preparative reversed phase high-performance liquid chromatography (Column: Boston Symmetrix ODS-H, 5 μηη; Mobile phase A: water containing 0.225% formic acid; Mobile phase B: acetonitrile; Gradient: 1 1 % to 31 % B) afforded 199 as a white solid (Yield: 1 1.3 mg, 39.5 μηιοΙ, 30%) and 200, also as a white solid (Yield: 7.0 mg, 24 μηιοΙ, 18%).
199: LCMS m/z 287.0 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 1 1.97 (br s, 1 H), 8.29 (s, 1 H), 7.31 (s, 1 H), 5.87-5.93 (m, 1 H), 4.30-4.36 (m, 2H), 3.68-3.78 (m, 6H), 3.36-3.43 (m, 4H), 2.21-2.29 (m, 2H).
200: LCMS m/z 287.0 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 1 1.83 (br s, 1 H), 8.26 (s, 1 H), 7.18 (s, 1 H), 6.65 (s, 1 H), 3.92-3.97 (m, 2H), 3.69-3.76 (m, 4H), 3.40-3.46 (m, 4H), 2.29-2.36 (m, 2H), 1.88-1.96 (m, 2H).
Example 201
4-(Mor
Figure imgf000074_0001
Step 1. Synthesis of 3-[4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C34).
3-[4-(Morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (4) was converted to the product using the method described for synthesis of 4-chloro-5-iodo-7-
{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine (C1 ) in Preparation P1.
The product was obtained as a yellow solid. Yield: 0.90 g, 2.1 mmol, 70%. 1H NMR
(400 MHz, CDCI3) 5 8.55 (s, 1 H), 7.86 (br s, 1 H), 7.79 (br d, J=7.6 Hz, 1 H), 7.63 (br d, J=7.6 Hz, 1 H), 7.57 (dd, J=7.6, 7.6 Hz, 1 H), 7.29 (s, 1 H), 5.67 (s, 2H), 3.58-3.64 (m,
2H), 3.52-3.58 (m, 4H), 3.27-3.32 (m, 4H), 0.92-0.98 (m, 2H), -0.03 (s, 9H). Step 2. Synthesis of /V'-hydroxy-3-[4-(morpholin-4-yl)-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzenecarboximidamide (C35).
Hydroxylamine hydrochloride (278 mg, 4.00 mmol) and sodium carbonate (318 mg, 3.00 mmol) were added to a stirred solution of 3-[4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile (C34) (436 mg, 1.00 mmol) in ethanol (10 mL) and water (5 mL). The reaction mixture was heated at reflux for 2 hours, then concentrated in vacuo, poured into water (25 mL), and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (25 mL), dried over sodium sulfate, filtered, and concentrated, affording the product as a white solid. Yield: 280 mg, 0.60 mmol, 60%. 1 H NMR (400 MHz, DMSO-d6) δ 9.67 (s, 1 H), 8.43 (s, 1 H), 7.89 (br s, 1 H), 7.72 (s, 1 H), 7.64 (br d, J=7.8 Hz, 1 H), 7.53 (br d, J=7.8 Hz, 1 H), 7.46 (dd, J=7.6, 7.6 Hz, 1 H), 5.89 (br s, -1.6H), 5.61 (s, 2H), 3.53-3.61 (m, 2H), 3.39-3.47 (m, 4H), 3.13-3.21 (m, 4H), 0.81 -0.88 (m, 2H), -0.09 (s, 9H).
Step 3. Synthesis of 4-(morpholin-4-yl)-5-[3-(1 ,2,4-oxadiazol-3-yl)phenyl]-7H- pyrrolo[2,3-c ]pyrimidine (201 ).
Triethyl orthoformate (760 mg, 5.1 mol) and boron trifluoride diethyl etherate (370 mg, 2.6 mol) were added to a 0 °C solution of A/'-hydroxy-3-[4-(morpholin-4-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl]benzenecarboximidamide (C35) (600 mg, 1.3 mmol) in tetrahydrofuran (25 mL). The reaction mixture was heated at 40 °C for 18 hours, then poured into water (50 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over sodium sulfate, filtered, and concentrated. Purification via preparative reversed phase high-performance liquid chromatography (Column: Phenomenex Gemini C18, 8 μηη; Mobile phase A: aqueous ammonia, pH 10; Mobile phase B: acetonitrile; Gradient: 30% to 50% B) provided the product as a yellow solid. Yield: 62 mg, 0.18 mmol, 14%. LCMS m/z 349.0 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 9.77 (s, 1 H), 8.40 (s, 1 H), 8.24 (br s, 1 H), 7.98 (br d, J=7.5 Hz, 1 H), 7.82 (br d, J=7.3 Hz, 1 H), 7.63-7.70 (m, 2H), 3.39-3.45 (m, 4H), 3.13-3.20 (m, 4H).
Example 202 3-{4-[2-(3-Methyl-1 ,2-oxazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c/]pyri
yl}benzonitrile (202)
Figure imgf000076_0001
Step 1. Synthesis of 4-benzyl-2-(3-methyl-1 ,2-oxazol-5-yl)morpholin-2-ol (C36).
A solution of 2-bromo-1-(3-methyl-1 ,2-oxazol-5-yl)ethanone (2.50 g, 12.2 mmol) and 2-(benzylamino)ethanol (3.70 g, 24.5 mmol) in acetonitrile (25 mL) was stirred at 35 °C for 18 hours. The reaction mixture was concentrated in vacuo and purified using silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) to provide the product as a yellow oil. Yield: 1.2 g, 4.4 mmol, 36%. 1H NMR (400 MHz, CDCI3) δ 7.27-7.38 (m, 5H), 6.22 (s, 1 H), 4.1 1-4.19 (m, 1 H), 3.76-3.84 (m, 1 H), 3.60 (AB quartet, JAB=13.0 Hz, ΔνΑΒ=13.2 Hz, 2H), 2.99 (br d, J=1 1.0 Hz, 1 H), 2.71-2.79 (m, 1 H), 2.55 (d, J^ ^ .Q Hz, 1 H), 2.42 (ddd, J=11 .7, 1 1.5, 3.6 Hz, 1 H), 2.29 (s, 3H).
Step 2. Synthesis of 4-benzyl-2-(3-methyl-1 ,2-oxazol-5-yl)morpholine (C37).
Trimethylsilyl trifluoromethanesulfonate (2.9 g, 13 mmol) and triethylsilane (2.6 g,
22 mmol) were added to a solution of 4-benzyl-2-(3-methyl-1 ,2-oxazol-5-yl)morpholin-2- ol (C36) (1.2 g, 4.4 mmol) in dichloromethane (15 mL), and the reaction mixture was heated at 80 °C for 2 hours. The reaction mixture was then adjusted to a pH of ~5 to 6 via addition of saturated aqueous sodium bicarbonate solution. After extraction with dichloromethane (3 x 20 mL), the combined organic layers were washed with saturated aqueous sodium chloride solution (25 mL), dried over sodium sulfate, filtered, and concentrated. Purification via silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 500 mg, 1.9 mmol, 43%. LCMS m/z 258.9 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 7.27-7.37 (m, 5H), 6.07 (s, 1 H), 4.75 (dd, J=9.7, 2.3 Hz, 1 H), 3.96 (ddd, J=1 1.3, 2.8, 2.4 Hz, 1 H), 3.81 (ddd, J=11 .3, 10.8, 2.5 Hz, 1 H), 3.52-3.61 (m, 2H), 3.02 (br d, J=^ A Hz, 1 H), 2.68-2.75 (m, 1 H), 2.29 (s, 3H), 2.27-2.37 (m, 2H).
Step 3. Synthesis of 2-(3-methyl-1 ,2-oxazol-5-yl)morpholine (C38).
Ammonium cerium(IV) nitrate (442 mg, 0.806 mmol) was added to a solution of 4-benzyl-2-(3-methyl-1 ,2-oxazol-5-yl)morpholine (C37) (100 mg, 0.39 mmol) in acetonitrile / water (5: 1 mixture, 6 mL). The reaction mixture was stirred at 25 °C for 4 hours, then concentrated in vacuo; preparative thin-layer chromatography on silica gel (Eluent: 10:1 dichloromethane / methanol) provided the product as a yellow oil. Yield: 40 mg, 0.24 mmol, 62%. 1H NMR (400 MHz, CDCI3) δ 6.1 1 (s, 1 H), 4.79 (dd, J=10.0, 2.4 Hz, 1 H), 4.01 (ddd, J=1 1.8, 2.5, 2.4 Hz, 1 H), 3.81-3.89 (m, 1 H), 3.35 (dd, J=12.7, 2.5 Hz, 1 H), 2.99-3.07 (m, 3H), 2.30 (s, 3H).
Step 4. Synthesis of 3-{4-[2-(3-methyl-1 ,2-oxazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile (202).
To a solution of 2-(3-methyl-1 ,2-oxazol-5-yl)morpholine (C38) (20 mg, 0.12 mmol) in n-butanol (7 mL) was added 3-(4-chloro-7H-pyrrolo[2,3-c ]pyrimidin-5- yl)benzonitrile (C14) (36.2 mg, 0.142 mol), and the reaction mixture was placed in a sealed tube and heated at 150 °C in a microwave reactor for 2 hours. After removal of solvent, the residue was purified by preparative reversed phase high-performance liquid chromatography (Column: YMC-Actus Triart C18, 5 μηη; Mobile phase A: water containing 0.225% formic acid; Mobile phase B: acetonitrile; Gradient: 33% to 53% B) to afford the product as a white solid. Yield: 0.78 mg, 2.0 mol, 2%. LCMS m/z 387.0 [M+H+]. 1H NMR (400 MHz, DMSO-d6), characteristic peaks: δ 12.45 (br s, 1 H), 8.45 (s, 1 H), 8.00-8.03 (m, 1 H), 7.85 (br d, J=8 Hz, 1 H), 7.76 (br d, J=8 Hz, 1 H), 7.72 (d, J=2.8 Hz, 1 H), 7.66 (dd, J=8, 8 Hz, 1 H), 6.25 (s, 1 H), 4.58-4.63 (m, 1 H), 3.71-3.83 (m, 2H), 3.01 -3.09 (m, 1 H), 2.88-2.97 (m, 1 H), 2.20 (s, 3H).
Methods
Method A
Introduction of a 4-amino substituent onto 3-(4-chloro-7H-pyrrolo[2,3-c/]pyrimidin-5- yl)benzonitrile via chloride displacement
Figure imgf000078_0001
C14
A solution of 3-(4-chloro-7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl)benzonitrile (C14) in dimethyl sulfoxide (0.1 M, 500 μΙ_, 50 μηηοΙ) was added to a vial containing the appropriate amine (150 μηηοΙ). After addition of cesium fluoride (23 mg, 150 μηηοΙ), the reaction mixture was shaken at 100 °C for 16 hours, then purified via preparative HPLC using an appropriate gradient with one of the following systems: 1 ) Column: DIKMA Diamonsil(2) C18, 5 μηη; Mobile phase A: 0.1 % trifluoroacetic acid in water; Mobile phase B: acetonitrile; 2) Column: Boston Symmetrix ODS-H, 5 μηη or Phenomenex Synergi C18, 4 μηι or Agella Venusil ASB C18, 5 μηι; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile.
Method B
Synthesis of 5-substituted-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c ]pyrimidi via Suzuki reaction
Figure imgf000078_0002
Step 1. Suzuki reaction
A solution of the appropriate boronic ester in aqueous 1 ,4-dioxane (1 :5 v/v water / 1 ,4-dioxane) (0.3 M, 400 μΙ_, 120 μηηοΙ) was combined with a solution of 5-iodo-4- [(3S)-3-methylpiperidin-1-yl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3- c ]pyrimidine (P5) (0.25 M in 1 :5 water / 1 ,4-dioxane; 400 μΙ_, 100 μηηοΙ). The solution was treated with cesium carbonate (65 mg, 200 μηηοΙ) and degassed by bubbling nitrogen through it. [1 ,1 '-Bis(di-ferf-butylphosphino)ferrocene]dichloropalladium(ll) (3 mg, 5 μηιοΙ) was added to the reaction mixture, which was again degassed with nitrogen, then shaken at 150 °C for 4 hours. After removal of solvent using a Speedvac® concentrator, the products were purified via preparative thin layer chromatography in an appropriate solvent system and taken to the following step.
Step 2. Deprotection
The product from the previous step was treated with a solution of trifluoroacetic acid in dichloromethane (1 :5 v/v; 2 ml_), and the reaction mixture was shaken at 30 °C for 2 hours. After concentration using the Speedvac®, the residue was treated with a solution of ammonium hydroxide in methanol (1 :4 v/v; 2 ml.) and shaken at 30 °C for 16 hours. Solvents were removed on the Speedvac® and the product was purified via preparative HPLC using an appropriate gradient (Column: DIKMA Diamonsil(2) C18, 5 μηη or Agella Venusil ASB C18, 5 μηη; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile).
Method C
Synthesis of 5-substituted-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidines via Suzuki reaction
Figure imgf000079_0001
Step 1. Suzuki reaction
A solution of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/- pyrrolo[2,3-c ]pyrimidine (P1 ) in 1 ,4-dioxane (0.20 M, 400 μΙ_, 80 μηηοΙ) was combined with a solution of the appropriate boronic acid in 1 ,4-dioxane (0.50 M, 200 μΙ_, 100 μηηοΙ). An aqueous solution of potassium phosphate (0.80 M, 200 μΙ_, 160 μηηοΙ) was added, followed by [1 , 1 '-bis(di-ferf-butylphosphino)ferrocene]dichloropalladium(ll) (3 mg, 5 μηηοΙ), and the reaction mixture was shaken at 100 °C for 16 hours. The mixture was filtered and the filtrate was concentrated on a Speedvac®. The residue was partitioned between dichloromethane and saturated aqueous sodium carbonate solution, and the aqueous layer was extracted with dichloromethane (2 x 1 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated using the Speedvac® to afford the crude product, which was used directly in the next step.
Step 2. Deprotection
The product of the preceding reaction was treated with a solution of concentrated hydrochloric acid in ethanol (1 :6 v/v; 1 mL), and the reaction mixture was shaken at 80 °C for 16 hours. After removal of solvents on the Speedvac®, the residue was purified via preparative HPLC using an appropriate gradient with one of the following systems: 1 ) Column: Kromasil Eternity-5-C18, 5 μηη or Boston Symmetrix ODS-H, 5 μηη or Phenomenex Synergi C18, 4 μηη; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; 2) Column: Phenomenex Gemini C18, 8 μηη; Mobile phase A: aqueous ammonium hydroxide, pH 10; Mobile phase B: acetonitrile.
Method D
Introduction of a 4-amino substituent onto 7H-pyrrolo[2,3-c ]pyrimidines via chloride
Figure imgf000080_0001
A solution of the 4-chloro-7H-pyrrolo[2,3-c ]pyrimidine substrate in dimethyl sulfoxide (0.5 M, 200 μί, 100 μηηοΙ) was added to a solution of the appropriate amine in dimethyl sulfoxide (0.8 M, 200 μΙ_, 160 μηιοΙ). /V,/V-Diisopropylethylamine (120 μΙ_, 700 μηηοΙ) was added, and the reaction mixture was shaken at 80 °C for 16 hours. After removal of solvents using a Speedvac®, the product was purified via preparative HPLC using an appropriate gradient with one of the following systems: 1 ) Column: Phenomenex Gemini C18, 8 μηη or Agela Durashell C18, 5 μηη; Mobile phase A: aqueous ammonium hydroxide, pH 10; Mobile phase B: acetonitrile; or 2) Column: DIKMA Diamonsil(2) C18, 5 μηη or Phenomenex Synergi C18, 4 μηη; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile.
Method E Synthesis of 4-amino-substituted, 5-substituted-7H-pyrrolo[2,3-c ]pyrimidines from 4- chlo -5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c ]pyrimidine
Figure imgf000081_0001
Step 1. Amine displacement reaction
A solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3- c ]pyrimidine (C1 ) in /V,/V-dimethylformamide (0.25 M, 500 μΙ_, 125 μmol) was added to the appropriate amine (150 μηηοΙ). Triethylamine (35 μΙ_, 250 μηηοΙ) was added, and the reaction mixture was shaken at 100 °C for 16 hours. This solution was used directly in the following step.
Step 2. Suzuki reaction
The product solution from the preceding step (<125 μηηοΙ) was mixed with a solution of the appropriate boronic acid in /V,/V-dimethylformamide (0.25 M, 500 μΙ_, 125 μηηοΙ). An aqueous solution of cesium carbonate (1.25 M, 200 μΙ_, 250 μηηοΙ) was added, followed by [1 , 1 '-bis(di-ferf-butylphosphino)ferrocene]dichloropalladium(ll) (1.6 mg, 2.5 μηηοΙ), and the reaction mixture was shaken at 120 °C for 4 hours. Removal of solvent using a Speedvac® provided a residue, which was used directly in the following step.
Step 3. Deprotection
The product from the previous step (<125 μηηοΙ) was treated with a solution of concentrated hydrochloric acid in ethanol (1 :6 v/v; 2 mL), and the reaction mixture was shaken at 80 °C for 16 hours. After removal of solvent via the Speedvac®, the residue was taken up in a solution of ammonium hydroxide (30% aqueous) in methanol (1 :4 v/v, 2 mL). The mixture was shaken at 30 °C for 16 hours, concentrated on the Speedvac® and purified via preparative HPLC using an appropriate gradient (Column: DI KMA Diamonsil(2) C18, 5 μηι or Agella Venusil ASB C18, 5 μηι; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile).
Method F
Introduction of a 5-substituent onto 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c ]pyrimidin-4-amines via Suzuki reaction
Figure imgf000082_0001
Step 1. Suzuki reaction
A solution of the 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c ]pyrimidine substrate in 1 ,4-dioxane (0.1 M, 1 ml_, 100 μηηοΙ) was added to the appropriate aryl or heteroaryl halide (100 μηηοΙ). An aqueous solution of cesium carbonate (1.0 M, 200 μΙ_, 200 μηηοΙ) was added, followed by [1 , 1 '-bis(di-ferf-butylphosphino)ferrocene]dichloropalladium(ll) (1.3 mg, 2.0 μηηοΙ), and the reaction mixture was shaken at 120 °C for 4 hours. Removal of solvent using a Speedvac® provided a residue, which was used directly in the following step. Step 2. Deprotection
Protecting group removal and purification were carried out as described in the final step of Method E.
The following table (Table 1 ) provides Examples 1 1-197 and Examples 203-225 of the present invention, the structure of the compound, reference to the method of preparation and characterizing data for the compound. Certain of the compounds depicted in the table are racemic and others are depicted as single enantiomers with the absolute stereochemistry as shown. In certain cases the racemic compound has been separated into the individual enantiomers, although the absolute stereochemistry of the single enantiomer(s) may not have been determined. In the table the individual separated enantiomers may be referred to as ENT-1 or ENT-2, which are abbreviations for the separated enantiomer-1 and enantiomer-2, respectively. It is to be understood that one of the compounds designated as ENT-1 or ENT-2 will have the {R) absolute stereochemistry at the chiral center while the other will have the (S) absolute stereochemistry.
Table 1
Figure imgf000083_0001
1.3 d, 2.82- 1H),
3.0 H),
s,
1H), 3.95
(m, Hz,
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
obscured by water peak); 322.2
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
1 H),
(d,
7.84- Hz,
J=8
J=4.5, 3H); s, d, (m, 1H),
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
(m, Hz, Hz,
s,
7.78 (br
(dd, 1.99- s, d,
dd, Hz,
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
1 . In this case, tetrakis(triphenylphosphine)palladium(0) was used in the Suzuki reaction.
2. Boronate ester 1-methyl-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1 /- -pyrazole was used in the Suzuki reaction.
3. Conditions for analytical HPLC. Column: Waters XBridge C18, 2.1 x 50 mm, 5 μιη; Mobile phase A: 0.1 % trifluoroacetic acid in water; Mobile phase B: 0.1 % trifluoroacetic acid in acetonitrile; Gradient: 5% B for 1.0 minute, then 5% to 100% B over 5.75 minutes; Flow rate: 0.5 mL/minute.
4. Dichlorobis(triphenylphosphine)palladium(ll) was used in the Suzuki reaction.
5. 1 N Sodium hydroxide solution was employed in the Suzuki reaction; this served to remove the (4-methylphenyl)sulfonyl protecting group.
6. In this case, preparative HPLC purification was carried out using a 10 μιη Sunfire C- 18 column; Eluent: 1 : 1 acetonitrile / (0.1 % formic acid in water).
7. A boronic acid was used rather than a boronic ester.
8. The final deprotection was carried out using tetrabutylammonium fluoride in tetrahydrofuran.
9. Conditions for analytical HPLC. Column: Waters XBridge C18, 2.1 x 50 mm, 5 μιη; Mobile phase A: 0.0375% trifluoroacetic acid in water; Mobile phase B: 0.01875% trifluoroacetic acid in acetonitrile; Gradient: 1 % to 5% B over 0.60 minutes; then 5% to 100% B over 3.40 minutes; Flow rate: 0.8 mL/minute.
10. Conditions for analytical HPLC as in footnote 9, except that the gradient employed was 10% to 100% B over 4.00 minutes.
1 1. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AD, 5 μιη; Eluent: 68:32 carbon dioxide / methanol.
12. This Example was the second-eluting enantiomer from the supercritical fluid chromatographic separation. 13. Conditions for analytical HPLC. Column: Waters XBridge C18, 2.1 x 50 mm, 5 μιη; Mobile phase A: 0.05% ammonium hydroxide in water; Mobile phase B: acetonitrile; Gradient: 5% to 100% B over 3.40 minutes; Flow rate: 0.8 mL/minute.
14. [1 , 1 '-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) was used in the Suzuki reaction.
15. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AD, 5 μιη; Eluent: 60:40 carbon dioxide / (methanol containing 0.05% diethylamine).
16. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AD, 20 μιη; Eluent: 60:40 carbon dioxide / (ethanol containing 0.05% diethylamine).
17. This Example was the first-eluting enantiomer from the supercritical fluid chromatographic separation.
18. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AS, 5 μιη; Eluent: 60:40 carbon dioxide / (2-propanol containing 0.05% diethylamine).
19. 3-lodo-1-methyl-1 /-/-pyrazole was used in the Suzuki reaction.
20. The requisite 2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholine may be prepared from 4- benzylmorpholine-2-carbonitrile using chemistry described by D. Sakai and K. Watanabe, PCT Int. Appl. 2009, WO 2009035159 A1 20090319.
21. In this case, the displacement reaction was carried out at 1 10 °C.
22. The requisite 2-{[(6-methylpyridin-3-yl)oxy]methyl}morpholine may be prepared via a Mitsunobu reaction between ieri-butyl 2-(hydroxymethyl)morpholine-4-carboxylate and 6- methylpyridin-3-ol, followed by acidic removal of the protecting group.
23. 2-{[5-(Difluoromethyl)-1 ,2,4-oxadiazol-3-yl]methyl}morpholine may be prepared in the following manner: reaction of (4-benzylmorpholin-2-yl)acetonitrile with hydroxylamine hydrochloride and base provides 2-(4-benzylmorpholin-2-yl)-A/'-hydroxyethanimidamide. Coupling of this compound with difluoroacetic acid may be carried out using any of a number of coupling reagents, such as 1 ,3-dicyclohexylcarbodiimide. Subsequent cyclization using thermal conditions or tetrabutylammonium fluoride (see A. R. Gangloff et al., Tetrahedron Lett. 2001 , 42, 1441-1443), followed by debenzylation, provides the requisite amine.
24. Reaction of 4-benzylmorpholine-2-carbonitrile with hydroxylamine hydrochloride and sodium hydroxide provided 4-benzyl-A/'-hydroxymorpholine-2-carboximidamide, which was condensed with cyclopropanecarboxylic acid using 1 ,3-dicyclohexylcarbodiimide. Cyclization using tetrabutylammonium fluoride (see A. R. Gangloff et al., Tetrahedron Lett. 2001 , 42, 1441- 1443), followed by debenzylation, afforded 2-(5-cyclopropyl-1 ,2,4-oxadiazol-3-yl)morpholine. 25. The requisite 3-(morpholin-2-ylmethoxy)benzonitrile may be prepared in a manner analogous to that described in footnote 22.
26. 2-(Pyrimidin-4-yl)morpholine may be prepared from 1-(4-benzylmorpholin-2- yl)ethanone via conversion to the enamine and reaction with 1 ,3,5-triazine (see D. L. Boger et al., J. Org. Chem. 1982, 47, 2673-2675), followed by debenzylation.
27. 2-[(5-Methyl-1 ,2,4-oxadiazol-3-yl)methyl]morpholine may be prepared via the chemistry described in footnote 23, by employing acetic acid in place of difluoroacetic acid.
28. Compound C20 was /V-alkylated with ethyl iodide and potassium iert-butoxide at 30 °C in tetrahydrofuran. Deprotection was carried out using the procedure described in step 2 of Method C.
29. 2-Chloro-6-methoxypyrazine was used in the Suzuki reaction.
30. 2-Chloro-1-fluoro-3-iodo-4-methoxybenzene may be prepared by iodination of 2- chloro-1 -fluoro-4-methoxybenzene according to the method of R. Sanz et al., J. Org. Chem. 2007, 72, 51 13-51 18 .
31. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AS, 5 μιη; Eluent: 63:37 carbon dioxide / (methanol containing 0.05% ammonium hydroxide).
32. In this case, potassium phosphate and 1 ,2-dimethoxyethane were used in place of sodium carbonate and 1 ,4-dioxane.
33. 5-Bromoimidazo[2, 1-ib][1 ,3]thiazole may be prepared via bromination of imidazo[2, 1-
£>][1 ,3]thiazole using /V-bromosuccinimide.
34. The two enantiomers were separated by supercritical fluid chromatography. Example 213 was the second-eluting enantiomer, and Example 214 was the first-eluting isomer, using a Chiral Technologies Chiralcel OJ-3 column, and gradient of 5% to 40% methanol in carbon dioxide containing 0.05% diethylamine.
35. In this case, the Suzuki reaction was carried out using bis[di-ieri-butyl(4- dimethylaminophenyl)phosphine]dichloropalladium(ll) and cesium fluoride in a mixture of 1 ,4- dioxane and water at 100 °C for 18 hours.
36. Treatment of 4-bromo-1-methyl-1 /- -imidazole with lithium diisopropylamide and N,N- dimethylformamide provided 4-bromo-1-methyl-1 /- -imidazole-2-carbaldehyde, which was converted to the requisite 4-bromo-1 -methyl-1 /- -imidazole-2-carbonitrile via reaction with ammonium hydroxide and iodine, according to the method of J. -J. Shie and J.-M. Fang, J. Org. Chem. 2007, 72, 3141-3144.
37. Conditions for analytical HPLC. Column: Waters Atlantis dC18, 4.6 x 50 mm, 5 μιη; Mobile phase A: 0.05% trifluoroacetic acid in water (v/v); Mobile phase B: 0.05% trifluoroacetic acid in acetonitrile (v/v); Gradient: 5.0% to 95% B, linear over 4.0 minutes; Flow rate: 2 mL/minute.
38. Conditions for analytical HPLC. Column: Waters XBridge C18, 4.6 x 50 mm, 5 μιη; Mobile phase A: 0.03% ammonium hydroxide in water (v/v); Mobile phase B: 0.03% ammonium hydroxide in acetonitrile (v/v); Gradient: 5.0% to 95% B, linear over 4.0 minutes; Flow rate: 2 mL/minute).
39. 3-Bromo-1-methyl-1 /-/-pyrazole-5-carbaldehyde was converted to 3-bromo-1-methyl- 1 /-/-pyrazole-5-carbonitrile using the method of J. -J. Shie and J.-M. Fang; see footnote 36.
40. Treatment of (4-benzylmorpholin-2-yl)acetonitrile with ammonium cerium(IV) nitrate provided the requisite morpholin-2-ylacetonitrile.
Biological Assays
LRRK2 assay
LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat # PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat # PR8975A). The assay was carried out under the following protocol: 3 μΙ_ of a working solution of substrate (233 nM LRRKtide, 1 17 μΜ ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCI2, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by half- log in DMSO 1 1 times. Aliquots (3.5 μί) of the 100% DMSO dose response were mixed with 46.5 μ\- water then 1 μί of this mixture was added to the 3 μΙ_ substrate mix in the 384-well plate. The kinase reaction was started with 3 μΙ_ of a working solution of LRRK2 enzyme at a concentration of 4 μg/mL. The final reaction concentrations were 100 nM LRRKtide, 50 μΜ ATP, 1.7 μg/mL LRRK2 enzyme and a compound dose response with a top dose of 32 μΜ. The reaction was allowed to progress at room temperature for two hours and then stopped with the addition of 7 μ\- of detection buffer (20 mM Tris pH 7.6, 0.01 % NP-40, 0.02% NaN3, 6 mM EDTA with 2 nM terbium labeled anti-phospho-ERM). After an incubation of 1 hour at room temperature, the plate was read on an Envision with an excitation wavelength of 340 nm and a reading emission at both 520 nm and 495 nm. The ratio of the 520 nm and 495 nm emission was used to analyze the data.
Inhibition of mutant G2019S LRRK2 (Invitrogen cat # PV4881 ) was measured in the exact same method. All final concentrations of substrate ATP and enzyme were the same. However, since the mutant enzyme is more active the reaction time was reduced to 90 minutes to ensure that inhibition was measured at steady state before any substrate depletion could occur.
Table 2, below, provides the LRRK2 IC50 data for the compounds of the invention.
Table 2
Figure imgf000122_0001
3-[4-(3,3-dimethylpiperidin-1-yl)-7A -pyrrolo[2,3-
90 325 cf]pyrimidin-5-yl]benzonitrile
3-[4-(piperidin-1-yl)-7/- -pyrrolo[2,3-cf]pyrimidin-5-
6 28 yl]benzonitrile
1 -(5-phenyl-7/- -pyrrolo[2,3-c]pyrimidin-4-yl)piperidine-3-
41 39 carboxamide
3-{4-[(3S)-3-hydroxypiperidin-1-yl]-7A -pyrrolo[2,3-
17b 95 cf]pyrimidin-5-yl}benzonitrile
4-[(3S)-3-methylpiperidin-1-yl]-5-phenyl-7A -pyrrolo[2,3-
91 92 c]pyrimidine
3-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
16a 45a cf]pyrimidin-5-yl}benzonitrile
4-[(3S)-3-methylpiperidin-1 -yl]-5-(1 -methyl-1 /- -pyrazol-
14 12 4-yl)-7/- -pyrrolo[2,3-cf]pyrimidine
5-phenyl-4-(pyrrolidin-1-yl)-7/- -pyrrolo[2,3-c]pyrimidine 71 47
[1 -(5-phenyl-7/- -pyrrolo[2,3-c]pyrimidin-4-yl)piperidin-4-
38 29 yl]methanol
1 -{5-[3-(hydroxymethyl)phenyl]-7/- -pyrrolo[2,3-
56 31 c]pyrimidin-4-yl}piperidine-3-carbonitrile
1 -[5-(3-cyanophenyl)-7/- -pyrrolo[2,3-c]pyrimidin-4-
57 183 yl]piperidine-3-carbonitrile
4-(3,5-c;'s-dimethylpiperidin-1-yl)-5-(1-methyl-1 /- -
16 16 pyrazol-4-yl)-7/- -pyrrolo[2,3-c]pyrimidine
4-methoxy-3-[4-(3-methylpiperidin-1 -yl)-7/- -pyrrolo[2,3-
25 46 cf]pyrimidin-5-yl]benzonitrile
3-[4-(dimethylamino)-7/- -pyrrolo[2,3-c]pyrimidin-5-yl]-4-
24 30 methoxybenzonitrile
5-(5-chloro-2-methoxyphenyl)-A/,A/-dimethyl-7/- -
22 19 py rrolo[2 , 3 -d\ py ri m id i n-4-a m i ne
3-{4-[4-(1 H-imidazol-2-yl)piperidin-1-yl]-7A -pyrrolo[2,3-
42 230 cf]pyrimidin-5-yl}benzonitrile, trifluoroacetate salt
3-{4-[3-(methoxymethyl)piperidin-1-yl]-7/- -pyrrolo[2,3-
95 219 cf]pyrimidin-5-yl}benzonitrile -[4-(9-methyl-1 -oxa-4,9-diazaspiro[5.5]undec-4-yl)-7/- -
40 201 pyrrolo[2,3-cdpyrimidin-5-yl]benzonitrile
3-[4-(3-methoxypiperidin-1 -yl)-7/- -pyrrolo[2,3-
79 154 cf]pyrimidin-5-yl]benzonitrile
3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/- -pyrrolo[2,3-
17 121 cf]pyrimidin-5-yl}benzonitrile
A/ -[5-(3-cyanophenyl)-7/- -pyrrolo[2 ,3-cf]pyrim id in-4-yl]-
54 248 A/,A/-dimethyl-beta-alaninamide
3-[4-(4,4-difluoropiperidin-1-yl)-7A -pyrrolo[2,3-
67 333 cf]pyrimidin-5-yl]benzonitrile
3-[4-(4-fluoropiperidin-1-yl)-7/- -pyrrolo[2,3-c]pyrimidin-
17 96 5-yl]benzonitrile
3-[4-(4-fluoropiperidin-1-yl)-7/- -pyrrolo[2,3-c]pyrimidin-
17 56 5-yl]benzonitrile
3-{4-[4-(1 H-pyrazol-3-yl)piperidin-1-yl]-7A -pyrrolo[2,3-
69 136 cf]pyrimidin-5-yl}benzonitrile
3-{4-[(3S)-3-fluoropyrrolidin-1 -yl]-7A -pyrrolo[2,3-
30 155 cf]pyrimidin-5-yl}benzonitrile
3-{4-[2-(1 A -pyrazol-3-yl)morpholin-4-yl]-7A -pyrrolo[2,3-
43 238 cf]pyrimidin-5-yl}benzonitrile
3-{4-[3-(1 A -pyrazol-3-yl)piperidin-1-yl]-7A -pyrrolo[2,3-
84 200 cf]pyrimidin-5-yl}benzonitrile
3-{4-[3-(1 A -imidazol-2-yl)piperidin-1-yl]-7A -pyrrolo[2,3-
53 331 c]pyrimidin-5-yl}benzonitrile, formate salt
3-{4-[(1-methylpiperidin-3-yl)amino]-7/- -pyrrolo[2,3-
78 243 d]pyrimidin-5-yl}benzonitrile, formate salt
3-[4-(3-oxo-2,7-diazaspiro[4.5]dec-7-yl)-7A -pyrrolo[2,3-
35 1 19 cf]pyrimidin-5-yl]benzonitrile
-[4-(3-methylpiperidin-1 -yl)-7/- -pyrrolo[2,3-c]pyrimidin-
70 172 5-yl]benzonitrile, ENT-2
3-(4-{[2-(morpholin-4-yl)ethyl]amino}-7A -pyrrolo[2,3-
89 487 d]pyrimidin-5-yl)benzonitrile, formate salt
3-[4-(2-oxa-7-azaspiro[4.5]dec-7-yl)-7A -pyrrolo[2,3-
34 244 cf]pyrimidin-5-yl]benzonitrile A/-{1-[5-(3-cyanophenyl)-7/- -pyrrolo[2,3-c]pyrimidin-4-
50 190 yl]piperidin-4-yl}acetamide
5-(1 H-indazol-5-yl)-4-[(3S)-3-methylpiperidin-1 -yl]-7A -
67 66 pyrrolo[2,3-c/]pyrimidine
3-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
24 33 cf]pyrimidin-5-yl}benzenesulfonamide
5-(2-fluorophenyl)-4-[(3S)-3-methylpiperidin-1 -yl]-7A -
97 122 pyrrolo[2,3-c/]pyrimidine
5-(1 H-indazol-4-yl)-4-[(3S)-3-methylpiperidin-1 -yl]-7A -
10a 14 pyrrolo[2,3-c/]pyrimidine
5-(6-f luoro-5-m ethyl pyrid in-3-yl )-4-[(3 S)-3- methylpiperidin-1-yl]-7/- -pyrrolo[2,3-c]pyrimidine, 64 65 trifluoroacetate salt
5-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
33 33 cf]pyrimidin-5-yl}-2,3-dihydro-1 /- -isoindol-1-one
4-[(3S)-3-methylpiperidin-1-yl]-5-(pyridin-3-yl)-7A -
56 95 pyrrolo[2,3-c/]pyrimidine, formate salt
4-[(3S)-3-methylpiperidin-1 -yl]-5-(5-methylpyridin-3-yl)-
15 19 7/- -pyrrolo[2,3-cf]pyrimidine, formate salt
4-[(3S)-3-methylpiperidin-1 -yl]-5-(7A -pyrrolo[2,3-
74 69 ib]pyridin-5-yl)-7/- -pyrrolo[2,3-cf]pyrimidine, formate salt
6-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
68 59 cf]pyrimidin-5-yl}-2,3-dihydro-1 /- -isoindol-1-one
4-[(3S)-3-methylpiperidin-1 -yl]-5-(1 A -pyrrolo[3,2-
53 50 ib]pyridin-6-yl)-7/- -pyrrolo[2,3-cf]pyrimidine, formate salt
4-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
26 28 d]pyrimidin-5-yl}phenol
4-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
13 9b d]pyrimidin-5-yl}benzamide
3-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
9 12 d]pyrimidin-5-yl}phenol
5-(2-chloro-5-methylpyridin-3-yl)-4-[(3S)-3- methylpiperidin-1-yl]-7/- -pyrrolo[2,3-c]pyrimidine, 30 30 formate salt 3-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
86 58 d]pyrimidin-5-yl}benzamide
-[4-(3-fluoropiperidin-1-yl)-7/- -pyrrolo[2,3-c]pyrimidin-
12 80 5-yl]benzonitrile
-[4-(4-methylpiperidin-1 -yl)-7/- -pyrrolo[2,3-c]pyrimidin-
91 273 5-yl]benzonitrile, hydrochloride salt
3-{4-[(3S)-3-methylpiperidin-1 -yl]-7A -pyrrolo[2,3-
55 39 d]pyrimidin-5-yl}benzoic acid
3-[4-(methylamino)-7/- -pyrrolo[2,3-c]pyrimidin-5-
45 97 yl]benzonitrile
3-[4-(3,5-c;'s-dimethylpiperidin-1-yl)-7/- -pyrrolo[2,3-
85 176 cf]pyrimidin-5-yl]-4-methoxybenzonitrile
4-methoxy-3-{4-[(3S)-3-methylpiperidin-1-yl]-7A -
21 51 pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
2-fluoro-3-{4-[(3S)-3-methylpiperidin-1-yl]-7A -
1 1 35 pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
A/,A/-dimethyl-5-phenyl-7/- -pyrrolo[2,3-c]pyrimidin-4-
63 39 amine
-[4-(dimethylamino)-7/- -pyrrolo[2,3-c]pyrimidin-5-yl]-2-
6 17 fluorobenzonitrile
3-[4-(pyrrolidin-1-yl)-7/- -pyrrolo[2,3-c]pyrimidin-5-
8 64 yl]benzonitrile
-[4-(3-methylpyrrolidin-1-yl)-7/- -pyrrolo[2,3-cf]pyrimidin-
21 102 5-yl]benzonitrile, ENT-2
-[4-(dimethylamino)-7/- -pyrrolo[2,3-c]pyrimidin-5-yl]-4-
37 190 fluorobenzonitrile
3-[4-(diethylamino)-7/- -pyrrolo[2,3-cf]pyrimidin-5-
13 1 19 yl]benzonitrile
-{4-[2-(methoxymethyl)morpholin-4-yl]-7/- -pyrrolo[2,3-
12 100 d]pyrimidin-5-yl}benzonitrile, ENT-1
-[4-(dimethylamino)-7/- -pyrrolo[2,3-c]pyrimidin-5-yl]-5-
53 396 fluorobenzonitrile
-{4-[2-(1 A -pyrazol-3-yl)morpholin-4-yl]-7A -pyrrolo[2,3-
23 208 d]pyrimidin-5-yl}benzonitrile, ENT-2, formate salt, 3-[4-(3-methylpyrrolidin-1-yl)-7/- -pyrrolo[2,3-cf]pyrimidin-
77 39 158
5-yl]benzonitrile, ENT-1
2-fluoro-3-[4-(morpholin-4-yl)-7A -pyrrolo[2,3-
78 2 7 cf]pyrimidin-5-yl]benzonitrile
3-{4-[(2R)-2-methylmorpholin-4-yl]-7A -pyrrolo[2,3-
79 18 69 cf]pyrimidin-5-yl}benzonitrile
4-fluoro-3-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
80 49 393 cf]pyrimidin-5-yl]benzonitrile
4-(4-fluoropiperidin-1-yl)-5-(1 -methyl-1 /- -pyrazol-4-yl)-
81 36 50
7/- -pyrrolo[2,3-cf]pyrimidine
2-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-ci]pyrimidin-5-
82 95 148 yl]benzonitrile
5-(3-chlorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
83 8 13 c]pyrimidine
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
84 22 30 c]pyrimidine
5-(3-fluoro-5-methoxyphenyl)-4-(morpholin-4-yl)-7/- -
85 9 20 pyrrolo[2,3-c/]pyrimidine
5-(2,5-difluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
86 76 145 c]pyrimidine
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
87 12 24 c]pyrimidine
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7/- -
88 9 12 pyrrolo[2,3-c]pyrimidine
{2-fluoro-3-[4-(morpholin-4-yl)-7A -pyrrolo[2,3-
89 32 75 c]pyrimidin-5-yl]phenyl}methanol
5-(2,4-difluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
90 41 62 c]pyrimidine
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
91 9 21 c]pyrimidine
5-(3,5-difluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
92 92 238 c]pyrimidine
93 4-(morpholin-4-yl)-5-phenyl-7/- -pyrrolo[2,3-c]pyrimidine 9 14 5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/- -
94 7 10 pyrrolo[2,3-c/]pyrimidine
5-(2-chlorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
95 21 33 c]pyrimidine
5-(5-fluoro-2-methylphenyl)-4-(morpholin-4-yl)-7/- -
96 91 223 pyrrolo[2,3-c/]pyrimidine
5-(3-methoxyphenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
97 28 46 c]pyrimidine
{2-fluoro-5-[4-(morpholin-4-yl)-7A -pyrrolo[2,3-
98 70 135 d]pyrimidin-5-yl]phenyl}methanol
5-(4-fluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
99 95 154 c]pyrimidine
{3-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-c]pyrimidin-5-
100 12 19 yl]phenyl}methanol
5-(2-methoxyphenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
101 14 23 c]pyrimidine
5-[3-(methylsulfanyl)phenyl]-4-(morpholin-4-yl)-7/- -
102 52 78 pyrrolo[2,3-c]pyrimidine
4-(morpholin-4-yl)-5-(pyridin-3-yl)-7/- -pyrrolo[2,3-
103 35 159 c]pyrimidine, formate salt
4-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-c(]pyrimidin-5-
104 27 51 yl]isoquinoline, formate salt
5-(5-bromopyridin-3-yl)-4-(morpholin-4-yl)-7/- -
105 6 14 pyrrolo[2,3-c]pyrimidine, formate salt
5-(2-chloro-5-methylphenyl)-4-(morpholin-4-yl)-7/- -
106 22 44 pyrrolo[2,3-c]pyrimidine
5-(3-methylphenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
107 13 20 c]pyrimidine
5-(1-methyl-1 /- -pyrazol-3-yl)-4-(morpholin-4-yl)-7/- -
108 53 90 pyrrolo[2,3-c]pyrimidine
3-[4-(4-hydroxypiperidin-1 -yl)-7/- -pyrrolo[2,3-
109 52 109 cf]pyrimidin-5-yl]benzonitrile
3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-
110 20 176
7/- -pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile 3-methyl-5-[4-(morpholin-4-yl)-7A -pyrrolo[2,3-
111 14 64 cf]pyrimidin-5-yl]benzonitrile
3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-
112 10 41
7/- -pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
3-[4-(6-oxa-3-azabicyclo[3.1.1]hept-3-yl)-7A -pyrrolo[2,3-
113 58 523 cf]pyrimidin-5-yl]benzonitrile
3-chloro-5-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
114 77b 406 cf]pyrimidin-5-yl]benzonitrile
4-methoxy-3-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
115 48 121 cf]pyrimidin-5-yl]benzonitrile
5-(5-chloro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/- -
116 85 67 pyrrolo[2,3-c/]pyrimidine
6-methyl-5-(1-methyl-1 /- -pyrazol-4-yl)-4-(morpholin-4-
117 47 89 yl)-7/- -pyrrolo[2,3-c]pyrimidine
3-methoxy-5-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
118 77 177 cf]pyrimidin-5-yl]benzonitrile
5-(1 -methyl-1 /- -pyrazol-4-yl)-4-(thiomorpholin-4-yl)-7/- -
119 71 51 pyrrolo[2,3-c/]pyrimidine
1 -[5-(1-methyl-1 tf-pyrazol-4-yl)-7tf-pyrrolo[2,3-
120 44 34 cf]pyrimidin-4-yl]piperidin-3-ol
4-[(2S)-2-methylmorpholin-4-yl]-5-(1 -methyl-1 A -pyrazol-
121 57 59
4-yl)-7/- -pyrrolo[2,3-cf]pyrimidine
4-[(2R)-2-methylmorpholin-4-yl]-5-(1-methyl-1 A -pyrazol-
122 67 31
4-yl)-7/- -pyrrolo[2,3-cf]pyrimidine
4-(3-fluoropiperidin-1-yl)-5-(1 -methyl-1 /- -pyrazol-4-yl)-
123 31 27
7/- -pyrrolo[2,3-cf]pyrimidine
{4-[5-(1-methyl-1 A -pyrazol-4-yl)-7A -pyrrolo[2,3-
124 77 80 c]pyrimidin-4-yl]morpholin-2-yl}methanol
5-(1 -methyl-1 A -pyrazol-4-yl)-4-(2-{[(6-methylpyridin-3-
125 yl)oxy]methyl}morpholin-4-yl)-7/- -pyrrolo[2,3- 54 87 c]pyrimidine
N, N-d im ethyl-5-( 1 -m ethyl- 1 A -py razol-4-yl)-7A -
126 55 35 py rrolo[2 , 3 -d\ py ri m id i n-4-a m i ne
A/-cyclopropyl-A/-m ethyl-5-( 1 -m ethyl- 1 /- -py razol-4-yl )-
127 37 37
7/-/-pyrrolo[2,3-cf]pyrimidin-4-amine 3-[4-(3,3-difluoropiperidin-1-yl)-7A -pyrrolo[2,3-
128 79 169 cf]pyrimidin-5-yl]benzonitrile
3-[4-(3-aminopiperidin-1-yl)-7/- -pyrrolo[2,3-c]pyrimidin-
129 14 21
5-yl]benzonitrile
3-[4-(2-{[5-(difluoromethyl)-1 ,2,4-oxadiazol-3-
130 yl]methyl}morpholin-4-yl)-7/- -pyrrolo[2,3-c]pyrimidin-5- 44 134 yl]benzonitrile
3-{4-[2-(1 ,3-thiazol-2-yl)morpholin-4-yl]-7H-pyrrolo[2,3-
131 45 181 cf]pyrimidin-5-yl}benzonitrile
3-[4-(4-oxopiperidin-1-yl)-7/- -pyrrolo[2,3-c]pyrimidin-5-
132 66 223 yl]benzonitrile
3-{4-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]-7/- -
133 42 106 pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
3-{4-[2-(3-hydroxyphenyl)morpholin-4-yl]-7/- -
134 91 281 pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
3-{4-[2-(5-cyclopropyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-
135 19 47 yl]-7/- -pyrrolo[2,3-ci]pyrimidin-5-yl}benzonitrile
3-[4-(3,3-difluoropyrrolidin-1-yl)-7A -pyrrolo[2,3-
136 74 194 cf]pyrimidin-5-yl]benzonitrile
3-(4-{2-[(3-cyanophenoxy)methyl]morpholin-4-yl}-7/- -
137 30 51 pyrrolo[2,3-cdpyrimidin-5-yl)benzonitrile
3-[4-(3-hydroxypiperidin-1 -yl)-7/- -pyrrolo[2,3-
138 10 27 cf]pyrimidin-5-yl]benzonitrile
1 -[5-(3-cyanophenyl)-7/- -pyrrolo[2,3-c]pyrimidin-4-
139 49 136 yl]piperidine-3-carboxamide
3-[4-(2-ethylmorpholin-4-yl)-7/- -pyrrolo[2,3-c]pyrimidin-
140 61 95
5-yl]benzonitrile
3-{4-[2-(pyrimidin-4-yl)morpholin-4-yl]-7/- -pyrrolo[2,3-
141 79 193 cf]pyrimidin-5-yl}benzonitrile
3-{4-[2-(3-cyclopropyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-
142 30 84 yl]-7/- -pyrrolo[2,3-ci]pyrimidin-5-yl}benzonitrile
3-(4-{2-[(dimethylamino)methyl]morpholin-4-yl}-7/- -
143 45 1 10 pyrrolo[2,3-c]pyrimidin-5-yl)benzonitrile
3-[4-(1 /- -pyrazol-4-ylamino)-7/- -pyrrolo[2,3-c]pyrimidin-
144 69 36
5-yl]benzonitrile 3-(4-{2-[(5-m ethyl- 1 ,2 , 4-oxad iazol-3-
145 yl)methyl]morpholin-4-yl}-7/- -pyrrolo[2,3-c]pyrimidin-5- 55 155 yl)benzonitrile
3-{4-[3-(5-methyl-1 ,3,4-oxadiazol-2-yl)piperidin-1-yl]-7A -
146 96 217 pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
3-[4-(dimethylamino)-7/- -pyrrolo[2,3-c]pyrimidin-5-yl]-5-
147 37 93 methoxybenzonitrile
5-(1-ethyl-1 /- -pyrazol-4-yl)-4-(morpholin-4-yl)-7/- -
148 77b 92 pyrrolo[2,3-c]pyrimidine
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7/- -
149 18 30 pyrrolo[2,3-c]pyrimidine
5-(5-chloropyridin-3-yl)-4-(morpholin-4-yl)-7/- -
150 28 36 pyrrolo[2,3-c]pyrimidine
5-(6-methoxypyrazin-2-yl)-4-(morpholin-4-yl)-7/- -
151 32 37 pyrrolo[2,3-c]pyrimidine
5-(1 ,3-dimethyl-1 /- -pyrazol-4-yl)-4-(morpholin-4-yl)-7/- -
152 60 91 pyrrolo[2,3-c]pyrimidine, formate salt
3-{4-[(3S)-3-methylmorpholin-4-yl]-7A -pyrrolo[2,3-
153 44 165 cf]pyrimidin-5-yl}benzonitrile
2-fluoro-3-[2-methyl-4-(morpholin-4-yl)-7A -pyrrolo[2,3-
154 30 365 cf]pyrimidin-5-yl]benzonitrile
3-{4-[(3R)-3-hydroxypiperidin-1-yl]-7A -pyrrolo[2,3-
155 8b 37 cf]pyrimidin-5-yl}benzonitrile
1 -[5-(3-fluorophenyl)-7/- -pyrrolo[2,3-c(]pyrimidin-4-
156 57 86 yl]piperidin-3-ol
5-(5-fluoro-2-methoxyphenyl)-4-[2-(5-methyl-1 ,2,4-
157 oxadiazol-3-yl)morpholin-4-yl]-7/- -pyrrolo[2,3- 44 46 c]pyrimidine
2-fluoro-3-[4-(4-fluoropiperidin-1-yl)-7A -pyrrolo[2,3-
158 18 86 cf]pyrimidin-5-yl]benzonitrile
4-(4-fluoropiperidin-1-yl)-5-(2-methoxyphenyl)-7/- -
159 67 74 pyrrolo[2,3-c]pyrimidine
5-(3-fluoro-5-methoxyphenyl)-4-(4-fluoropiperidin-1 -yl)-
160 84 96
7/- -pyrrolo[2,3-cf]pyrimidine 3-[4-(4,4-difluoropiperidin-1-yl)-7A -pyrrolo[2,3-
N.D.° N.D. d]pyrimidin-5-yl]-2-fluorobenzonitrile
-[5-(5-m ethyl pyrid i n-3-y I )-7/- -pyrrolo[2 , 3-d\ pyrim id in-4-
36 67 yl]piperidin-3-ol, formate salt
-(5-fluoro-2-methoxyphenyl)-4-(4-fluoropiperidin-1 -yl)-
25 29 7/- -pyrrolo[2,3-cf]pyrimidine
1-[5-(3-fluoro-5-methoxyphenyl)-7/- -pyrrolo[2,3-
29 38 cf]pyrimidin-4-yl]piperidin-3-ol
1-[5-(2-methoxyphenyl)-7/- -pyrrolo[2,3-c]pyrimidin-4-
58 62 yl]piperidin-3-ol
2-fluoro-3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5- yl)morpholin-4-yl]-7/- -pyrrolo[2,3-c]pyrimidin-5- 38 272 yl}benzonitrile
2-fluoro-3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/- -
61 372 pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
4-(azetidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-7/- -
85 75 pyrrolo[2,3-c/]pyrimidine
-[(2S)-2-methylmorpholin-4-yl]-5-(5-methylpyridin-3-yl)-
99 280 7/- -pyrrolo[2,3-cf]pyrimidine, formate salt
5-(3-fluorophenyl)-4-(pyrrolidin-1 -yl)-7/- -pyrrolo[2,3-
N.D. N.D. c]pyrimidine
5-(3-fluorophenyl)-4-[2-(5-methyl-1 ,2,4-oxadiazol-3-
N.D. N.D. yl)morpholin-4-yl]-7/- -pyrrolo[2,3-c]pyrimidine
5-(2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-
N.D. N.D. 7/- -pyrrolo[2,3-cf]pyrimidine
5-(2-methoxyphenyl)-A/,A/-dimethyl-7/- -pyrrolo[2,3-
43 29 cf]pyrimidin-4-amine
2-fluoro-3-{4-[(3S)-3-fluoropyrrolidin-1-yl]-7A -
N.D. N.D. pyrrolo[2,3-cdpyrimidin-5-yl}benzonitrile
-[(3S)-3-fluoropyrrolidin-1 -yl]-5-(2-methoxyphenyl)-7A -
41 54 pyrrolo[2,3-c]pyrimidine
-(2-methoxyphenyl)-4-(pyrrolidin-1-yl)-7/- -pyrrolo[2,3-
54 68 c]pyrimidine
5-(3-fluoro-5-methoxyphenyl)-A/,A/-dimethyl-7/- -
41 49 pyrrolo[2,3-c]pyrimidin-4-amine 2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7/- -pyrrolo[2,3-
178 9 42 cf]pyrimidin-5-yl]benzonitrile
5-(5-fluoro-2-methoxyphenyl)-4-[(2S)-2-
179 19 30 methylmorpholin-4-yl]-7/- -pyrrolo[2,3-cf]pyrimidine
2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7A -
180 10 62 pyrrolo[2,3-cdpyrimidin-5-yl}benzonitrile
5-(5-fluoro-2-methoxyphenyl)-4-(3-fluoropiperidin-1 -yl)-
181 22 24
7/- -pyrrolo[2,3-cf]pyrimidine
5-(3-fluorophenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7A -
182 38 82 pyrrolo[2,3-c/]pyrimidine
5-(5-fluoro-2-methoxyphenyl)-A/,A/-dimethyl-7/- -
183 13 1 1 py rrolo[2 , 3 -d\ py ri m id i n-4-a m i ne
2-fluoro-3-[4-(pyrrolidin-1 -yl)-7/- -pyrrolo[2,3-c]pyrimidin-
184 15 82
5-yl]benzonitrile
5-(5-fluoro-2-methoxyphenyl)-4-[(3S)-3-fluoropyrrolidin-
185 15 23
1-yl]-7/- -pyrrolo[2,3-c]pyrimidine
2-fluoro-3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-
186 yl)morpholin-4-yl]-7/- -pyrrolo[2,3-c]pyrimidin-5- 17 90 yl}benzonitrile
5-(4-methyl-1 ,3-thiazol-2-yl)-4-(morpholin-4-yl)-7A -
187 N.D. N.D.
pyrrolo[2,3-c]pyrimidine
5-(4-methylpyridin-2-yl)-4-(morpholin-4-yl)-7/- -
188 43 90 pyrrolo[2,3-c]pyrimidine, formate salt
5-(2-fluoro-6-methoxyphenyl)-A/,A/-dimethyl-7/- -
189 40 27 pyrrolo[2,3-c]pyrimidin-4-amine
5-(2-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7/- -
190 25 34 pyrrolo[2,3-c]pyrimidine
5-(2,6-difluorophenyl)-4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
191 N.D. N.D.
c]pyrimidine
5-(3-methyl-1 ,2-thiazol-5-yl)-4-(morpholin-4-yl)-7A -
192 23 73 pyrrolo[2,3-cdpyrimidine
5-(2-chloro-3-fluoro-6-methoxyphenyl)-4-(morpholin-4-
193 47 51 yl)-7/- -pyrrolo[2,3-c]pyrimidine
5-(4-methoxypyridin-3-yl)-4-(morpholin-4-yl)-7/- -
194 N.D. N.D.
pyrrolo[2,3-c]pyrimidine, formate salt 3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-
195 8 73
7/- -pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile, ENT-1
3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-
196 N.D. N.D.
7/- -pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile, ENT-2
3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/- -pyrrolo[2,3-
197 214 245 d]pyrimidin-5-yl}benzonitrile, ENT-2
3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7A -pyrrolo[2,3-
198 127 1080 cf]pyrimidin-5-yl]benzonitrile
5-(5,6-dihydro-2A -pyran-3-yl)-4-(morpholin-4-yl)-7A -
199 97.8b 351 b pyrrolo[2,3-c/]pyrimidine
5-(3,4-dihydro-2A -pyran-5-yl)-4-(morpholin-4-yl)-7A -
200 76.7b 167b pyrrolo[2,3-c/]pyrimidine
4-(morpholin-4-yl)-5-[3-(1 ,2,4-oxadiazol-3-yl)phenyl]-
201 129b 475b
7/- -pyrrolo[2,3-cf]pyrimidine
3-{4-[2-(3-methyl-1 ,2-oxazol-5-yl)morpholin-4-yl]-7A -
202 64.7 350 pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
2-methyl-3-[4-(morpholin-4-yl)-7A -pyrrolo[2,3-
203 13.2 90.1 cf]pyrimidin-5-yl]benzonitrile
4-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-ci]pyrimidin-5-
204 1 1.7 32.7 yl]pyridin-2(1 /- )-one
5-(imidazo[2, 1-j ][1 ,3]thiazol-5-yl)-4-(morpholin-4-yl)-7H-
205 15.8 60.5 pyrrolo[2,3-c]pyrimidine
re/-3-{4-[(3a S, 6a S)-hexahyd ro-5A -f u ro[2 , 3-c] pyrrol-5-
206 139 591 yl]-7/- -pyrrolo[2,3-ci]pyrimidin-5-yl}benzonitrile
re/-3-{4-[(3aR,6aS)-tetrahydro-1 A -furo[3,4-c]pyrrol-
207 223b 687b
5(3/- )-yl]-7/- -pyrrolo[2,3-cf]pyrimidin-5-yl}benzonitrile
re/-3-{4-[(4aR,7aS)-hexahydrocyclopenta[b][1 ,4]oxazin-
208 27.2 186
4(4a/- )-yl]-7/- -pyrrolo[2,3-c]pyrimidin-5-yl}benzonitrile
4-[5-(3-cyanophenyl)-7/- -pyrrolo[2,3-c]pyrimidin-4-
209 42.2 336 yl]morpholine-2-carbonitrile
3-[4-(2,2-dimethylmorpholin-4-yl)-7A -pyrrolo[2,3-
210 35.2 304 cf]pyrimidin-5-yl]benzonitrile
5-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-ci]pyrimidin-5-
211 21.9 1 18 yl]thiophene-2-carbonitrile 5-(imidazo[1 ,2-£>]pyridazin-3-yl)-4-(morpholin-4-yl)-7/- -
212 6.26 12.3 pyrrolo[2,3-cdpyrimidine
2-fluoro-3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5-
213 yl)morpholin-4-yl]-7/- -pyrrolo[2,3-c]pyrimidin-5- 7.71 95.7 yl}benzonitrile, ENT-2
2-fluoro-3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5-
214 yl)morpholin-4-yl]-7/- -pyrrolo[2,3-c]pyrimidin-5- N.D. N.D.
yl}benzonitrile, ENT-1
6-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-c(]pyrimidin-5-
215 30.6 79.3 yl]pyridine-2-carboxamide, formate salt
4-(morpholin-4-yl)-5-(pyrazolo[1 ,5-a]pyrimidin-3-yl)-7/- -
216 35.6 1 19 pyrrolo[2,3-c]pyrimidine
1-methyl-4-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
217 6.37 13 d]pyrimidin-5-yl]-1 /- -pyrrole-2-carbonitrile
5-(6-methylimidazo[2, 1-ib][1 ,3]thiazol-5-yl)-4-(morpholin-
218 37.4b 135b
4-yl)-7/- -pyrrolo[2,3-cf]pyrimidine, formate salt
3-{4-[2-(1 ,2-oxazol-5-yl)morpholin-4-yl]-7A -pyrrolo[2,3-
219 37 234 cf]pyrimidin-5-yl}benzonitrile
1-methyl-4-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
220 cf]pyrimidin-5-yl]-1 /- -imidazole-2-carbonitrile, 7.47 14.7 trifluoroacetate salt
4-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-c(]pyrimidin-5-
221 N.D. N.D.
yl]thiophene-2-carbonitrile
4-(morpholin-4-yl)-5-(pyrazolo[1 ,5-a]pyridin-3-yl)-7/- -
222 N.D. N.D.
pyrrolo[2,3-c]pyrimidine
1 ,5-dimethyl-4-[4-(morpholin-4-yl)-7/- -pyrrolo[2,3-
223 N.D. N.D.
d]pyrimidin-5-yl]-1 /- -pyrrole-2-carbonitrile
1-methyl-3-[4-(morpholin-4-yl)-7A -pyrrolo[2,3-
224 d]pyrimidin-5-yl]-1 /- -pyrazole-5-carbonitrile, N.D. N.D.
trifluoroacetate salt
3-{4-[2-(cyanomethyl)morpholin-4-yl]-7/- -pyrrolo[2,3-
225 N.D. N.D.
cf]pyrimidin-5-yl}benzonitrile
* Geometric mean of 2 - 5 determinations unless otherwise indicated
a. IC50 value represents the geometric mean of >6 determinations.
b. IC50 value derived from a single determination.
c. N.D. - not determined Certain of the compounds of the present invention were assessed for kinase selectivity using a commercially available ActiveX targeted kinase probe in which the tissue employed was human peripheral blood mononuclear cells (PBMC). The test compounds were provided to ActivX Biosciences, Inc., 1 1025 North Torrey Pines Road, Suite 120; LaJolla, CA, USA 92037. The compounds were run in the ActivX proprietary kinase assay and results were obtained at compound test concentrations of 1 μΜ (columns 2, 4 and 6) and 0.1 μΜ (columns 3, 5 and 7). The results as percent inhibition obtained for the compounds of Examples 1 , 4 and 217 are provided below in Table 3.
TABLE 3
Example 1 Example 4 Example 217
Kinase 1 μΜ 0.1 μΜ 1 μΜ 0.1 μΜ Ι μΜ 0.1 μΜ
ABL,ARG 22.5 25.8 -0.9 -29.4 -1.6 4.6
ACK -8 5.2 7.7 0.8 -19.5 -9.8
AKT1 18.8 11.3 -6.3 -8.8 -3.6 5.5
AKT2,AKT3 10.7 1.6 6.8 -2.6 -3.8 -9.7
AMPKal 27 1.5 16.4 -2.1 48.8 27.2
AMPKal,AMPKa2 49.7 10.8 32.5 -4.5 16.5 5.7
BRAF -51.5 -6.5 -1.2 1.2 -10.4 -8.4
BTK 3.7 8.7 9.5 -2.2 8.5 24.3
CaMKla 6.3 2 1.9 -9.2 -7.1 -5.4
CaMKld 3.2 8.4 0.9 -12.1 3.1 11.7
CaMK2d -38.1 -45.3 10.8 -0.4 16.1 9.8
CaMK2g -15.5 -16.9 2.9 -13.6 18.7 4.3
CDC2 14.7 -4 12.9 -6.7 24.4 28.7
CDK11,CDK8 2.4 4.4 36 5 -5.2 -5.6
CDK2 9.5 -12.1 9.2 11 16.5 3.6
CDK5 -35.1 -6.5 0.1 -12.2 7.9 0.5
CHK2 17.7 0.9 2.2 -6.8 6.4 8.6
DGKA -16.6 -21 -8.7 -15.9 4.7 -2.8
DNAPK -30 -4.4 14.7 -19.3 31.5 31.0 eEF2K -6.5 -9.6 2.8 -27.1 2.2 -12.1
EphAl 19.6 -9.5 -2.5 -17 -16.1 11.1
Erk5 -41.9 -32.8 -6.3 -5 -5.4 -2.6
FAK 20 18 11.1 -8.9 17.4 8.1
FER -17.9 -7.3 1.6 -26.4 16.3 5.2
FES -0.9 4.3 6.9 -9.2 6.2 8.4
FGR 4.6 12.9 1.7 -10.8 -0.5 -1.2
FRAP -1.2 -3.2 9.8 -20.7 0.9 0.7
FYN -10.1 6.7 -9.1 -1.9 -6.8 -2.1
FYN,SRC,YES -56.3 -24.1 -8.8 -22.8 -1.4 18.4 GCK -6.7 4.4 31.2 3.6 27.2 -5.2
GCN2 -25.1 0.1 0.6 -13.6 -3.1 -7.7
GP K6 23.7 8.9 10.9 -3.9 3.6 -0.8
GSK3A -11.4 -0.2 7.2 -0.9 8.9 0.6
GSK3B -5.2 2.4 6.7 -3.7 12.4 -4.3
HPK1 -14.9 -9.7 5.7 -1.5 1.7 -13.7
IKKa -40.5 -20 -6.6 -12.1 -3.7 -2.5
IKKb 10.8 16.1 -15.8 -15.5 6.5 7.1
IKKe 17.7 2.6 7.4 -7 20.4 -3.0
IKKeJBKl 23.7 1.5 18.8 -6.7 13.3 2.3
ILK -56.6 -34 -31.6 -8.9 -3.8 -6.3
IRAKI -9.1 -13.8 2.1 -2.9 7.5 -1.7
IRAK3 68.7 30.1 33.7 29.8 72.4 16.0
IRAK4 34.7 17.7 10.7 -12.8 34.5 14.7
IRE1 -8 -1.3 1.8 -16 -19.5 3.2
JAK1 54.2 15 5 -9.3 11.4 -3.0
JAK1 domain2 -13.7 -8.1 18.9 -6.2 10.1 7.4
JAK2 domain2 16.7 13.8 16.4 0.7 -6.4 4.8
JAK3 domain2 -5.2 2.7 6.8 6.9 4.9 -7.8
JNK1,JNK2,JNK3 7.7 7.1 5.4 -5.3 -6.4 -18.2
KHS1 24.6 17.8 12.9 -25.9 7.6 10.7
KSR1,KSR2 -14 1.5 11.7 -8.7 -6.8 -6.2
LATS1 -16.2 4.2 5.4 -4.8 1.9 -3.9
LATS2 11 21.2 16.2 -7.2 -23.7 5.8
LKB1 -14 -1.1 16.5 3.5 2.4 -5.3
LOK 22.6 5.7 53.6 11.9 56.1 -6.4
LRRK2 88.1 69 94.1 79.9 88.4
LYN 7.8 3.8 0.8 -5.4 -19.2 8.3
MAP2K1 17 3.5 14 -17.2 -1.5 17.2
MAP2K1,MAP2K2 -2.2 1 6.4 -7.1 -2.6 10.9
MAP2K3 -9 14.4 6.2 -12.5 3.3 2.5
MAP2K4 9.6 10.1 19.2 -20.5 1.6 2.3
MAP2K6 19 17.5 13.5 -15.1 -0.1 11.3
MAP3K1 11.9 -9.4 44.5 6.4 14.8 -17.3
MAP3K3 7.2 -9.2 7.4 -0.5 -6.7 -3.4
MAP3K4 6.9 -14 29.8 9.7 -27.4 -35.5
MAP3K5 2.1 6.2 21.3 3.3 44.5 7.0
MARK2 41.6 10.1 27.3 -4.7 13.1 -5.0
MARK3 29.1 1 23.7 -2.6 18.4 16.2
MAST3 -6.7 9 0.8 2.6 0.4 -11.7
MLK3 4.5 1.4 19.9 -14.1 -9.6 -13.5
MLKL 8.4 1.6 14.5 -10.1 -3.3 2.5
MSK1 domainl -30.4 -7 -3.8 1 -2.2 -12.1 MST1 50.8 13.2 82.2 41.9 73.5 25.6
MST1,MST2 24.8 -14.5 70.8 34.4 72.6 21.9
MST2 49.4 10.1 82.6 47.3 83.2 34.9
MST3 28.4 10.9 46.2 0.1 10.9 6.7
MST4,YSK1 15.1 -11.4 60.7 11.9 9.9 5.3
NDR1 -7.8 -19.6 1.7 -4.4 -17.7 16.3
NDR2 31.2 22.8 22.1 -18.7 -6.0 28.9
NEK1 -10.1 7 -1.9 -8.9 -5.1 4.8
NEK6,NEK7 -17 -1.7 -4.9 -5.3 6.4 -2.9
NEK7 -18.8 -0.6 7.3 2.2 -2.3 -9.0
NEK9 12.6 -0.9 1 -7.1 1.5 -11.0
NuaK2 8.9 3.6 18.1 -11.9 24.9 1.3
0SR1 -4 -7.8 -55.4 -23.1 -12.3 5.2 p38a -19.8 -23.5 -1.7 -14.6 -4.6 -1.1 p38d,p38g -24 -37.3 -5.7 -17.5 1.5 -0.4 p70S6K 18.9 23 11.1 -9 -9.6 3.5 p70S6K,p70S6Kb -3.5 9.4 -9.6 -10.5 5.4 5.5 p70S6Kb 10.1 15 18.5 11.4 -16.7 -2.2
PAN3 0.8 0.6 15.1 -0.2 -7.5 5.6
PCTAIRE2,PCTAIRE3 -2.5 7.5 24.7 -5.4 15.1 -2.6
PI4KB 16.1 34 4.9 -7.4 -0.5 9.9
PIK3C3 4.8 23.3 13.6 -2.4 10.2 19.9
PIK3CB -29.8 -2.6 -2.5 0.5 -29.7 -5.3
PIK3CD -65.4 -101.6 -12.4 -14 10.0 -0.4
PIK3CG -62.9 -18.6 -5.6 -20.4 -22.0 -3.4
PIP4K2A 6.8 12.1 1.9 -12.1 8.2 7.8
PIP4K2C -1.4 1.4 58.4 3.1 -11.9 6.2
PIP4K2C 0.9 -48 54.3 9.3 4.0 -4.7
PIP5K3 15 1.9 21.6 -11.2 2.5 16.0
PITSLRE -3.2 -13 10.7 -12.4 6.6 -6.7
PKD2 20.1 2.7 9.4 0.7 4.5 5.8
PKR -17.3 -4.3 7.2 -3.3 1.8 -7.7
PRPK -13.8 -3.4 -3.7 3 12.5 2.6
PYK2 19.5 5.9 2.5 -3.9 8.4 -1.0
RIPK3 -4.2 5.6 8 -3.2 -9.1 -7.3
RSK1 domainl 59.8 16.3 32.9 -26.8 45.6 27.6
RSK1 domain2 18.1 -12.7 55.8 2.7 5.0 -3.4
RSK1,RSK2,RSK3 domainl 18.7 3 13.4 -0.4 48.5 5.0
RSK2 domainl 5.6 -6.8 -11.2 -6 61.6 13.2
RSK2 domain2 9.1 0.6 21.4 -10 2.8 -4.1
RSKL1 domainl -0.2 5.5 -1.8 1.1 -30.6 -15.9
SGK3 9.9 2.5 -0.8 -5.5 16.9 8.5
SLK 50.6 22.9 60.7 10.5 39.1 22.5 SMG1 -19.2 -1.3 13 -2.5 -6.1 1.5 smMLCK -1.9 -11.5 16.2 -21.6 3.5 1.7
SRC 9.7 1.5 -2.2 -18.3 1.1 -1.0
STLK5 -46.5 -1.5 1.2 -15.4 -11.5 -6.9
SYK -6.1 -8.9 7.2 -8.3 -5.1 -2.0
ΤΑ01/ΓΑ03 -14.9 -24 5.9 -6.5 -16.5 -9.7
TA02 -24.2 -6.3 -2.5 -12.7 -18.4 -20.2
TBK1 13.4 0.1 16.4 7.3 0.1 1.9
TLK1 2.7 7.8 -3.7 -4.6 16.7 7.6
TLK2 -21.1 -5.8 -9.4 -8.4 16.0 11.1
ULK3 8 -1.9 5.2 3.1 17.4 -8.6
Wnkl,Wnk2,Wnk3 -24 -18.8 -6 1.7 -21.1 -6.3
Wnkl,Wnk2,Wnk4 -13.5 -15 -1.3 -1.9 -5.4 2.2
ZAK 23.1 15 -42.2 -20.5 -1.2 -2.9
ZAP70 3.1 -23.2 6.8 -4.9 -6.0 -25.0
ZCl/HG K,ZC2/TN 1 K,ZC3/M 1 N K 4.9 -18 14.8 -3.2 7.7 -1.2
ZC2/TNI 31.2 -10.6 29.2 -7.9 3.9 -10.7

Claims

CLAIMS We claim:
1. A compound of Formula I
Figure imgf000140_0001
or a pharmaceutically acceptable salt thereof wherein
R1 and R2 are each independently hydrogen, d-Cealkyl, Ca-Czcycloalkyl, a four to seven membered heterocycloalkyi which contains one to three heteroatoms selected from N, O and S; or a five to six membered heteroaryl which contains one to four heteroatoms selected from N, O and S, wherein the C-i-Cealkyl, C3-C7cycloalkyl, four to seven membered heterocycloalkyi, or five to six membered heteroaryl are optionally substituted with one to three R6;
or R1 and R2 taken together with the nitrogen to which they are attached are a four to seven membered heterocycloalkyi which optionally contains one to two additional heteroatoms selected from N, O and S, and optionally contains one double bond; a six to eleven membered heterobicycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; or a six to twelve membered heterospirocycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; and wherein the four to seven membered heterocycloalkyi, six to eleven membered heterobicycloalkyl or six to twelve membered heterospirocycloalkyl is optionally substituted with one to three R7;
R3 is phenyl or a five to ten membered heteroaryl which contains one to four heteroatoms selected from N, O and S; wherein the phenyl and five to ten membered heteroaryl are optionally substituted with one to three R9 and wherein the phenyl is optionally fused with a Cs-Cecycloalkyl or a five to six membered heterocycloalkyi which contains one to three heteroatoms selected from N, O and S and which is optionally substituted with oxo;
R4 and R5 are each independently hydrogen or d-Caalkyl; R6 at each occurrence is independently selected from d-Caalkyl, d-Caalkoxy, hydroxy, halo, -NRaRb, -C(0)NRaRb, or a four to seven membered heterocycloalkyl which contains one to three heteroatoms selected from N, O and S;
R7 at each occurrence is independently selected from halo, hydroxy, cyano, - NRaRb, -C(0)NRaRb, C C6alkyl, C C6alkoxy, phenyl, a five to six membered heteroaryl containing one to four heteroatoms selected from N, O and S, or two R7 when attached to the same carbon and taken together can be oxo; wherein the C Cealkyl, phenyl and five to six membered heteroaryl are optionally substituted with one to three R8;
R8 at each occurrence is independently hydroxy, halo, cyano, C-i-C3alkoxy, NRaRb, Ci-C3alkyl optionally substituted with one to three halo, Ca-Czcycloalkyl, phenoxy optionally substituted with cyano, or a five to six membered heteroaryloxy containing one to four heteroatoms selected from N, O and S and which is optionally substituted with one or two halo or d-Caalkyl;
R9 at each occurrence is independently cyano, halo, hydroxy, CrC3alkyl-S-, - C02H, -C(0)NH2, -S(0)2NH2, C C3alkyl optionally substituted with one to three halo or hydroxy, or Ci-C3alkoxy optionally substituted with one to three halo or hydroxy; and
Ra and Rb at each occurrence are each independently hydrogen, C Cealkyl, C3- C/cycloalkyl or -C(0)CrC6alkyl.
2. The compound of claim 1 wherein R4 and R5 are each hydrogen; or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 wherein R1 and R2 taken together with the nitrogen to which they are attached are azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomo
Figure imgf000141_0001
each of which is optionally substituted with one to three R7; or a pharmaceutically acceptable salt thereof.
4. The compound of claim 3 wherein R1 and R2 taken together with the nitrogen to which they are attached are piperidin-1-yl or morpholin-4-yl; each optionally substituted with a hydroxy, methyl or 5-methyl-1 ,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 wherein R1 and R2 taken together with the nitrogen to which they are attached are morpholin-4-yl optionally substituted with a methyl or 5- methyl-1 ,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable salt thereof.
6. The compound of claim 2 wherein R1 and R2 taken together with the nitrogen to which they are attached are methylamino, dimethylamino, diethylamino, N- methylcyclopropylamino or pyrazolylamino; each of which is optionally substituted with one to three R6; or a pharmaceutically acceptable salt thereof.
7. The compound of claim 3 wherein R3 is phenyl substituted with one or two R9; and each R9 is independently selected from cyano, fluoro, chloro or methoxy; or a pharmaceutically acceptable salt thereof.
8. The compound of claim 3 wherein R3 is pyrazolyl, isothiazolyl, or pyridinyl, each optionally substituted with one R9; and R9 is cyano or methyl; or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 wherein
R1 and R2 taken together with the nitrogen to which they are attached is selected from the group consisting of:
Figure imgf000143_0001
R3 is 1-methylpyrazol-4-yl, 1 H-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1 ,2- thiazol-5-yl, 5-cyano-1 -methylpyrrol-3-yl, 3-methylpyridin-5-yl, 3-cyanophenyl, 2- fluorophenyl, 3-fluorophenyl, 2,3-difluorophenyl, 2-fluoro-5-chlorophenyl, 2-fluoro-3- cyanophenyl or 2-methoxy-5-fluorophenyl; and
R4 and R5 are each independently hydrogen or methyl;
or a pharmaceutically acceptable salt thereof.
10. The compound of claim 9 wherein R1 and R2 taken together with the nitrogen to which they are attached are a group selected from
Figure imgf000144_0001
1 1. The compound of claim 10 wherein R1 and R2 taken together with the nitrogen to which they are attached is
Figure imgf000144_0002
or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1 1 wherein
R3 is 3-cyanophenyl, 1 -methyl pyrazol-4-yl or 5-cyano-1-methylpyrrol-3-yl;
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 wherein
R1 and R2 taken together with the nitrogen to which they are attached are piperidinyl or 3-hydroxypiperidinyl;
R3 is 1-methylpyrazol-4-yl, 1 H-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1 ,2- thiazol-5-yl, 3-methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3- difluorophenyl, 2-fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 2-methoxy-5- fluorophenyl; and
R4 and R5 are each independently hydrogen or methyl;
or a pharmaceutically acceptable salt thereof.
14. A compound according to claim 1 selected from the group consisting of:
5- (1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile; 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3- {4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
(3-{4-[(3S)-3-methylpiperidin-1 -yl]-7H-pyrrolo[2,3-^
4- (morpholin-4-yl)-5-(1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
{3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol;
3-[4-(3,3-dimethylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(piperidin-1-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
1-(5-phenyl-7H-pyrrolo[2,3-Q0pyrimidin-4-yl)piperidine-3-carboxamide;
3- {4-[(3S)-3-hydroxypiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-methylpiperidin-1-yl]-5-phenyl-7H-pyrrolo[2,3-c ]pyrimidine;
3- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-methylpiperidin-1-yl]-5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-o0pyrimidin
5- phenyl-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
[1-(5-phenyl-7H-pyrrolo[2,3-(^pyrimidin-4-yl)piperidin-4-yl]methanol;
1-{5-[3-(hydroxymethyl)phenyl]-7H-pyrrolo[2,3-<^py^
1-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-Q0pyrimidin-4-yl]piperidine-3-carbonitrile;
4-(3,5-c/'s-dimethylpiperidin-1-yl)-5-(1-methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3- c ]pyrimidine;
4- methoxy-3-[4-(3-methylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile^
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-4-methoxybenzonitrile;
5- (5-chloro-2-methoxyphenyl)-/V,/V-dimethyl-7H-pyro
3-{4-[4-(1 H-imidazol-2-yl)piperidin-1-yl]-7H-pyrrolo[2,3- ]pyrimidin-5-yl}be
3-{4-[3-(methoxymethyl)piperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile; 3-[4-(9-methyl-1 -oxa-4,9-diazaspiro[5.5]undec-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5- yl]benzonitrile;
3-[4-(3-methoxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri /V3-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]-/V,/V-dimethyl-beta-alan
3-[4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[4-(1 H-pyrazol-3-yl)piperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidin-5-yl}benzonitrile; 3-{4-[(3S)-3-fluoropyrrolidin-1 -yl]-7H-pyro^
3-{4-[2-(1 H-pyrazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-^
3-{4-[3-(1 H-pyrazol-3-yl)piperidin-1-yl]-7H-pyrro^
3-{4-[3-(1 H-imidazol-2-yl)piperidin-1-yl]-7H-pyrrolo[^^
3-{4-[(1 -methylpiperidin-3-yl)amino]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri 3-[4-(3-oxo-2J-diazaspiro[4.5]dec-7-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile;
3-[4-((3R)-3-methylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-(4-{[2-(morpholin-4-yl)ethyl]amino}-7H-pyrrolo[2,3-(^pyrimidin-5-yl)benzonitri
3-[4-(2-oxa-7-azaspiro[4.5]dec-7-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile;
/V-{1 -[5-(3-cyanophenyl)-7H-pyrrolo[2,3-o0pyrimidin-4-yl]piperidin-4-yl}acetamid^
5-(1 H-indazol-5-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidine;
3- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzenesulfonami
5-(2-fluorophenyl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidine;
5-(1 H-indazol-4-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-o0pyrimidine;
5-(6-fluoro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3- c ]pyrimidine;
5- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}-2,3-dihydro-1 H- isoindol-1-one;
4- [(3S)-3-methylpiperidin-1-yl]-5-(pyridin-3-yl)-7H-pyrrolo[2,3-Q0pyrimidine;
4-[(3S)-3-methylpiperidin-1-yl]-5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-o0pyrimidine;
4-[(3S)-3-methylpiperidin-1-yl]-5-(7H-pyrrolo[2,3-6]pyridin-5-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
6- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}-2,3-dihydro-1 H- isoindol-1-one;
4-[(3S)-3-methylpiperidin-1-yl]-5-(1 H-pyrrolo[3,2-0]pyridin-6-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
4-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}phenol;
4- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzamide;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}phenol;
5- (2-chloro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1 -yl]-7/-/-pyrrolo[2,3- c ]pyrimidine;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzamide;
3-[4-(3-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(4-methylpiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile; 3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzoic acid;
3-[4-(methylamino)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
3- [4-(3,5-c/'s-dimethylpiperidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]-4- methoxybenzonitrile;
4- methoxy-3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzoni^
2- fluoro-3-{4-[(3S)-3-methylpiperidin-1 -yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri
/V,/V-dimethyl-5-phenyl-7H-pyrrolo[2,3-( ]pyrimidin-4-amine;
3- [4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-2-fluorobenzonitrile;
3-[4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-((3R)-3-methylpyrrolidin-1 -yl)-7H-pyrrolo^
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-4-fluorobenzonitrile;
3-[4-(diethylamino)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
3-{4-[(2/?)-2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5- yl}benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-5-fluorobenzonitrile;
3-{4-[2-(1 H-pyrazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-^
3-[4-((3S)-3-methylpyrrolidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
2- fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3- {4-[(2/?)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitri
4- fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
4- (4-fluoropiperidin-1 -yl)-5-(1 -methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
2-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-( ]pyrimidin-5-yl]benzonitrile;
5- (3-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3-fluoro-5-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(2,5-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-( ]pyrimidine;
{2-fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol; 5-(2,4-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3,5-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
4-(morpholin-4-yl)-5-phenyl-7/-/-pyrrolo[2,3-c ]pyrimidine; 5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(2-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(5-fluoro-2-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-( ]pyrimidine;
5-(3-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
{2-fluoro-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol;
5-(4-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
{3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]phenyl}methanol;
5-(2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-[3-(methylsulfanyl)phenyl]-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
4-(morpholin-4-yl)-5-(pyridin-3-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]isoquinoline;
5- (5-bromopyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2-chloro-5-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-( ]pyrimidine;
5-(3-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(1 -methyl-1 H-pyrazol-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3-[4-(4-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-Q0pyrimidin-5- yl}benzonitrile;
3-methyl-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-Q0pyrimidin-5- yl}benzonitrile;
3-[4-(6-oxa-3-azabicyclo[3.1.1]hept-3-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile;
3- chloro-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
4- methoxy-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
5- (5-chloro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
6- methyl-5-(1 -methyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
3- methoxy-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
5-(1 -methyl-1 H-pyrazol-4-yl)-4-(thiomorpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine; 1 -[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-4-yl]piperidin-3-ol;
4- [(2S)-2-methylmorpholin-4-yl]-5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
4-[(2R)-2-methylmorpholin-4-yl]-5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
4-(3-fluoropiperidin-1 -yl)-5-(1 -methyl-1 H-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine; {4-[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]morpholin-2- yl}methanol;
5-(1-methyl-1 H-pyrazol-4-yl)-4-(2-{[(6-methylpyridin-3-yl)oxy]methyl}morpholin-4-yl)-7H- pyrrolo[2,3-c ]pyrimidine;
/V,/V-dimethyl-5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrro^
/V-cyclopropyl-/V-methyl-5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-4- amine;
3-[4-(3,3-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-Q0pyrimidin-5-yl]benzonitrile;
3-[4-(3-aminopiperidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-[4-(2-{[5-(difluoromethyl)-1 ,2,4-oxadiazol-3-yl]methyl}morpholin-4-yl)-7H-pyrrolo[2,3- c ]pyrimidin-5-yl]benzonitrile;
3-{4-[2-(1 ,3-thiazol-2-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitri
3-[4-(4-oxopiperidin-1-yl)-7H-pyrrolo[2,3-( ]pyrimidin-5-yl]benzonitrile;
3-{4-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5- yl}benzonitrile;
3-{4-[2-(3-hydroxyphenyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile
3-{4-[2-(5-cyclopropyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
3-[4-(3,3-difluoropyrrolidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-(4-{2-[(3-cyanophenoxy)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-(^pyrimidin-5- yl)benzonitrile;
3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
1-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-Q0pyrimidin-4-yl]piperidine-3-carboxamide;
3-[4-(2-ethylmorpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-{4-[2-(pyrimidin-4-yl)morpholin-4-yl]-7H-pyrroto^
3-{4-[2-(3-cyclopropyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
3-(4-{2-[(dimethylamino)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-(^pyrimidin-5- yl)benzonitrile;
3-[4-(1 H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
3-(4-{2-[(5-methyl-1 ,2,4-oxadiazol-3-yl)methyl]morpholin-4-yl}-7H-pyrrolo[2,3- c ]pyrimidin-5-yl)benzonitrile;
3-{4-[3-(5-methyl-1 ,3,4-oxadiazol-2-yl)piperidin-1-yl]-7H-pyrrolo[2,3-o ]pyrimidin-5- yl}benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-5-methoxybenzonitrile; 5-(1-ethyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(5-chloropyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
5-(6-methoxypyrazin-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(1 ,3-dimethyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
3-{4-[(3S)-3-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
2- fluoro-3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,^^
3- {4-[(3R)-3-hydroxypiperidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
1- [5-(3-fluorophenyl)-7H-pyrrolo[2,3-c ]pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/- pyrrolo[2,3-c ]pyrimidine;
2- fluoro-3-[4-(4-fluoropiperidin-1 -yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
4- (4-fluoropiperidin-1 -yl)-5-(2-methoxyphenyl)-7H-pyrrolo[2,3-c ]pyrimidine;
5- (3-fluoro-5-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidine;
3- [4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-2-fluorobenzonitrile;
1-[5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-Q0pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidine;
1-[5-(3-fluoro-5-methoxyphenyl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]piperidin-3-ol;
1- [5-(2-methoxyphenyl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]piperidin-3-ol;
2- fluoro-3-{4-[2-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
2-fluoro-3-{4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5- yl}benzonitrile;
4- (azetidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-7H-pyrrolo[2,3-c ]pyrimidine;
4- [(2S)-2-methylmorpholin-4-yl]-5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-(^pyrimidi
5- (3-fluorophenyl)-4-(pyrrolidin-1-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
5-(3-fluorophenyl)-4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3- c ]pyrimidine;
5-(2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidine;
5-(2-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-(^pyrimidin-4-amine;
2-fluoro-3-{4-[(3S)-3-fluoropyrrolidin-1 -yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-fluoropyrrolidin-1-yl]-5-(2-methoxyphenyl)-7H-pyrrolo[2,3-Q0pyrimidine;
5- (2-methoxyphenyl)-4-(pyrrolidin-1 -yl)-7H-pyrrolo[2,3-c/]pyrimidine; 5-(3-fluoro-5-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-(^pyrimidin-4-am
2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3- c ]pyrimidine;
2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2^
5-(5-fluoro-2-methoxyphenyl)-4-(3-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(3-fluorophenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidine;
5-(5-fluoro-2-methoxyphenyl)-/V,/V-dimethyl-^
2-fluoro-3-[4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-7H-pyrrolo[2,3-(^pyrimidine^
2- fluoro-3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
5-(4-methyl-1 ,3-thiazol-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(4-methylpyridin-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2-fluoro-6-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-(^pyrimidin-4-amine
5-(2-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2,6-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3-methyl-1 ,2-thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine;
5-(2-chloro-3-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine
5-(4-methoxypyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
3- {4-[2-((5 ?)-5-methyl-1 ,2,4-oxadiazol-3-yl)morpho
yl}benzonitrile;
3-{4-[2-((5S)-5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-o0pyrimidin-5- yl}benzonitrile;
3-{4-[(2S)-2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-Q0pyrimidin-5- yl}benzonitrile;
or a pharmaceutically acceptable salt thereof.
15. A compound according to claim 1 selected from the group consisting of:
5- (1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]pyridine-2-carbonitrile;
3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile;
3- {4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c ]pyrimidin-5-yl}benzonitrile;
4- (morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine; 3-[4-(piperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
2-fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile;
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
1- [5-(1-methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-4-yl]piperidin-3-ol;
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidine;
2- fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]benzonitrile; 2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2^
2- fluoro-3-{4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
5-(3-methyl-1 ,2-thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidine; and
3- {4-[2-(5-methyl-1 ,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-Q0pyrimidin-5- yl}benzonitrile;
or a pharmaceutically acceptable salt thereof.
16. A compound according to claim 1 selected from the group consisting of:
3- [6-(difluoromethyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]benzonitrile; 5-(5,6-dihydro-2/-/-pyran-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
5-(3,4-dihydro-2/-/-pyran-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
4- (morpholin-4-yl)-5-[3-(1 ,2,4-oxadiazol-3-yl)phenyl]-7/-/-pyrrolo[2,3-c ]pyrimidine;
3- {4-[2-(3-methyl-1 ,2-oxazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c ]pyrimidin-5- yl}benzonitrile;
2-methyl-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c ]pyrimidin-5-yl]pyridin-2(1 /-/)-one;
5- (imidazo[2, 1-6][1 ,3]thiazol-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c ]pyrimidine;
re/-3-{4-[(3aS,6aS)-hexahydro-5H-furo[2,3-c]pyrrol-5-yl]-7H-pyrrolo[2,3-c ]pyrimidin-5- yl}benzonitrile;
re/-3-{4-[(3aR,6aS)-tetrahydro-1 H-furo[3,4-c]pyrrol-5(3H)-yl]-7H-pyrrolo[2,3-c ]pyrimidin- 5-yl}benzonitrile; re/-3-{4-[(4aR,7aS)-hexahydrocyclopenta[b][1 ,4]oxazin-4(4aH)-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
4- [5-(3-cyanophenyl)-7H-pyrrolo[2,3-<^pyrimidin-4-yl]m
3- [4-(2,2-dimethylmorpholin-4-yl)-7H-pyrrolo[2,3-<^p
5- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]thiophene-2-carboni
5- (imidazo[1 ,2-6]pyridazin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidi
2-fluoro-3-{4-[2(R)-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
2- fluoro-3-{4-[2(S)-(3-methyl-1 ,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- c ]pyrimidin-5-yl}benzonitrile;
6- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]pyridine-2-carboxamide^
4- (morpholin-4-yl)-5-(pyrazolo[1 ,5-a]pyrimidin-3-yl)-7H-pyrrolo[2,3-o0pyrimidi
1-methyl-4-[4-(morpholin-4-yl)-7H-pyTO^
5- (6-methylimidazo[2, 1 -b][1 ,3]thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3- c ]pyrimidine;
3- {4-[2-(1 ,2-oxazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzoni
1-methyl-4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-1 H-imi
carbonitrile;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]thiophene-2-carboni
4-(morpholin-4-yl)-5-(pyrazolo[1 ,5-a]pyridin-3-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
1 ,5-dimethyl-4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-(^pyrimidin-5-yl]-1 H-pyTO
carbonitrile;
1-methyl-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1 /-/-pyrazole-5- carbonitrile; and
3-{4-[2-(cyanomethyl)morpholin-4-yl]-7H-pyrrolo[2,3-(^pyrimidin-5-yl}benzonitrile;
or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
18. A method of treating Parkinson's disease in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16.
19. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16 for use in the treatment of Parkinson's disease.
PCT/IB2013/055039 2012-06-29 2013-06-19 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS WO2014001973A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
KR20157002334A KR20150027267A (en) 2012-06-29 2013-06-19 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
MD20140130A MD20140130A2 (en) 2012-06-29 2013-06-19 Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
EA201492125A EA025186B1 (en) 2012-06-29 2013-06-19 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
ES13752678.6T ES2637245T3 (en) 2012-06-29 2013-06-19 New 4- (substituted amino) -7H-pyrrolo [2,3-d] pyrimidines as LRRK2 inhibitors
UAA201413021A UA113436C2 (en) 2012-06-29 2013-06-19 4- (SUBSTITUTED AMINO) -7H-PYROL [2,3-d] PIRIMIDINE AS LRRK2 INHIBITOR
JP2015519416A JP6189948B2 (en) 2012-06-29 2013-06-19 Novel 4- (substituted amino) -7H-pyrrolo [2,3-d] pyrimidines as LRRK2 inhibitors
EP13752678.6A EP2867236B1 (en) 2012-06-29 2013-06-19 Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
NZ702571A NZ702571A (en) 2012-06-29 2013-06-19 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
CN201380034594.1A CN104395315B (en) 2012-06-29 2013-06-19 4-(substituted amino)-7H-pyrrolo-(2,3-d) miazines as LRRK2 inhibitor
SG11201408044QA SG11201408044QA (en) 2012-06-29 2013-06-19 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
BR112014032913A BR112014032913A2 (en) 2012-06-29 2013-06-19 novel 4- (amino-substituted) -7h-pyrrolo [2,3-d] pyrimidines as lrrk2 inhibitors
AU2013282869A AU2013282869B2 (en) 2012-06-29 2013-06-19 Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
MX2014015769A MX2014015769A (en) 2012-06-29 2013-06-19 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS.
AP2014008147A AP3902A (en) 2012-06-29 2013-06-19 Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
CA2878054A CA2878054C (en) 2012-06-29 2013-06-19 Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
CR20140566A CR20140566A (en) 2012-06-29 2014-12-08 7H-PIRROLO [2,3-D] PYRIMIDINS 4- (AMINO-SUBSTITUTES) NOVELTY AS INHIBITORS OF LRRK2
CU2014000140A CU20140140A7 (en) 2013-05-08 2014-12-08 7H-PIRROLO [2,3-d] PYRIMIDINS 4- (AMINO-SUBSTITUTES) NOVELTY AS INHIBITORS OF LRRK2
ZA2014/09136A ZA201409136B (en) 2012-06-29 2014-12-11 Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimides as lrrk2 inhibitors
IL236294A IL236294A (en) 2012-06-29 2014-12-15 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
MA37678A MA37678B2 (en) 2012-06-29 2014-12-22 New 4-amino-substituted 7h-pyrrolo [2,3-d] pyrimidines used as inhibitors of Irr2
PH12014502886A PH12014502886B1 (en) 2012-06-29 2014-12-23 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
TN2014000537A TN2014000537A1 (en) 2012-06-29 2014-12-26 4- (AMINO-SUBSTITUTED) - NEW 7H-PYRROLO [2,3-D] PYRIMIDINES AS INHIBITORS OF LRRK2
HK15105238.4A HK1204619A1 (en) 2012-06-29 2015-06-02 Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrim as lrrk2 inhibitors lrrk2 4-()-7h-[23-d]

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261666299P 2012-06-29 2012-06-29
US61/666,299 2012-06-29
US201361820828P 2013-05-08 2013-05-08
US61/820,828 2013-05-08

Publications (1)

Publication Number Publication Date
WO2014001973A1 true WO2014001973A1 (en) 2014-01-03

Family

ID=49029142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/055039 WO2014001973A1 (en) 2012-06-29 2013-06-19 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS

Country Status (32)

Country Link
US (2) US9156845B2 (en)
EP (2) EP3255049A1 (en)
JP (3) JP6189948B2 (en)
KR (1) KR20150027267A (en)
CN (2) CN104395315B (en)
AP (1) AP3902A (en)
AR (1) AR091628A1 (en)
AU (1) AU2013282869B2 (en)
BR (1) BR112014032913A2 (en)
CA (1) CA2878054C (en)
CL (1) CL2014003566A1 (en)
CO (1) CO7160063A2 (en)
CR (1) CR20140566A (en)
DO (1) DOP2014000303A (en)
EA (1) EA025186B1 (en)
ES (1) ES2637245T3 (en)
GE (1) GEP201706620B (en)
GT (1) GT201400301A (en)
HK (1) HK1204619A1 (en)
IL (1) IL236294A (en)
MD (1) MD20140130A2 (en)
MX (1) MX2014015769A (en)
NI (1) NI201400151A (en)
NZ (1) NZ702571A (en)
PE (1) PE20150153A1 (en)
PH (1) PH12014502886B1 (en)
SG (1) SG11201408044QA (en)
TN (1) TN2014000537A1 (en)
TW (1) TWI482774B (en)
UY (1) UY34883A (en)
WO (1) WO2014001973A1 (en)
ZA (1) ZA201409136B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015113451A1 (en) * 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2015113452A1 (en) * 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
FR3041640A1 (en) * 2015-09-30 2017-03-31 Servier Lab
US9642855B2 (en) 2012-06-29 2017-05-09 Pfizer Inc. Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
KR101992059B1 (en) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier
WO2022232931A1 (en) * 2021-05-05 2022-11-10 Kare Chemical Technologies Inc. Catalytic tryptamine processes and precursors
WO2023055731A1 (en) * 2021-09-28 2023-04-06 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080735A1 (en) 2010-12-16 2012-06-21 Convergence Pharmaceuticals Limited Ask1 inhibiting pyrrolopyrimidine derivatives
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US8963597B1 (en) * 2013-10-02 2015-02-24 Nanya Technology Corporation Cross-domain enablement method and electronic apparatus
WO2015176010A1 (en) * 2014-05-15 2015-11-19 The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services Treatment or prevention of an intestinal disease or disorder
CN104086553B (en) * 2014-06-13 2016-04-27 南京药石科技股份有限公司 One prepares the method for 7-bromine imidazo [2,1-f] [1,2,4] triazine-4-amine
EP3166637B1 (en) 2014-07-10 2020-01-29 The J. David Gladstone Institutes Compositions and methods for treating dengue virus infection
ES2792036T3 (en) 2014-11-14 2020-11-06 Nerviano Medical Sciences Srl 6-amino-7-bicyclo-7-deaza-purine derivatives as kinase inhibitors
AR107032A1 (en) 2015-12-09 2018-03-14 Padlock Therapeutics Inc PAD4 BICYCLIC INHIBITORS
JP2019534266A (en) 2016-10-14 2019-11-28 江蘇恒瑞医薬股▲ふん▼有限公司 Bridged ring derivative of 5-membered heteroaryl ring, process for its preparation and medical use thereof
WO2018141842A1 (en) * 2017-02-03 2018-08-09 Leo Pharma A/S 5-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NOVEL JAK KINASE INHIBITORS
CN106831790B (en) * 2017-02-17 2019-07-26 四川大学华西医院 7H-pyrrolo [2,3-d ] pyrimidine derivatives
SG11201908234WA (en) 2017-02-24 2019-10-30 Daegu Gyeongbuk Medical Innovation Found Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
KR20190131981A (en) * 2018-05-18 2019-11-27 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for use in preventing or treating Traumatic Brain Injury or stroke
KR101990739B1 (en) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier
WO2020040591A1 (en) * 2018-08-23 2020-02-27 재단법인 대구경북첨단의료산업진흥재단 Novel use of pyrimidine derivative comprising lrrk kinase inhibitor as effective ingredient
KR20220052859A (en) 2019-05-08 2022-04-28 비말란 바이오사이언스즈, 인크. JAK inhibitors
WO2021026465A1 (en) 2019-08-08 2021-02-11 Vimalan Biosciences, Inc. Jak inhibitors
WO2021062036A1 (en) * 2019-09-25 2021-04-01 Vimalan Biosciences, Inc. Jak inhibitors
CN115698047A (en) * 2020-02-25 2023-02-03 非营利性组织佛兰芒综合大学生物技术研究所 Leucine-rich repeat kinase 2 allosteric modulators
CN111671757A (en) * 2020-07-16 2020-09-18 福建医科大学附属协和医院 Pharmaceutical application of 3- [4- (4-morpholinyl) -7H-pyrrolo [2,3-D ] pyrimidine-5-yl ] benzonitrile
KR20230091871A (en) * 2020-10-20 2023-06-23 에프. 호프만-라 로슈 아게 Combination therapy of a PD-1 axis binding antagonist and a LRRK2 inhibitor
WO2022093685A1 (en) * 2020-10-26 2022-05-05 Neuron23, Inc. Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2
CA3230996A1 (en) * 2021-09-07 2023-03-16 Ptc Therapeutics, Inc. Methods for treating neurogenerative diseases
AR127470A1 (en) 2021-10-27 2024-01-31 H Lundbeck As LRRK2 INHIBITORS
WO2024056775A1 (en) 2022-09-15 2024-03-21 H. Lundbeck A/S Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040706A1 (en) * 1995-06-07 1996-12-19 Gensia-Sicor Orally active adenosine kinase inhibitors
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
WO1998023613A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO1999065908A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
US6051577A (en) * 1996-03-15 2000-04-18 Novartis Ag N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
EP0994728A1 (en) 1997-04-09 2000-04-26 Mindset, Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
EP1257584A2 (en) 2000-02-24 2002-11-20 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US20030073655A1 (en) 1997-04-09 2003-04-17 Chain Daniel G. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20050019328A1 (en) 1997-12-02 2005-01-27 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050043354A1 (en) 2003-06-19 2005-02-24 Pfizer Inc NK1 antagonist
US20050048049A1 (en) 1997-12-02 2005-03-03 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO2005025616A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
US20050256135A1 (en) 2004-05-12 2005-11-17 Graham Lunn Tetrahydronaphthyridine derivatives
US20050267095A1 (en) 2004-05-07 2005-12-01 Patrick Bernardelli 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands
WO2006036291A2 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US20060106035A1 (en) 2002-08-23 2006-05-18 Martin Hendrix Phenyl-substituted pyrazolopyrimidines
US20060111372A1 (en) 2002-08-23 2006-05-25 Bayer Healthcare Ag Alkyl-substituted pyrazolopyrimidines
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
US7115600B2 (en) 2004-02-02 2006-10-03 Pfizer Inc. Histamine-3 receptor modulators
WO2006118959A2 (en) 2005-04-29 2006-11-09 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
US20070179175A1 (en) 2005-11-04 2007-08-02 Graham Lunn Tetrahydronaphthyridine Derivative
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
US7285293B2 (en) 2000-11-03 2007-10-23 Gerardo Castillo Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
US20080096955A1 (en) 2005-10-27 2008-04-24 Pfizer Inc Histamine-3 receptor antagonists
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
US20080176925A1 (en) 2007-01-22 2008-07-24 Pfizer Inc Toluene sulfonic acid salt of a therapeutic compound and pharmaceutical compositions thereof
WO2008128072A2 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009000319A1 (en) 2007-06-22 2008-12-31 Schulz Hans M Manual input device
WO2009035159A1 (en) 2007-09-14 2009-03-19 Mitsubishi Tanabe Pharma Corporation 3-methyl-2- ( (2s) -2- (4- (3-methyl-l, 2, 4-0xadiaz0l-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor
WO2010106333A1 (en) * 2009-03-19 2010-09-23 Medical Research Council Technology Compounds
WO2011141756A1 (en) 2010-05-14 2011-11-17 Medical Research Council Technology Pyrazolopyridines as inhibitors of the kinase lrrk2
WO2012028629A1 (en) 2010-09-02 2012-03-08 Glaxo Group Limited 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors
WO2012058193A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
US11806208B2 (en) 2014-03-21 2023-11-07 Align Technology, Inc. Orthodontic appliances with shell segments and elastic segments

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JP2890448B2 (en) 1988-04-26 1999-05-17 日産化学工業株式会社 Pyrazolopyridine mevalonolactones
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
CA2011504C (en) 1989-03-07 1998-06-02 Kenji Ohmori Imidazoquinolone derivatives
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5763597A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
JPH03271289A (en) 1990-03-16 1991-12-03 Nissan Chem Ind Ltd Production of pyrazolopyridine derivative and dihydropyrazolopyridine derivative
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3130342B2 (en) 1991-10-04 2001-01-31 日産化学工業株式会社 Atherosclerotic intimal thickening inhibitor
JP3271289B2 (en) 1992-02-28 2002-04-02 スズキ株式会社 Valve drive for 4-cycle engine
PL175327B1 (en) 1992-04-03 1998-12-31 Upjohn Co Bicyclic heterocyclic amines
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
JPH05310700A (en) 1992-05-12 1993-11-22 Sagami Chem Res Center Condensed pyridine-based mevalonolactone intermediate and its production
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH0641114A (en) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd New mevalonolactones and its production
JPH06116239A (en) 1992-10-05 1994-04-26 Nissan Chem Ind Ltd 7-substituted-3, 5-dihydroxyhept-6-ynoic acid compounds
KR950703537A (en) 1992-10-16 1995-09-20 시모무라 도오루 PYRIMIDINE DERIVATIVE
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
DE4304455A1 (en) 1993-02-15 1994-08-18 Bayer Ag Heterocyclic substituted phenyl-cyclohexane-carboxylic acid derivatives
JP3119758B2 (en) 1993-02-24 2000-12-25 日清製粉株式会社 7-Azaindole derivative and antiulcer drug containing the same as active ingredient
JP3350739B2 (en) 1993-06-10 2002-11-25 コニカ株式会社 Method for developing black-and-white silver halide photographic materials
CN1102644A (en) 1993-11-11 1995-05-17 财团法人相模中央化学研究所 Condensed pyridine type mevalonolactone intermediate and process for its production
JPH07281365A (en) 1994-04-07 1995-10-27 Konica Corp Method for processing silver halide photographic sensitive material
DE59500788D1 (en) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative activity
JP3448724B2 (en) 1995-11-29 2003-09-22 コニカ株式会社 Developer for silver halide photographic material and processing method thereof
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JPH10213887A (en) 1996-11-26 1998-08-11 Konica Corp Treatment of black and white silver halide photographic sensitive material
EP0846981A1 (en) 1996-12-03 1998-06-10 Konica Corporation Method for processing black-and-white silver halide photographic light-sensitive material
JP3543249B2 (en) 1996-12-18 2004-07-14 コニカミノルタホールディングス株式会社 Processing method of black and white silver halide photographic material
YU25500A (en) 1999-05-11 2003-08-29 Pfizer Products Inc. Process for the synthesis of nucleosite analogues
US6309811B2 (en) 1999-07-21 2001-10-30 Eastman Kodak Company Color photographic element containing nitrogen heterocycle derivative and inhibitor releasing coupler
JP2001302515A (en) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd Poly(adp-ribose)polymerase inhibitor
WO2001098301A1 (en) 2000-06-20 2001-12-27 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
DK1355904T3 (en) 2000-12-22 2007-10-15 Wyeth Corp Heterocyclindazole and azaindazole Compounds as 5-Hydroxytryptamine-6 Ligands
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
WO2003000187A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
WO2003076658A2 (en) 2002-03-08 2003-09-18 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
WO2004014368A1 (en) 2002-08-12 2004-02-19 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202463D0 (en) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
DE10259382A1 (en) 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituted 3,4-dihydro-thieno [2,3-d] pyrimidin-4-one derivatives, their preparation and use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CN1925855B (en) 2003-12-19 2010-06-16 普莱希科公司 Compounds and methods for development of Ret modulators
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
DK1735278T3 (en) 2004-04-01 2010-04-12 Lilly Co Eli Histamine H3 receptor agents, preparation and therapeutic applications
KR20070002081A (en) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Azaindoles useful as inhibitors of rock and other protein kinases
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
CA2570043A1 (en) 2004-06-08 2005-12-22 Chiron Corporation Env polypeptide complexes and methods of use
MXPA06015237A (en) 2004-06-29 2007-12-10 Amgen Inc Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity.
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US8029986B2 (en) 2004-10-21 2011-10-04 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
DE102004054634A1 (en) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
WO2006091568A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc INHIBITORS OF Akt ACTIVITY
EP1962830B1 (en) 2005-12-23 2013-03-27 GlaxoSmithKline LLC Azaindole inhibitors of aurora kinases
JP2009529860A (en) 2006-03-14 2009-08-27 セルゾーム・アクチェンゲゼルシャフト Method for identification of molecules with which LRRK2 interacts and purification of LRRK2
WO2007124096A2 (en) 2006-04-21 2007-11-01 The Trustees Of Columbia University In The City Of New York Lrrk2 regulaton of neuronal process morphology
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2007149798A2 (en) 2006-06-20 2007-12-27 Novartis Ag Biomarkers for the progression of alzheimer's disease
US8466163B2 (en) 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
WO2008091799A2 (en) 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
FR2912744B1 (en) 2007-02-16 2012-09-07 Centre Nat Rech Scient PYRROLO-2,3-B-PYRIDINE COMPOUNDS, AZAIN-DOLES COMPOUNDS USEFUL IN THE SYNTHESIS OF THESE PYRROLO-2,3-B-PYRIDINE COMPOUNDS, METHODS OF MAKING THEM AND USES THEREOF.
GB0706709D0 (en) 2007-04-05 2007-05-16 Medical Res Council Methods
SI2152712T1 (en) 2007-05-11 2012-03-30 Pfizer Amino-heterocyclic compounds
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
DE102007028515A1 (en) 2007-06-21 2008-12-24 Merck Patent Gmbh 6- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
WO2009005730A1 (en) 2007-06-27 2009-01-08 Cornell University Transgenic animal models of parkinson's disease
WO2009030270A1 (en) 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
ATE535241T1 (en) 2007-12-05 2011-12-15 Univ Mainz Johannes Gutenberg USE OF 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE DERIVATIVES IN THE TREATMENT OF LEUKEMIA
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
CN103224497A (en) 2008-04-22 2013-07-31 波托拉医药品公司 Inhibitors of protein kinases
WO2009134658A2 (en) 2008-04-30 2009-11-05 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
DE102008025751A1 (en) 2008-05-29 2009-12-03 Merck Patent Gmbh New 4-(1H-pyrrolo(2,3-b)pyridin-3-yl)-pyridin-2-yl-amine derivatives are serine kinase modulators, useful to treat solid tumors, tumor growth, tumor metastasis, AIDS, occlusive neointimal lesions, arteriosclerosis, coronary artery disease
AR072008A1 (en) 2008-06-13 2010-07-28 Merck & Co Inc HETEROBICICLIC COMPOUNDS AS QUINASA P38 INHIBITION AGENTS
US20110201599A1 (en) 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
DE102008031517A1 (en) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amine derivatives
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
FR2935712A1 (en) 2008-09-05 2010-03-12 Ct Hospitalier Regional Univer METHOD FOR DETECTING THE DIFFERENTIAL EXPRESSION OF A MOLECULAR MARK SET ASSOCIATED WITH PARKINSON'S DISEASE
GB2463656B (en) 2008-09-18 2010-10-13 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US20100175140A1 (en) 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
EP2379559B1 (en) 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2210887A1 (en) 2009-01-14 2010-07-28 Isdin, S.A. Bis resorcinyl triazine derivatives as protecting agents against UV radiation
WO2010085799A2 (en) 2009-01-26 2010-07-29 Tautatis, Inc. Compositions and method for the treatment of parkinson's disease
WO2010093191A2 (en) 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
KR20100116765A (en) 2009-04-23 2010-11-02 인제대학교 산학협력단 Methods to screen materials to inhibit parkinson's disease
CN102482277B (en) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 Epidermal growth factor receptor inhibitor and the method for treating obstacle
DE102009019962A1 (en) 2009-05-05 2010-11-11 Merck Patent Gmbh 3 - ([1,2,3] triazol-4-yl) -pyrrolo [2,3-b] pyridine
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
JP5752691B2 (en) 2009-09-29 2015-07-22 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ New compounds
FR2951172B1 (en) 2009-10-13 2014-09-26 Pf Medicament PYRAZOLOPYRIDINE DERIVATIVES AS ANTI-CANCER AGENT
KR101690358B1 (en) 2009-10-29 2017-01-09 제노스코 Kinase inhibitors
KR20110049217A (en) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 Novel organic electroluminescent compounds and organic electroluminescent device using the same
WO2011057204A2 (en) * 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
MY160820A (en) 2009-11-13 2017-03-31 Genosco Kinase inhibitors
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
JP5822844B2 (en) 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー 1H-pyrazolo [3,4-b] pyridine and therapeutic use thereof
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US8367349B2 (en) 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
US20130040933A1 (en) 2010-04-27 2013-02-14 Brandon Cash Azaindoles as janus kinase inhibitors
WO2011144622A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh 1h - imidazo [4, 5 - c] quinolines
WO2011149827A1 (en) 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
US9303322B2 (en) 2010-05-24 2016-04-05 Integran Technologies Inc. Metallic articles with hydrophobic surfaces
DK2576541T3 (en) 2010-06-04 2016-05-30 Hoffmann La Roche Aminopyrimidine AS LRRK2 MODULATORS
KR101208198B1 (en) 2010-08-27 2012-12-04 인제대학교 산학협력단 Pharmaceutical composition for treating or preventing Parkinson's disease comprising compound having inhibitory effect of LRRK2 kinase activity
EP2616468A4 (en) 2010-09-16 2014-02-26 Hutchison Medipharma Ltd Fused heteroaryls and their uses
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JP5310700B2 (en) 2010-10-27 2013-10-09 パナソニック株式会社 LED package manufacturing system and resin coating method in LED package manufacturing system
EP3590933B1 (en) 2010-11-10 2021-01-06 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
BR112013013457A2 (en) 2010-11-30 2017-07-11 Genentech Inc methods for identifying a patient or subject, for predicting a subject's sensitivity, for identifying subjects who have parkinson's disease, and for determining the subject's response to therapy and assay for selecting compounds and compositions
US20130338106A1 (en) 2011-02-28 2013-12-19 John A. McCauley Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9493452B2 (en) 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
GB201105137D0 (en) 2011-03-28 2011-05-11 Isis Innovation Therapeutic molecules for use in the suppression of Parkinson's disease
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
AU2012244549B2 (en) 2011-04-21 2017-04-20 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
AP2013007253A0 (en) 2011-04-21 2013-11-30 Origenis Gmbh Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
US9187567B2 (en) 2011-05-18 2015-11-17 Parkinson's Institute Assay to determine LRRK2 activity in parkinson's disease
CA2837199A1 (en) 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Cinnoline compounds as inhibitor of lrrk2 kinase activity
US20140205537A1 (en) 2011-06-24 2014-07-24 Zenobia Therapeutics, Inc. Lrrk2 inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
BR112014007654A8 (en) 2011-09-30 2018-06-12 Ipsen Pharma MACROCYCLIC LRRK2 KINASE INHIBITORS.
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
US9187484B2 (en) 2012-05-02 2015-11-17 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
EP2844652B1 (en) 2012-05-03 2019-03-13 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP3255049A1 (en) * 2012-06-29 2017-12-13 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
US10000482B2 (en) 2012-10-19 2018-06-19 Origenis Gmbh Kinase inhibitors
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP6116239B2 (en) 2012-12-28 2017-04-19 キヤノン株式会社 Subject information acquisition apparatus and subject information acquisition method
WO2014146277A1 (en) 2013-03-21 2014-09-25 华为终端有限公司 Data transmission method, base station, and user equipment
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
ES2663622T3 (en) 2013-12-17 2018-04-16 Pfizer Inc. Novel 1-pyrrolo [2,3-b] 3,4-disubstituted pyridines and 7H-4,5-disubstituted pyridacins [2,3-c] pyridazines as inhibitors of LRRK2

Patent Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
WO1996040706A1 (en) * 1995-06-07 1996-12-19 Gensia-Sicor Orally active adenosine kinase inhibitors
US6051577A (en) * 1996-03-15 2000-04-18 Novartis Ag N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
WO1998023613A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
EP0994728A1 (en) 1997-04-09 2000-04-26 Mindset, Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US20030073655A1 (en) 1997-04-09 2003-04-17 Chain Daniel G. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20050019328A1 (en) 1997-12-02 2005-01-27 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050048049A1 (en) 1997-12-02 2005-03-03 Neuralab Limited Prevention and treatment of amyloidogenic disease
WO1999065909A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO1999065908A1 (en) * 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
EP1257584A2 (en) 2000-02-24 2002-11-20 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
US7285293B2 (en) 2000-11-03 2007-10-23 Gerardo Castillo Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
US20060106035A1 (en) 2002-08-23 2006-05-18 Martin Hendrix Phenyl-substituted pyrazolopyrimidines
US20060111372A1 (en) 2002-08-23 2006-05-25 Bayer Healthcare Ag Alkyl-substituted pyrazolopyrimidines
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20050043354A1 (en) 2003-06-19 2005-02-24 Pfizer Inc NK1 antagonist
WO2005025616A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
US7115600B2 (en) 2004-02-02 2006-10-03 Pfizer Inc. Histamine-3 receptor modulators
US20050267095A1 (en) 2004-05-07 2005-12-01 Patrick Bernardelli 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands
US20050256135A1 (en) 2004-05-12 2005-11-17 Graham Lunn Tetrahydronaphthyridine derivatives
WO2006036291A2 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
WO2006118959A2 (en) 2005-04-29 2006-11-09 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006136924A1 (en) 2005-06-22 2006-12-28 Pfizer Products Inc. Histamine-3 receptor antagonists
US20080096955A1 (en) 2005-10-27 2008-04-24 Pfizer Inc Histamine-3 receptor antagonists
US20070179175A1 (en) 2005-11-04 2007-08-02 Graham Lunn Tetrahydronaphthyridine Derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
US20080176925A1 (en) 2007-01-22 2008-07-24 Pfizer Inc Toluene sulfonic acid salt of a therapeutic compound and pharmaceutical compositions thereof
WO2008128072A2 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009000319A1 (en) 2007-06-22 2008-12-31 Schulz Hans M Manual input device
WO2009035159A1 (en) 2007-09-14 2009-03-19 Mitsubishi Tanabe Pharma Corporation 3-methyl-2- ( (2s) -2- (4- (3-methyl-l, 2, 4-0xadiaz0l-5-yl) phenyl) morpholino) -6- (pyrimidin-4-yl) pyrimidin-4 (3h) -one as tau protein kinase inhibitor
WO2010106333A1 (en) * 2009-03-19 2010-09-23 Medical Research Council Technology Compounds
WO2011141756A1 (en) 2010-05-14 2011-11-17 Medical Research Council Technology Pyrazolopyridines as inhibitors of the kinase lrrk2
WO2012028629A1 (en) 2010-09-02 2012-03-08 Glaxo Group Limited 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors
WO2012058193A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
US11806208B2 (en) 2014-03-21 2023-11-07 Align Technology, Inc. Orthodontic appliances with shell segments and elastic segments

Non-Patent Citations (40)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
"Compendium of Organic Synthetic Methods", vol. I-XII, WILEY-INTERSCIENCE
"Diagnostic and Statistical Manual of Mental Disorders", 2000, AMERICAN PSYCHIATRIC ASSOCIATION
"Handbook of Pharmaceutical Excipients (3 Ed.", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
"Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
A. F. LITTKE ET AL., J. AM. CHEM. SOC., vol. 122, 2000, pages 4020 - 4028
A. JORGENSEN ET. AL.: "Synthesis of 7H-Pyrrolo[2,3-d]pyrimidin-4-amines.", LIEBIGS ANNALEN DER CHEMIE, vol. 1985, 1 January 1985 (1985-01-01), pages 142 - 148, XP002712719 *
A. R. GANGLOFF ET AL., TETRAHEDRON LETT., vol. 42, 2001, pages 1441 - 1443
A. SUZUKI, J. ORGANOMET. CHEM., vol. 576, 1999, pages 147 - 168
B. C. BOOKSER ET. AL.: "Adenosine Kinase Inhibitors. 6. Water Solubility and Antinociceptive Activity of 5-Phenyl-7-(5-deoxay-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines Substituted at C4 with Glycinamides and Related Compounds.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 24, 1 December 2005 (2005-12-01), pages 7808 - 7820, XP002712717 *
B. G. UGARKAR ET. AL.: "Adenosine Kinase Inhibtors. 2. Synthesis, Enzyme Inhibiton, anmd Antiseizure Activity of Diaryltubercidin Analogues.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 15, 27 July 2000 (2000-07-27), pages 2894 - 2905, XP002712716 *
D. L. BOGER ET AL., J. ORG. CHEM., vol. 47, 1982, pages 2673 - 2675
E. C. TAYLOR ET. AL.: "Synthesis of 4-Amino-5-cyanopyrrolo[2,3-d]pyrimidine, the Agycone of Toyocamycin.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 86, no. 5, 1 May 1964 (1964-05-01), pages 951 - 951, XP002712722 *
E. ERDIK, TETRAHEDRON, vol. 48, 1992, pages 9577 - 9648
FINNIN; MORGAN, J. PHARM. SCI., vol. 88, no. 10, October 1999 (1999-10-01), pages 955 - 958
GILLARDON, F. ET AL., NEUROSCIENCE, vol. 208, 2012, pages 41 - 48
GLENNER ET AL., J. NEUROL. SCI., vol. 94, 1989, pages 1 - 28
H. BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER
HAAN ET AL., CLIN. NEUROL. NEUROSURG., vol. 92, no. 4, 1990, pages 305 - 310
HALEBLIAN, J. PHARM. SCI., vol. 64, no. 8, August 1975 (1975-08-01), pages 1269 - 1288
HOOVER; JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
J.-J. SHIE; J.-M. FANG, J. ORG. CHEM., vol. 72, 2007, pages 3141 - 3144
L. WILDER ET. AL.: "7-Alkyl and 7-Cycloalkyl-5-aryl-pyrrolo[2,3-d]pyrimidines- Potent Inhibitors of the Tyrosine Kinase c-Src.", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 11, 26 March 2001 (2001-03-26), pages 849 - 852, XP002712721 *
LIU, Z. ET AL., NAT. IMMUNOL., vol. 12, 2011, pages 1063 - 1070
LIU, Z.; LENARDO, M., CELL RESEARCH, 2012, pages 1 - 3
MOEHLE, M. ET AL., J. NEUROSCI., vol. 32, no. 5, 2012, pages 1602 - 1611
N. MIYAURA; A. SUZUKI, CHEM. REV., vol. 95, 1995, pages 2457 - 2483
P. M. TRAXLER ET. AL.: "4-(Phenylamino)pyrrolopyrimidines: Potent and Selective ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 12, 1 June 1996 (1996-06-01), pages 2285 - 2292, XP002712718, ISSN: 0022-2623 *
R. SANZ ET AL., J. ORG. CHEM., vol. 72, 2007, pages 5113 - 5118
S.H. BOYER ET. AL.: "Adenosine Kinase Inhibitors. 5. Synthesis, Enzyme Inhibiton, adn Analgesic Activity of Diaryl-erythro-furanosyltubercidin Analogues.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 20, 6 October 2005 (2005-10-06), pages 6430 - 6441, XP002712715 *
SAUNDERS- PULLMAN, R. ET AL., MOVEMENT DISORDERS, vol. 25, no. 15, 2010, pages 2536 - 2541
T. BANNO ET AL., J. ORGANOMET. CHEM., vol. 653, 2002, pages 288 - 291
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14, ACS SYMPOSIUM SERIES
T. W. GREENE: "Protective Groups in Organic Chemistry", 1981, JOHN WILEY & SONS
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1991, JOHN WILEY & SONS
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Chemistry", 1999, JOHN WILEY & SONS
T. WU ET. AL.: "One-Pot, Two-Step Microwave-Assisted Reaction in Constructing 4,5-Disubstituted Pyrazolopyrimidines.", ORGANIC LETTERS, vol. 5, no. 20, 9 June 2003 (2003-06-09), pages 3587 - 3590, XP002712720, DOI: 10.1021/ol035226w *
V. FARINA ET AL., ORGANIC REACTIONS, vol. 50, 1997, pages 1 - 652
ZHAO, Y. ET AL., NEUROBIOLOGY OF AGING, vol. 32, 2011, pages 1990 - 1993
ZIMPRACH, A. ET AL., NEURON, vol. 44, 2004, pages 601 - 607

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9642855B2 (en) 2012-06-29 2017-05-09 Pfizer Inc. Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10618901B2 (en) 2014-01-29 2020-04-14 Glaxosmithkline Intellectual Property Development Limited LRRK2 inhibitors for the treatment of Parkinson's disease
CN105980388A (en) * 2014-01-29 2016-09-28 葛兰素史密斯克莱知识产权发展有限公司 Compounds
JP2017504631A (en) * 2014-01-29 2017-02-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Compound
WO2015113451A1 (en) * 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
US10087186B2 (en) 2014-01-29 2018-10-02 Glaxosmithkline Intellectual Property Development Limited Compounds as LRRK2 kinase inhibitors
CN105940004A (en) * 2014-01-29 2016-09-14 葛兰素史密斯克莱知识产权发展有限公司 Compounds
WO2015113452A1 (en) * 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
CN105940004B (en) * 2014-01-29 2018-02-02 葛兰素史密斯克莱知识产权发展有限公司 Compound
EA029774B1 (en) * 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Compounds
US10039753B2 (en) 2015-09-14 2018-08-07 Pfizer Inc. Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors
FR3041640A1 (en) * 2015-09-30 2017-03-31 Servier Lab
WO2017055533A1 (en) * 2015-09-30 2017-04-06 Les Laboratoires Servier New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
KR101992059B1 (en) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating brain cancer comprising compounds penetrating blood-brain barrier
WO2020040610A1 (en) * 2018-08-23 2020-02-27 재단법인 대구경북첨단의료산업진흥재단 Pharmaceutical composition for preventing or treating brain cancer, comprising, as active ingredient, compound capable of penetrating blood-brain barrier
WO2022232931A1 (en) * 2021-05-05 2022-11-10 Kare Chemical Technologies Inc. Catalytic tryptamine processes and precursors
WO2023055731A1 (en) * 2021-09-28 2023-04-06 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus

Also Published As

Publication number Publication date
CA2878054A1 (en) 2014-01-03
GT201400301A (en) 2015-06-02
DOP2014000303A (en) 2015-03-15
CO7160063A2 (en) 2015-01-15
US9156845B2 (en) 2015-10-13
JP2017226684A (en) 2017-12-28
IL236294A0 (en) 2015-02-26
HK1204619A1 (en) 2015-11-27
US20140005183A1 (en) 2014-01-02
US9642855B2 (en) 2017-05-09
JP6462795B2 (en) 2019-01-30
JP2019073522A (en) 2019-05-16
PH12014502886A1 (en) 2015-02-23
MD20140130A2 (en) 2015-04-30
BR112014032913A2 (en) 2017-06-27
GEP201706620B (en) 2017-02-10
ES2637245T3 (en) 2017-10-11
CN104395315B (en) 2016-08-17
JP6189948B2 (en) 2017-08-30
AP2014008147A0 (en) 2014-12-31
IL236294A (en) 2016-09-29
AR091628A1 (en) 2015-02-18
CA2878054C (en) 2018-09-11
EP2867236B1 (en) 2017-06-14
ZA201409136B (en) 2016-08-31
UY34883A (en) 2014-01-31
CN104395315A (en) 2015-03-04
MX2014015769A (en) 2015-04-10
CR20140566A (en) 2015-01-09
NZ702571A (en) 2017-02-24
PE20150153A1 (en) 2015-02-05
AU2013282869B2 (en) 2015-12-24
CN105732639A (en) 2016-07-06
AU2013282869A1 (en) 2015-01-15
KR20150027267A (en) 2015-03-11
PH12014502886B1 (en) 2015-02-23
CL2014003566A1 (en) 2015-04-10
EP3255049A1 (en) 2017-12-13
EP2867236A1 (en) 2015-05-06
EA025186B1 (en) 2016-11-30
AP3902A (en) 2016-11-17
NI201400151A (en) 2015-06-05
US20150366874A1 (en) 2015-12-24
JP2015522002A (en) 2015-08-03
EA201492125A1 (en) 2015-06-30
TW201414736A (en) 2014-04-16
TN2014000537A1 (en) 2016-03-30
TWI482774B (en) 2015-05-01
SG11201408044QA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
JP6462795B2 (en) Novel 4- (substituted amino) -7H-pyrrolo [2,3-d] pyrimidines as LRRK2 inhibitors
EP3083618B1 (en) Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EP3350178B1 (en) Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
PT2152712E (en) Amino-heterocyclic compounds
EP2828262A1 (en) Imidazotriazinone compounds
AU2018230109B2 (en) Cyclic substituted imidazo[4,5-c]quinoline derivatives
WO2015166366A1 (en) Heterocyclic compounds and their use as dopamine d1 ligands
OA17357A (en) Novel 4-(substituted-amino)-7H-pyrrolo[2,3d]pyrimidines as LRRK2 inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13752678

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: CR2014-000566

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 20140130

Country of ref document: MD

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A 2014 0130

Country of ref document: MD

WWE Wipo information: entry into national phase

Ref document number: 201492125

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/015769

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 14278415

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 002533-2014

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2878054

Country of ref document: CA

Ref document number: 2015519416

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13675

Country of ref document: GE

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014003566

Country of ref document: CL

Ref document number: IDP00201408256

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 2013282869

Country of ref document: AU

Date of ref document: 20130619

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2013752678

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013752678

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A201413021

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 20157002334

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014032913

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014032913

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141229